A Phase II Study in Healthy Adults 19 Years and Older  to Assess the Safety, 
Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated 
Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant  
DMID Prot
ocol Number:  
17-0075
DMID Funding Mechanism:  Vaccine and Treatment Evaluation Units 
Pharmaceutical Support:  
Sanofi Pasteur  
GlaxoSmithKline Biologicals  
IND Sponsor:  Division of Microbiology and Infectious Diseases, National 
Institute of Allergy and Infectious Diseases, National Institutes of Health  
Lead Principal Investigator:  Lisa A. Jackson, MD, MPH 
DMID Clinical Project Manager: Robin M. Mason, MS  
DMID Medical Monitor: Mohamed Elsafy , MD  
DMID Medical Officer:  Francisco J. Leyva MD, PhD, ScM
DMID Scientific Lead: Chris Roberts, PhD 
Version:  5.0 
3 April, 2019 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
i STATEMENT OF COMPLIANCE 
This trial will be carried out in accordance with Good Clinical Practice  (GCP) and as required by 
the following: 
• United States Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects 
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 (Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical 
Investigators), 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug Application), 21 CFR 812 
(Investigational Device Exemptions) 
• International Conference on Harmonisation: Good Clinical Practice (ICH E6); 62 
Federal Register 25691 (1997); and future revisions 
• Belm ont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research, Report of the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research 
Involving Human Subjects, as applicable 
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , as applicable  
• Applicable Federal, State, and Local Regulations and Guidance 
 
 
  
 
   
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
ii SIGNATURE PAGE  
The signature below provides the necessary assurance that this trial will be conducted according 
to all stipulations of the protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations and ICH E6 Good Clinical Practice (GCP) guidelines. 
 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
 I agree to conduct the study in accordance with the current protocol and will not ma ke changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when necessary to protect the safety, rights, or welfare of subjects.  
 
Site Principal Investigator:  
 
Signed:  
 Date:   
 Name  
Title  
   
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
iii TABLE OF CONTENTS 
 
STATEMENT OF COMPLIANCE  ................................................................................................. i  
SIGNATURE PAGE  ...................................................................................................................... ii 
TABLE OF CONTENTS  ............................................................................................................... iii 
LIST OF TABLES  ........................................................................................................................ vii  
LIST OF FIGURES  ..................................................................................................................... viii 
LIST OF ABBREVIATIONS  ........................................................................................................ ix 
PROTOCOL SUMMARY ........................................................................................................... xiii 
1 Key Roles  ..............................................................................................................................22  
2 Background Inf ormation and Scientific Rationale  ...............................................................24  
2.1 Background Information ...........................................................................................24  
2.1.1  Public Readiness and Emergency Preparedness Act  ....................................27  
2.2 Scientific Rationale  ...................................................................................................28  
2.3 Potential Risks and Benefits  .....................................................................................30  
2.3.1  Potential Risks  ..............................................................................................30  
2.3.2  Known Potential Benefits .............................................................................37  
3 Study Objectives and Outcome Measures  ............................................................................38  
3.1 Study Objectives  .......................................................................................................38  
3.1.1  Primary  ..........................................................................................................38  
3.1.2  Secondar y ......................................................................................................38  
3.1.3  Exploratory ...................................................................................................39  
3.2 Study Outcome Measures .........................................................................................39  
3.2.1  Primary  ..........................................................................................................39  
3.2.2  Secondary  ......................................................................................................40  
3.2.3  Exploratory ...................................................................................................41  
4 Study Design  .........................................................................................................................42  
5 Study Enrollment and Withdrawal........................................................................................44  
5.1 Eligibility Criteria  .....................................................................................................44  
5.1.1  Subject Inclusion Criteria  .............................................................................44  
5.1.2  Subject Exclusion Criteria  ............................................................................45  
5.2 Treatment Assignment Procedures  ...........................................................................48  
5.2.1  Enrollment and Randomization Procedures..................................................48  
5.2.2  Masking Procedures ......................................................................................49  
5.2.3  Reasons for Withdrawals and Discontinuation of Treatment .......................49  
5.2.4  Handling of Withdrawals and Discontinuation of Treatment .......................51  
5.2.5  Termination of Study ....................................................................................52  
6 Study Intervention/Investigational Product ..........................................................................53  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
iv 6.1 Study Product Description ........................................................................................53  
6.1.1  Acquisition  ....................................................................................................53  
6.1.2  Formulation, Storage, Packaging, and Labeling ...........................................54  
6.1.3  Study Product Storage and Stability Procedures ..........................................55  
6.2 Dosage, Preparation, and Administration of Study Intervention/ Investigational 
Product ......................................................................................................................56  
6.3 Modification of Study Intervention/Investigational Product for a Subject ...............57  
6.4 Accountability Procedures for the Study Intervention/ Investigational Product ......58  
6.5 Assessment of Subject Compliance with Study Intervention/ Investigational Product
...................................................................................................................................58  
6.6 Concomitant Medications/Treatments  ......................................................................59  
7 Study Procedures and Evaluations ........................................................................................60  
7.1 Clinical Evaluations  ..................................................................................................60  
7.2 Laboratory Evaluations .............................................................................................61  
7.2.1  Clinical Laboratory Evaluations ...................................................................61  
7.2.2  Special Assays or Procedures  .......................................................................62  
7.2.3  Specimen Preparation, Handling, and Shipping ...........................................64  
7.2.3.1 Instructions for Specimen Preparation, Handling, and Storage ........64 
7.2.3.2  Specimen Shipment ..........................................................................65  
8 Study Schedule......................................................................................................................66  
8.1 Screening (Optional) and Enrollment Visits  .............................................................66  
8.1.1  Visit 00, Screening Clinic Visit (Optional) (Day -28 to -1) .........................66  
8.1.2  Visit 01 Day 01, Enrollment (for subjects previously screened at Day -28 to -1) and First Vaccination (Dose 1), Clinic Visit ...........................................67
 
8.1.3  Visit 01, Day 1, Enrollment/Baseline (for subjects not previously screened 
at Day -28 to - 1) and First Study Vaccination (Dose 1), Clinic Visit ...........69  
8.2 Follow- up Visits ........................................................................................................71  
8.2.1  Visit 02, Day 4, Memory Aid Review, Phone Call  ......................................71  
8.2.2  Visit 03, Day 8, Clinic Visit ..........................................................................71  
8.2.3  Visit 04, Day 22, Second Study Vaccination (Dose 2), Clinic Visit ............72  
8.2.4  Visit 05, Day 25, Memory Aid Review, Phone Call ....................................74  
8.2.5  Visit 06, Day 29, Clinic Visit ........................................................................75  
8.2.6  Visit 07, Day 43, Clinic Visit ........................................................................75  
8.2.7  Visit 08, Day 82, Safety Follow-up, Phone Call...........................................76  
8.2.8  Visit 09, Day 142, Safety Follow-up, Phone Call.........................................77  
8.2.9  Visit 10, Day 202, Safety Follow- up, Clinic Visit ........................................77  
8.2.10  Visit 11, Day 387, Safety Follow-up, Phone Call.........................................78  
8.2.11  Early Termination Visit (if needed)  ..............................................................78  
8.2.12  Unscheduled Visit (if needed) ......................................................................79  
9 Assessment of Safety  ............................................................................................................81  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
v 9.1 Specification of Safety Parameters  ...........................................................................81  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters 81  
9.2.1  Adverse Events  .............................................................................................81  
9.2.2  Reactogenicity ...............................................................................................83  
9.2.3  Additional Adverse Event Severity Grading ................................................85  
9.2.4  Serious Adverse Events ................................................................................88  
9.2.5  Procedures to be Followed in the Event of Abnormal Laboratory Test 
Values or Abnormal Clinical Findings  .........................................................89  
9.3 Reporting Procedures ................................................................................................90  
9.3.1  Serious Adverse Events ................................................................................90  
9.3.2  Regulatory Reporting for Studies Conducted Under DMID- Sponsored IND
.......................................................................................................................91  
9.3.3  Reporting of Pregnancy ................................................................................91  
9.4 Type and Duration of Follow-up of Subjects after Adverse Events .........................91  
9.5 Halting Rules  ............................................................................................................92  
9.6 Safety Oversight ........................................................................................................93  
9.6.1  Independent Safety Monitor (ISM) ...............................................................93  
9.6.2  Data and Safety Monitoring Board (DSMB) ................................................94  
10 Clinical Monitoring  ...............................................................................................................96  
10.1  Site Monitoring Plan .................................................................................................96  
11 Statistical Considerations  ......................................................................................................97  
11.1  Introduction ...............................................................................................................97  
11.2  Study Hypotheses ......................................................................................................97  
11.3  Study Outcome Measures .........................................................................................97  
11.4  Sample Size Considerations ......................................................................................97  
11.4.1  Study Population ...........................................................................................97  
11.4.2  Subject Enrollment and Follow-up ...............................................................98  
11.4.3  Sample Size  ...................................................................................................98  
11.5  Planned Interim Analyses .......................................................................................101  
11.5.1  Interim Safety Review  ................................................................................101  
11.5.2  Interim Immunogenicity Review  ................................................................102  
11.6  Final Analysis Plan  .................................................................................................103  
11.6.1  Analysis Populations ...................................................................................103  
11.6.2  Safety Data  ..................................................................................................104  
11.6.3  Immunogenicity Data ..................................................................................105  
11.6.4  Missing Values and Outliers  .......................................................................106  
12 Data Collection Forms and Access to Source Data/Documents  .........................................107  
13 Quality Control and Quality Assurance ..............................................................................108  
14 Ethics/Protection of Human Subjects .................................................................................109  
14.1  Ethical Standard  ......................................................................................................109  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
vi 14.2  Institutional Rev iew Board  .....................................................................................109  
14.3  Informed Consent Process ......................................................................................109  
14.3.1  Informed Consent........................................................................................109  
14.4  Exclusion of Women, Minorities, and Children (Special Populations) ..................110  
14.5  Subject Confidentiality  ...........................................................................................111  
14.6  Study Discontinuation .............................................................................................112  
14.7  Costs, Subject Compensation, and Research Related Injuries ................................112  
14.8  Future Use of Stored Spec imens  .............................................................................113  
15 Data Handling and Record Keeping  ...................................................................................115  
15.1  Data Management Responsibilities .........................................................................115  
15.2  Data Capture Methods  ............................................................................................115  
15.3  Types of Data  ..........................................................................................................116  
15.4  Timing/Reports  .......................................................................................................116  
15.5  Study Records Retention.........................................................................................117  
16 Protocol Deviations .............................................................................................................118  
17 Publication Policy  ...............................................................................................................119  
18 Literature References  ..........................................................................................................120  
APPENDICES  .............................................................................................................................125  
Appendix A.  SCHEDULE OF STUDY PROCEDURES AND EVALUATIONS  .........126  
Appendix B.  LIST OF POTENTIALLY IMMUNE- MEDIATED MEDICAL 
CONDITIONS  ..........................................................................................................................
 130 
 
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
vii LIST OF TABLES  
Table 1: Study Design  ....................................................................................................................xx  
Table 2: Venipuncture Volumes (mL): ..........................................................................................64  
Table 3: Power (%) to Detect Safety Events:  ................................................................................99  
Table 4: Precision of Binomial Confidence Intervals: ...................................................................99  
Table 5: Minimum Detectable Difference in Proportion Respo nders with 80% Power..............100  
Table 6: Lower Confidence bound2 for difference in proportion of responders  between 
Adjuvanted (N = 100) and unadjuvanted (N = 50) arms, 19- 64 years stratum  ........100  
Table 7: Lower Confidence bound2 for difference in proportion of responders  between 
Adjuvanted (N = 50) and unadjuvanted (N = 25) arms, ≥65 years stratum  .............100  
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
viii LIST OF FIGURES  
Figure 1: Schematic of Study Design  .......................................................................................... xxi  
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
ix LIST OF ABBREVIATIONS  
A/H1N1  Influenza A Virus of the H1N1 Subtype  
A/H2N2  Influenza A Virus of the H2N2  Subtype  
A/H3N2  Influenza A Virus of the H3N2 Subtype  
A/H3N2v  Influenza A Virus of the H3N2 Variant Subtype  
A/H5N1  Influenza A Virus of the H5N1 Subtype  
A/H5N2  Influenza A Virus of the H5N2  Subtype  
A/H5N3  Influenza A Virus of the H5N3 Subtype  
A/H5N6  Influenza A Virus of the H5N 6 Subtype  
A/H5N8  Influenza A Virus of the H5N8 Subtype  
A/H7N1  Influenza A Virus of the H7N1 Subtype  
A/H7N7  Influenza A Virus of the H7N7 Subtype  
A/H7N9  Influenza A Virus of the H7N9  Subtype  
A/H9N2  Influenza A Virus of the H9N2  Subtype  
AS03 Adjuvant System 03  
AdvantageEDCSM Electronic Data Capture System  
AE Adverse Event/Adverse Experience  
ALT  Alanine Aminotransferase  
BARDA  Biomedical Advanced Research and Development Authority  
BLA  Biologics License Applications  
BMI  Body Mass Index  
BP Blood Pressure  
BPM  Beats Per Minute  
CDC  Centers for Disease Control  and Prevention  
CFR  Code of Federal Regulations  
CHMP  Committee for Medicinal Products for  Human Use  
CI Confidence Interval  
CMS  Clinical Materials Services  
Cr Creatinine  
CSL Commonwealth Serum Laboratories  
CSR  Clinical Study Report  
CVV  Candidate Vaccine Virus  
°C Degrees Celsius  
°F Degrees Fahrenheit  
D Day(s)  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH  
DSMB  Data and Safety Monitoring Board  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
x eCRF  Electronic Case Report Form  
EIA Enzyme Immunoassay  
ELISpot  Enzyme -Linked Immunosorbent Spot  
ESR Erythrocyte Sedimentation  Rate 
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act  
FWA  Federalwide Assurance  
g/dL  Grams per Deciliter  
GBS  Guillain -Barré Syndrome  
GCP  Good Clinical Practice  
GMT  Geometric Mean Titer  
GSK  GlaxoSmithKline Biologicals  
HA Hemagglutinin  
HAI Hemagglutination Inhibition  
Hgb Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HPAI  Highly Pathogenic Avian Influenza  
HPLC  High -Performance Liquid Chromatography  
HRSA  Health Resources and Services Administration  
IATA  International Air Transport Association  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IgG Immunoglobulin G  
IGHV  Immunoglobulin G Heavy Chain Variable  
IIV Inactivated Influenza Virus Vaccine  
IIV3  Trivalent Inactivated Influenza Vaccine  
IM Intramuscular  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IU/L  International Unit(s) per Liter  
mcg  Microgram(s)  
µL Microliter(s)  
MAAEs  Medically -Attended Adverse Events  
MedDRA Medical Dictionary for Regulatory Activities  
MF59  MF59C.1 Adjuvant  
mg/dL  Milligram(s) per Deciliter  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xi mITT  Modified Intent -to-Treat  
mL Milliliter(s)  
mm Millimeter(s)  
mmHg  Millimeters of Mercury  
MOP  Manual of Procedures  
N Number of Subjects  
NA Neuraminidase  
Neut  Neutralizing or Neutralization  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
NSAIDs  Non-Steroidal Anti -Inflammatory Drugs  
NOCMCs  New -Onset Chronic Medical Conditions  
NVD  Novartis Vaccines and Diagnostics  
OER  Office of Extramural Research  
OHRP  Office for Human Research Protections  
PBS Phosphate  Buffered Saline  
PCR  Polymerase Chain Reaction  
PHI Personal Health Information  
PIMMCs  Potentially Immune -Mediated Medical Conditions  
PLT Platelets  
PP Per Protocol  
PREP Act  Public Readiness and Emergency Preparedness Act  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SDCC  Statistical and Data Coordinating Center  
SDS-PAGE  Sodium Dodecyl Sulfate -Polyacrylamide Gel Electrophoresis  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SRID  Single Radial Immunodiffusion  
T. Bili  Total Bilirubin  
TBD  To Be Determined  
TGA  Therapeutics Goods Administration  
UK United Kingdom  
US United States  
USDA  US Department of Agriculture  
V Visit(s)  
VTEU  Vaccine and Treatment Evaluation Unit  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xii WBC  White Blood Cells  
WHO  World Health Organization  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xiii PROTOCOL SUMMARY  
Title:  A Phase II Study in Healthy Adults 19 Years and O lder to Assess 
the Safety, Reactogenicity and Immunogenicity of a Sanofi 
Pasteur A/H7N9  Inactivated Influenza Vaccine Administered 
Intramuscularly  With or Without AS03 Adjuvant  
Phase:  II 
Population: Approximately 400 (up to 420) individuals 19-64 years old, and 
approximately 240 (up to 300) individuals greater than or equal to 
(≥) 65 years old who have no history of influenza A/H7N9 infection or prior receipt of  an influenza virus H7  subtype vaccine. 
Number of Sites:  Up to 9 Vaccine and Treatment Evaluation Unit (VTEU) sites  
Study Duration:  Approximately six teen (1 6) months 
Subject Participation Duration: Approximately thirteen (13) months 
Estimated  Time to Complete 
Enrollment:  Approximately 12 weeks  
Description of Agent:  Two doses delivered intramuscularly  (IM)  approximately 21 days 
apart of a monovalent inactivated pre-pandemic influenza A/H7N9 
vaccine ( 2017 H7N9 IIV ) manufactured by Sanofi Pasteur, at 
different dosages administered with AS03 adjuvant 
(GlaxoSmithKline  Biologicals (GSK))  and Phosphate Buffered 
Saline ( PBS) diluent (3.75 micrograms /0.5mL of hemagglutinin 
(HA)  from A/Hong Kong/125/2017 H7N9  vaccine per dose) , or at 
dosages administered with AS03 adjuvant (GlaxoSmithKline Biologicals (GSK)) (7.5 and 15 micrograms  /0.5mL of 
hemagglutinin (HA) from A/Hong Kong/125/2017 H7N9 vaccine 
per dose) or without adjuvant (15 mcg HA and 45 mcg HA per dose). 
Study Objectives:  
 
Primary:  
Safety:  
• To assess the safety and reactogenicity following receipt of two doses of 2017 H7N9 IIV administered intramuscularly 
at different dosages approximately 21 days apart given 
with or without AS03 adjuvant  
Immunogenicity : 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xiv • To assess the serum hemagglutination inhibition (HAI) and 
neutralizing (Neut) antibody responses following receipt of 
two doses of 2017 H7N9 IIV administered intramuscularly  
at different dosages approximately 21 days apart with or 
without AS03 adjuvant, stratified by age of recipient.  
Secondary:  
Safety:  
• To assess unsolicited non- serious adverse events (AEs) 
following receipt of two doses of a 2017 H7N9 IIV 
administered IM at different dosages approximately 21 
days apart with or without AS03 adjuvant  
• To assess medically -attend ed adverse events (MAAEs) 
including new-onset chronic medical conditions (NOCMCs), potentially immune- mediated medical 
conditions (PIMMCs), and all serious adverse events (SAEs) following receipt of two doses of a 2017 H7N9 IIV  
administered IM at different  dosages approximately 21 
days apart  with  or without  AS03  adjuvant 
Immunogenicity : 
• To assess the serum HAI and Neut antibody responses 
approximately 7 and 21 days following receipt of a single 
dose, and approximately 7 days following receipt of two 
doses of 2017 H7N9 IIV administered IM at different 
dosages approximately 21 days apart with or without AS03  
adjuvant, stratified by age of recipient.  
Exploratory: 
Immunogenicity:  
• To assess the effects of age, sex, body mass index, and 
prior receipt of seasonal influenza vaccine(s) on serum 
HAI and Neut antibody responses following receipt of two 
doses of a 2017 H7N9 IIV administered IM at different 
dosages approximately 21 days apart with or without AS03 
adjuvant. 
• To assess, in at least a subset of samples, the cross -
reactivity of serum HAI and Neut antibody responses to 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xv antigenically drifted  variants of influenza A/H7 viruses 
following receipt of two doses of a 2017 H7N9 IIV 
administered intramuscularly at different dosages 
approximately 21 days apart with or without AS03 
adjuvant, stratified by age of recipient.  
• To assess the durability of serum HAI and Neu t antibody 
responses at approximately 180 days fol lowing receipt of 
two doses of 2017 H7N9 IIV administered intramuscularly 
at different dosages approximately 21 days apart with or 
without AS03 adjuvant, stratified by age of recipient.  
• To assess the neuraminidase ( NA) content of the 2017 
H7N9 IIV and determine the serum antibody responses to 
NA following receipt of 2017 H7N9 IIV. 
Study Outcome Measures:  
 Primary:  
Safety:  
• Occurrence of study vaccine- related serious adverse events 
(SAEs) from the time of the first study vaccination through 
approximately 12 months after the last study vaccination. 
• Occurrence of solicited injection site and systemic reactogenicity events from the time of each study vaccination through 7 days after each study vaccination. 
• Occurrence of  clinical safety laboratory adverse events 
from the time of each study vaccination through approximately 7 days after each study vaccination.  
Immunogenicity:  
• For HAI and Neut antibodies, percentage of subjects achieving seroconversion against the influenza 2017 H7N9 study vaccine strain (defined as either a pre -vaccination 
titer <1:10 and a post-vaccination titer ≥1:40 or a pre-
vaccination titer ≥1:10 and a minimum four-fold rise in 
post- vaccination antibody titer) at approximately 21 days 
after the second study vaccination (Study Day 43). 
• For HAI and Neut antibodies, percentage of subjects  
achieving  titer ≥1:40 against the influenza 2017 H7N9 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xvi study vaccine strain  at approximately 21 days after the 
second study vaccination (Study Day 43) . 
• Geometric Mean Titers  (GMTs)  of serum HAI and Neut 
antibodies against the influenza 2017 H7N9 vaccine strain 
at approximately 21 days after the second study 
vaccination  (Study Day 43) . 
Secondary:  
Safety:  
• Occurrence of study vaccine-related unsolicited non-serious AEs from the time of each study vaccination 
through approximately 21 days after each study vaccination.  
• Occurrence of all unsolicited adverse events, regardless of 
the assessment of seriousness or relatedness, from the time 
of each study vaccination through approximately 21 days 
after each study vaccination.  
• Occurrence of MAAEs, including NOCMCs, and PIMMCs 
from the time of the first study vaccination through 
approximately 12 months after the last study vaccination. 
• Occurrence of all serious adverse events (SA Es), 
regardless of the assessment of relatedness, from the time 
of the first vaccination through approximately 12 months 
after the last study vaccination.  
Immunogenicity : 
• For HAI and Neut antibodies, percentage of subjects 
achieving seroconversion against the influenza 2017 H7N9 
vaccine strain at approximately 7, 21, and 28 days  after the 
first study vaccination  (Study Days 8, 22, 29). 
• For HAI and Neut antibodies, percentage of subjects 
achieving  antibody titers of 1:40 or greater against the 
influenza 2017 H7N9 vaccine strain at  baseline and 
approximately 7, 21, and 28 days  after the first study 
vaccination  (Study Days 8, 22, 29). 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xvii • GMTs  of serum HAI and Neut antibodies against the 
influenza 2017 H7N9 vaccine virus at  baseline and 
approximately 7, 21, and 28 days  after the first study 
vaccination  (Study Days 8, 22, 29). 
Exploratory: 
Immunogenicity:  
• For HAI and Neut antibodies, percentage of subjects 
achieving seroconversion and the Geometric Mean Titers of serum HAI antibody against the 2017 H7N9 study vaccine strain approximately 21 and 180 days after the 
second study vaccination (Study Days 43 and 202), 
stratified by age, sex, body mass index, and prior receipt of 
seasonal influenza vaccine(s).  
• For HAI and Neut antibodies, f or at least a subset of 
subjects, percentage achieving seroconversion , percentage 
with titer ≥1:40, and Geometric Mean Titers against antigenically drifted variants of influenza A/H7 viruses at baseline and approximately 21  and 180 days after the 
second st udy vaccination  (Study Day 43  and 202). 
• For HAI and Neut antibodies, percentage of subjects 
achieving seroconversion, percentage with titer ≥1:40, and Geometric Mean Titers against  the 2017 H7N9 study 
vaccine strain at approximately 180 days after the seco nd 
study vaccination (Study Day 202).  
• Percentage of subjects with detectable levels of serum N9 NA specific antibody elicited by 2017 H7N9 vaccination, and the correlation of the NA content of 2017 H7N9 IIV with the elicited NA specific antibody responses  at 
baseline and approximately 8 and 21 days after the first study vaccination (Study Day 1, 9 and 21) and 8, 21 and 180 days after the second study vaccination (Study Day, 29, 43 and 202). 
 
Description of Study Design:  This is a randomized, double -blinde d, Phase II study in  males and 
non-pregnant females, who are in good health, aged 19 years and 
older. This clinical trial is designed to assess the safety, 
reactogenicity, and immunogenicity of a pre-pandemic 2017 
monovalent inactivated influenza A/H7N9 vi rus vaccine  (2017 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xviii H7N9 IIV) ,), manufactured by Sanofi Pasteur , administered at 
different dosages given 1) with AS03 adjuvant and Phosphate 
Buffered Saline ( PBS) diluent [manufactured by GlaxoSmithKline 
(GSK) and Sanofi Pasteur, respectively],  (3.75 mcg of HA per 
dose), 2) with AS03 adjuvant       (7.5 mcg and 15 mcg of HA per 
dose), or 3)   without adjuvant (15 mcg and 45 mcg of HA per 
dose). The 2017 H7N9 IIV was manufactured using a reverse 
genetics -derived reassortant candidate vaccine virus IDCDC 
RG56 B (H7N9),  containing the HA and NA from low pathogenic 
influenza A/Hong Kong/125/2017 ( H7N9 ) and the PB2, PB1, PA, 
NP, M and NS from A/Puerto Rico/8/1934 (H1N1). 
 Subjects who are in good health and meet all eligibility criteria 
(including an erythrocyte sedimentation rate [ESR] , urine or serum 
pregnancy test, history and physical exam) within 28 days prior to 
the first vaccination or on the day of, but prior to, first vaccination, will be randomized into  one of five  study groups, stratified by age  
as shown in Table 1. Baseline clinical safety laboratories will be 
drawn prior to the first vaccine dose and will not be used to screen subjects for eligibility . 
Reactogenicity will be measured by the occurrence of solicited injection site and systemic reactions from the time of each study vaccination through 7 days after each study vaccination. 
Unsolicited non- serious AEs will be collected from the time of 
each st udy vaccination through approximately 21 days after each 
study vaccination. SAEs, MAAEs, including NOCMCs, and 
PIMMCs, will be collected from the time of the first study 
vaccination through approximately 12 months after the last study 
vaccination. Clinical  laboratory evaluations for safety will be 
performed on venous blood collected prior to each study vaccination  and approximately 7 days after each study 
vaccination.  
Immunogenicity testing will include performing HAI and Neut antibody assays against the 2017 H7N9 vaccine virus on serum samples obtained immediately prior to each study vaccination 
(Day s 1 and approximately Day 22), approximately 7 days after 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xix each study vaccination (Days 8 and 29), and approximately 21  and 
180 days after the second study vaccination (Days 43 and 202).  
Novel methods for identifying and assessing alternative correlates 
of protection against influenza infection are needed.  To assess the NA specific antibody response to vaccination, it is first necessary to determine the NA c ontent of inactivated influenza vaccine; this 
assay is under development.  If successful, the NA content in a dosage specific manner can be correlated to the N9 NA -specific 
antibody responses elicited by the 2017 H7N9 IIV. 
Subjects who have not received licensed 2017-2018 seasonal 
trivalent or quadrivalent inactivated influenza vaccine (IIV3 or 
IIV4 , including high dose vaccine for the elderly) prior to 
enrollment may receive it anytime following completion of the 
Day 43 study visit or upon early terminatio n. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xx Table 1: Study Design  
Treatment Arms  Stratum  Day 1  Day 22  
Group 1, n=160 Age 19 -64, n=100 Sanofi Pasteur H7N9 
vaccine 3.75 mcg / PBS  
diluent plus GSK AS03 
adjuvant  Sanofi Pasteur H7N9 
vaccine 3.75 mcg /PBS 
diluent plus GSK AS03 
adjuvant  Age ≥ 65, n=60  
Group 2, n=160 Age 19 -64, n=100 Sanofi Pasteur H7N9 
vaccine 7.5 mcg plus GSK 
AS03 adjuvant  Sanofi Pasteur H7N9 
vaccine 7.5 mcg plus GSK 
AS03 adjuvant  Age ≥ 65, n=60  
Group 3, n=160 Age 19 -64, n=100 Sanofi Pasteur H7N9 
vaccine 15 mcg plus GSK 
AS03 adjuvant  Sanofi Pasteur H7N9 
vaccine 15 mcg plus GSK 
AS03 adjuvant  Age ≥ 65, n=60  
Group 4, n=80 Age 19 -64, =50 Sanofi Pasteur H7N9 
vaccine 15 mcg 
unadjuvanted Sanofi Pasteur H7N9 
vaccine 15 mcg 
unadjuvanted Age ≥ 65, n=30 
Group 5, n=80 Age 19 -64, n=50 Sanofi Pasteur H7N9 
vaccine 45 mcg 
unadjuvanted Sanofi Pasteur H7N9 
vaccine 45 mcg 
unadjuvanted Age ≥ 65, n=30 
Total Enrollment,  
n = 640 Age 19 -64, n=400* *Over enrollment up to 420 subjects may be allowed to 
ensure approximately 100 subjects in each AS03 
adjuvanted treatment arm, and 50 subjects in each of the 
unadjuvanted treatment arm are eligible for inclusion in 
post Dose 2 immunogenicity analyses  
Age ≥ 65, n=240**  **Over enrollment up to 300 subjects may be allowed to 
ensure 60 subjects in each of the AS03 adjuvanted 
treatment arms, and 30 subjects in each of the 
unadjuvanted treatment arms are eligible for inclusion in 
post Dose 2 immunogenicity analyses  
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
xxi Figure 1: Schematic of Study Design  
 
 
≥ 65 Years Old  
(N = 240) 
Randomize 2:2:2:1:1 
Planned Enrollment: Total N= 640 S ubjects * 
 
*The study is planned to enroll a minimum of  640 subjects  with a target of  (n=160 in each treatment 
arm with AS03 adjuvant, (100 in the subjects 19 -64 years old, 60 in the subjects  ≥ 65 years old) ) and 
(n=80 in each treatment arm with no adjuvant, (50 in the subjects 19 -64 years old, 30 in the subjects  ≥ 
65 years old) ), but may continue enrollment up to a maximum of 420 subjects in the 19 -64 years old 
age stratum and 30 0 subjects in the ≥65 years old age stratum.  
 
Administe r Study Vaccine per Subject Treatment 
Assignments on Day 1 and approximately Day 22  
Assessment of 
Final Outcome 
Measures  
Consent  
 
Assess Eligibility  
19-64 Years Old 
(N = 400) 
Randomize 2:2:2:1:1 
Clinical, Safety, Reactogenicity, and 
Immunogenicity  Assessment s 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
22 1 KEY ROLES  
Lead Principal Investigator:  
 Lisa A. Jackson, MD, MPH  
Kaiser Permanente Washington Health Research Institute  
 
DMID Clinical Project Manager:  Robin M. Mason , MS 
Division of Microbiology and Infectious Diseases 
NIAID, NIH  
 
DMID Medical Monitor:  Mohamed Elsafy , MD  
Division of Microbiology and Infectious Diseases NIAID, NIH  
 
DMID Medical Officer:  
 Francisco J. Leyva MD, PhD, ScM  
Division of Microbiology and Infectious Diseases 
NIAID, NIH  
 
DMID Scientific Lead:  
 Chris Roberts, Ph.D.  
Division of Microbiology and Infectious Diseases 
NIAID/NIH/DHHS  
 
Safety and Pharmacovigilance 
Contractor:  
 DMID Pharmacovigilance Group  
Clinical Research Operations and Management Support 
(CROMS)  
 
 
 
 
Site Principal Investigators:  Lisa A. Jackson, MD, MPH  
Kaiser Permanente Washing ton Health Research Institute  
Kaiser Permanente  
 
Jack Stapleton, MD  
Depts. of Internal Medicine & Microbiology and Immunology University of Iowa  
Wilbur Chen, MD University of Maryland  
 
 

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
23 Emmanuel “Chip” Walter, MD, MPH  
Duke University School of Medicine 
 Evan J. Anderson, MD Emory University School of Medicine 
 
Nadine Rouphael, MD Emory University School of Medicine  
Statistical and Data Coordinating Center:  
The E mmes  Corporation  
 
Clinical Materials Services : Fisher BioServices  
 
HAI and N eut Antibody Assays 
Laboratory: South ern Research  
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
24 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE 
2.1 Background Information  
The continued emergence of novel influenza A viruses in humans including subtypes H5N1, 
H3N2v, H7N7, H9N2, 2009 H1N1, and most recently H5N6 and H7N9, underscores the need 
for focused efforts to prepare for the next influenza pandemic [1 -6]. Four pandemics occurred 
during the last century. It was estimated that during the 1918 influenza A/H1N1 pandemic as 
many as 40 million deaths occurred worldwide [7]. Excess mortality, high morbidity, and social 
disruption were all noted during the 1957 influenza A/H2N2 and the 1968 influenza A/H3N2 pandemics  [8]. In April 2009, a novel influenza virus (2009 A/H1N1) originated in pigs and 
spread to humans around the world becoming the first pandemic of this century. In each of these 
influ enza pandemics, human populations lacked significant levels of pre- existing immunity to a 
highly transmissible form of the virus enabling it to spread rapidly. Thus, each emergence of a 
new strain  of influenza virus in the human population has the potentia l to result in a global public 
health emergency.  
A major cornerstone of pandemic preparedness is the capacity to rapidly produce and deliver sufficient quantities of safe and effective strain -specific pandemic influenza vaccines. The threat 
of pandemic influenza in 1976 (swine influenza) and again in 1977 (Russian influenza) resulted 
in inactivated influenza virus vaccine (IIV) development programs that provided important 
insights into variables influencing the immune responses to immunization  [9, 10] . Vaccine- 
associated factors potentially affecting the immunogenicity of IIVs that were noted during the 
1976 experience and have been refined in subsequent years include the amount of viral 
hemagglutinin (HA) protein in the vaccine, the number and intervals of doses administered, the addition of immune stimulating components (i.e. , adjuvants), and the manufacturing methods 
used to produce the vaccine (i.e. , whole virus, split virus, or purified surface antigen). Host-
specific factors, including the recipient ’s age, their prior influenza infections and/or vaccinations, 
and the presence of underlying diseases and their treatments, all can influence the immune responses elicited by an influenza vaccine.  
Serum antibodies targeting the influenza virus HA and neuraminidase (NA), the major surface 
glycoproteins on influenza viruses, play a key role in protective immunity to influenza virus infection  [11]. Since protection against infection with seasonal influenza virus strains has been 
shown to correlate with both serum hemagglutination inhibition (HAI) and neutralizing (Neut) 
antibody levels,  their measurements  are used routinely to assess the immunogenicity of both 
seasonal and pandemic IIVs. Recent data also supports an important role for neuraminidase 
inhibiting (NI) antibodies in protection against disease [12]. In a recent human influenza 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
25 challenge study, serum NI antibody le vels were also identified as an independent correlate of 
protection against influenza illness [13].  In the current study, we plan to assess the NA content 
of 2017 H7N9 IIV and determine the correlation of NA content at different vaccine dosages with 
the elicited humoral antibody responses to the NA. 
Several approaches have been used to increase the immu nogenicity of IIVs. Standard -dose 
inactivated seasonal influenza vaccines contain 7.5 mcg of HA antigen per vaccine strain (for 
children aged <36 months) or 15 mcg of HA antigen per vaccine strain (for persons aged ≥36 months). Clinical studies evaluating increased HA -containing influenza vaccines performed over 
the past 35 years have shown dose- related increases in serum and mucosal antibody responses 
[14-22]. Higher HA dosage vaccines can lead to enhanced antibody responses in the elderly [23]. In 2009, a high-dose IIV containing 4 times the standard HA antigen per seasonal  vaccine strain 
was approved in the United States (US) for use in individuals 65 years of age and older.  
In general, clinical studies evaluating vaccines made from novel avian influenza viruses (e.g., 
A/H5N1, A/H7N7)  suggest that these vaccines are substantially less immunogenic  than those 
from other novel subtypes (e. g., 2009 A/H1N1 pandemic virus, even when administered at high 
HA dosages  [24, 25]). Due to the poor immunogenicity of H5 an d H7 vaccines, the inclusion of 
adjuvants was evaluated to assess their ability to boost anti-viral serum IgG  levels. In the United 
States, aluminum salts are licensed as adjuvants in combination with several vaccines; however, 
their use in subvirion influenza A/H5N1 vaccines has shown either no effect or a very modest 
enhancement of immune responses compared to non- aluminum salt containing formulations  [26-
28]. In contrast, the use of oil- in-water emulsion adjuvants, most notably proprietary adjuvants 
AS03 and MF59 produced by GlaxoSmithKline Biologicals (GSK) and Seqirus, respectively, 
has resulted in increased antibody responses to IIVs containing novel HAs in numerous clinical 
trials [29-33]. In an early study, dosage levels ranging from 3.75 to 30 mcg of A/H5N1 antigen 
administered with or without AS03 resulted in significant increases in antibody Geometric Mean 
Titers (GMTs) in groups who received the adjuvanted formulations [31]. These GMTs met the Committee for Medicinal Products for Human Use (CHMP) criterion for seroconversion rate 
(>40%) after a single dose with adjuvant . Following the second va ccine dose, all adjuvanted 
formulations complied with both CHMP and US Food and Drug Administration (FDA) criteria for seroconversion and seroprotection rates, whereas from the non-adjuvanted groups only the 30 
mcg formulation met the CHMP criterion for se roconversion [31]. GSK received approval for 
the re gistration of a pre -pandemic AS03 -adjuvanted, monovalent inactivated A/H5N1 virus 
vaccine by European regulatory authorities in 2008 and FDA approval of their Biologics License 
Applications (BLA) for an Influenza A (H5N1) Virus Monovalent Vaccine Adjuvanted (with 
AS03) in 2013. 
Following the 2009 emergence of the novel A/H1N1 pandemic virus, the European Commission 
granted marketing authorization of GSK’s egg-derived AS03-adjuvanted monovalent inactivated 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
26 2009 A/H1N1 virus vaccine (Pandemrix™) and Novartis’ egg-derived MF59-adjuvanted, 
monovalent inactivated 2009 A/H1N1 virus vaccine (FOCETRIATM). These adjuvanted 
monovalent inactivated 2009 A/H1N1 virus vaccines were widely used throughout Europe and in 
many other countries, albeit not in the US. 
The inclusion of adjuvants in clinical trials evaluating IIVs has also frequently been associated 
with increased injection site reactogenicity [26]. Additionally, in late 2010, a possible association 
between an increased risk of narcolepsy in children and adolescents who had received the AS03-
containing Pandemrix™ was reported in Finland and Sweden. Some, but not all, countries in which retrospective studies were conducted showed a similar association [34-43]. ( See also 
Section 2.3.1 Potential Risks for further discussion). 
Because of the substantial increases in antibody responses when these o il-in-water emulsion  
adjuvants were added to otherwise poorly immunogenic, novel HA influenza vaccines, they may 
be a critical component of the public health response to the next influenza pandemic. As part of its pandemic preparedness efforts, the US Government maintains stockpiles of unique HA-
containing influenza vaccines, including those against influenza A/H7N9  and A/ H5N1  viruses, 
as well as AS03 and MF59 adjuvants. The National Institute of Allergy and Infectious Diseases  
(NIAID) has conducted s everal clinical trials to  evaluate A/H7N9 and A/ H5N1 vaccines  
administered with and without these adjuvants in healthy adult and elderly populations and found that the vaccines co -administered with adjuvants were w ell tolerated , exhibited dose- sparin g and 
substantially increased the immunogenicity of strain -specific novel HA vaccines  compared to 
non-adjuvanted formulations [44-49]. In response to emerging H5N8 viruses that have caused 
extensive outbreaks in domestic poultry and wild birds in South East Asia [50, 51], NIAID is also co nducting 2 ongoing clinical trials with an H5N8 vaccine produced by bioCSL (Seqirus) 
administered with either AS03 (GSK) or MF59 (Seqirus) in healthy individuals 19- 64 years of 
age ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). 
Since March of 2013 [52], avian influenza A/H7N9 virus es have continued to circulate in China 
causing discrete outbreaks (or waves) in humans  with high mortality  over the past 5 years . By 
late 2016, a “fifth wave” of outbreaks was identified in China and  as of December  7, 2017 a total 
of 1,565 laboratory-confirmed human infections with avian influenza A/H7N9 virus have been 
reported by the World Health Organization [53, 54] . Whereas  most cases have been centered in 
and around mainland China, there have been several traveler associated cases, including two in travelers reported by Canada who were returning from China in early  2015 [55]. Most  of the 
reported human cases have been associated with exposure to infected live poultry or contaminated environments, including markets where live poultry are sold. Influenza A/H7N9 
viruses continue to be detected in poultry and their environments in the areas where human cases 
are occurring. Information to date indicates that these viruses do not transmit easily from human to human with most isolates appearing to  have retained their  suscepti bility  to NA inhibitors [53] . 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
27 Laboratory studies have shown that A/H7N9 influenza viruses readily infect cells from human 
respiratory tract tissue samples and can spread from ferret to ferret by dro plet transmission, 
thereby increasing the concern about the pandemic potential of these viruses [56, 57]. 
Since the onset of the “fifth wave” of H7N9 outbreaks in October 2016, more human cases of 
H7N9 infection have been reported in China than any prior H7N9 epidemic wave [54]. In 
addition, an antigenically distinct lineage of these fifth wave H7N9 viruses known as the Yangtze River Delta lineage, has recently  emerged and has been associated with  an increasing 
number of human cases . This  lineage has also resulted in a broader geographic spread of infected 
birds and human cases within China than previously seen. Further, several  H7N9 viruses in the 
Yangtze River Delta lineage have recently acquired genetic changes characteristic of highly pathogenic avian influenza (HPAI) viruses and have now shown an increased ability to infect and kill poultry [53, 58].  
The U.S. Department of Health and Human Services (HHS) recently  assessed  H7N9 influenza 
virus as having a significant potential to cause a pandemic, and the greatest risk of causing 
severe disease.  As a result, HHS has supported the production of fifth wave inactivated influenza 
H7N9 vaccine for the U.S. stockpile and for an assessment of its safety and immunogenicity in 
clinical trials.  
2.1.1 Public Readiness and Emergency Preparedness Act  
For this protocol the study products monovalent inactivated influenza 2017 H7N9 virus vaccine manufactured by Sanofi Pasteur  and adjuvant (AS03) manufactured by GSK, are covered under 
the Public Readiness and Emergency Preparedness Act (PREP Act).  Under the PREP Act, 
covered persons are immune from liability actions brought from the administration or use of a 
covered countermeasure that is the subject of a declaration.  The PREP Act provides immunity 
for covered persons (such as manufacturers, distributers, program planners, and other qualified persons who prescribe, administer, or dispense the 2017 H7N9 IIV with or without adjuvant ) 
from tort liability, unless the injury was caused by willful misconduct.  
The PREP Act also established the Countermeasures Injury Compensation Program (CICP)to 
provide compensation for serious injuries that occur as the result of the administration or use of certain countermeasur es. Any requests for compensation must be filed within one year of 
administratio n or use of the countermeasure. Requests would go to the Health Resources and 
Services Administration ( HRSA) Preparedness Countermeasures Injury Compensation Program 
(http://www.hrsa.gov/cicp/ ). Compensation may then be available for medical benefits, lost 
wages, and death benefits to eligible individuals for specified injuries in accordance with 
regulations published by the Secretary of HRSA . Eligibility for compensation and the injuries for 
which compensation may be available are further defined by regulation. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
28 An individual who suffers a serious physical injury or death from administration and use of the 
2017 H7N9 IIV with or without adjuvant may request benefits from the CICP. A serious physical 
injury means an injury that is life threatening, results in, or  requires , medical or surgical 
intervention to prevent permanent impairment of a body function, or perma nent damage to body 
structure.  The CICP is the payer of last resort. This means that it only covers expenses or 
provides benefits that other third-party payers, such as health insurance, the Department of 
Veterans Affairs, or Workers’ Compensation programs don’t have an obligation to pa y.  
If no funds have been appropriated to the compensation program, the Secretary of HRSA  does 
not make a final determination on the individual’s request within 240 days, or if the individual 
decides not to accept the compensation, the injured individual or his representative may pursue a 
tort claim in the US District Court for the District of Columbia, but only if the claim involves 
willful misconduct, is pled with particularity required under the PREP Act, verified, and 
accompanied by an affidavit by a ph ysician who did not treat the individual and certified medical 
records.  Any award is reduced by any public or private insurance or worker’s compensation 
available to the injured individual. Awards for non-economic damages, such as pain, suffering, 
physical  impairment, mental anguish, and loss of consortium are also limited.  If the individual 
accepts compensation, or if there is no willful misconduct, then the individual does not have a tort claim that can be filed in a United States Federal or a State court. 
2.2 Scientific Rationale  
As part of the US Government’s past pandemic preparedness efforts, Sanofi Pasteur under 
contract to the Biomedical Advanced Research and Development Authority 
(BARDA)/Department of Health and Human Services (DHHS), produced several  novel pre-
pandemic vaccines that were evaluated by NIAID’s  VTEU sites to assess their safety, 
reactogenicity, and immunogenicity when mixed prior to administration with either AS03 or MF59 oil- in-water adjuvants manufactured by GSK and Seqir us, respectively. In general, these 
trials have demonstrated that adjuvant use results in a significant dose- sparing effect . NIAID  is 
currently conducting similar “mix and match” clinical trials  using an H5N8 vaccine antigen 
produced by Seqirus and mixed with either AS03 or MF59 adjuvants ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED]).  
The large number of human infections starting with the “fifth wave” of H7N9 outbreaks in late 
2016, has raised the pandemic risk assessment of influenza A/H7N9 viruses circulating in China. 
The Yang tze River Delta lineage, a distinct H7N9 viral lineage, has now emerged and has been 
associated with many  of the cases in the fifth epidemic wave. This has also resulted in a broader 
geographic spread of infected birds and human cases within China than previously reported . 
Further, several  H7N9 viruses in the Yangtze River Delta lineage have recently acquired genetic 
changes characteristic of highly pathogenic avian influenza (HPAI) viruses and have now shown 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
29 an increased ability to infect and kill poultry [54, 58]. To date, no cases of H7N9 from the new 
lineage have been identified in birds or people infected outside of China; however, a few cases 
have been identified in Hong Kong and Taiwan in infected travelers returning from China. Importantly, antigenic analysis of the fifth wave H7N9 viruses and serology studies indicate that the stockpiled H7N9 vaccine manufactured several years ago does not induce protective HAI or 
Neut antibodies against the Yangtze River Delta lineage. Hence, there is broad consensus across HHS and interagency leadership that a new  vaccine should be developed that would be effective 
against the current ly predominat ing H7N9 vir uses.  
Several candidate vaccine viruses are under evaluation by the CDC and the World H ealth 
Organization ( WHO) H5 Reference Laboratories Network.  Under  contract to BARDA/DHHS, 
Sanofi has produced a monovalent inactivated influenza pre -pandemic 2017 A/H7N9  virus 
vaccine (2017 H7N9 IIV) using largely the same manufacturing process as its licensed seasonal 
trivalent inactivated influenza virus vaccine . The availability of the US Government-stockpiled 
AS03 (GSK) oil -in-water adjuvant provides an opportunity to determine if dose- sparing effects 
occur when mixing the Sanofi 2017 H7N9 vaccine with  the AS03 adjuvant ( See Sections 2.3.1 
and 6.1 for additional details on the H7N9 vaccine). 
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of two 
doses of the 2017 H7N9 IIV administered with or without AS03 in healthy adult and the elderly 
individuals.  The  2017 H7N9 IIV manufactured by Sanofi will be mixed at the site with or 
without AS03 and will be administered IM at different dosages with AS03 [3.75, 7.5 and  15 mcg 
HA per dose (based on label content )] or without AS03 (15 or 45 mcg HA per dose) to evaluate 
the dose- sparing potential of the adjuvant. Data from phase I clinical trials of avian IIVs suggest 
that they are poorly immunogenic and require multiple high -doses or the inclusion of an adjuvant 
to induce serum HAI titer of 40 or greater  against the study vaccine virus. In previous NIAID 
sponsored clinical trials of 2013 H7N9 IIV, 2 doses of non-adjuvanted 45 mcg of HA per dose 
did not confer significant seroprotection [46, 48].  However, to confirm the poor immunogenicity 
of the 2017 H7N9 IIV, a study arm with 2 high-doses (45 mcg HA per dose administered 
approximately 21 days apart) of non-adjuvanted 2017 H7N9 IIV is included in the study 
design.  The 45 mcg dosage represents a 12 -, 6-, and 3-fold excess of vaccine antigen, 
respectively, over the 3.75 mcg, 7.5 mcg, and 15 mcg dose- sparing formulations achievable with 
the AS03 adjuvant. In addition  to assessing a ntigen- sparing strategies, another goal of this study 
is to assess in at least a subset of samples, if serum IgG elicited by the  2017 H7N9 IIV recognize 
antigenically drifted variants of influenza A/H7 viruses. Since antibodies targeting the NA may represent an independent correlate of protection against influenza infection [11-13], we plan to assess the NA content of the 2017 H7N9 vaccine and determine if there is a dose- specific 
correlation of NA content with elicited humoral antibody responses to the N9 NA.  
Based on previously conducted studies with a 2013 H7N9 IIV manufactured by Sanofi Pasteur 
administered with or without AS03, we anticipate that two doses of the 2017 H7N9 IIV 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
30 administered IM at different dosages with AS03 adjuvant approximately 21 days apart will be 
well-tolerated and more immunogenic compared to the non- adjuvanted vaccine in healthy adult 
and elderly individuals. 
2.3 Potential Risks and Benefits  
2.3.1 Potential Risks  
The potential risks of participating in this trial are those associated with having blood drawn, the 
IM injection and possible reactions to the monovalent inactivated influenza H7N9  vaccine, with 
or without PBS diluent, and/or AS03  adjuvant , and  breach of confidentiality.  
Drawing blood may cause transient discomfort and fainting.  Fainting is usually transient and 
managed  by having the subject lie down and elevate his/her legs . Bruising at the blood draw site 
may occur , but can be prevented or lessened by applying pressure to the blood draw site for a 
few minutes  after the  blood is taken. IM injection may also cause transient discomfort and 
fainting.  Drawing blood and IM injection may  cause infection. The use of aseptic (sterile) 
technique will make infection at the site where blood will be drawn or where the study 
vaccination will be  given extremely unlikely.  
There is a small amount of risk to subjects who report that they are in good health but who have 
an unknown health problem at the time of screening . This trial will screen by  physical exam, 
history, vital signs  and sedimentation rate . Baseline safety labs for white blood cells (WBC), 
hemoglobin (Hgb), platelets (P LT), alanine aminotransferase (ALT), total bilirubin  (T. Bili) , and 
creatinine ( Cr) will be drawn prior to study vaccination but results will not be reviewed until 
after study vaccination . To minimize the risk,  subject s will not receive the second study 
vaccination  unless , the most recently evaluated clinical safety laboratory values obtained prior to 
the second study vaccination are Grade 2 or less and the subject does not meet any of the other 
criteria listed in Section 5.2.3. 
There is potential for AEs to occur more frequently in the adjuvanted vaccine groups [59] than in 
the non-adjuvanted group and there is potentially a higher risk for AEs  to occur more frequently 
in the higher dose influenza antigen groups than in the lower dose viral antigen groups. T he 
monoval ent A/H7N9 v accine to be  used  in this st udy has not been  tested for safety in animals 
and has not previously been evaluated in humans. The Division of Microbiology and  Infectious 
Diseases  (DMID), NIAID sponsored two  Phase I I clinical trials that included an assessment of  
the safety , reactogenicity, and immunogen icity o f two IM doses of a monoval ent A/H7N9 
vaccine pr oduced  by Sanofi Pasteur, Swiftwater, PA, administer ed with or without AS03 in 
healthy adults (DMI D Protocol 13-0032; NC T01938742 and DMI D Protocol 13-0033 ; 
[STUDY_ID_REMOVED]).  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
31 Overa ll, the study products administer ed in both of these c linical trials were genera lly safe and  
well-tolerated. Fo r DMI D Protocol 13-0032, nine SAE s were repo rted. Al l were asses sed as 
being not relat ed to study product. Two AEs  of special interest (AESIs) were  reported in this 
clinical trial: Hashimoto’s di sease ( assessed as not relat ed to study product) and H ashimoto’s 
thyroiditis ( assessed  as relat ed to study product). For DMI D Protocol 13-0033, sixt een SAE s 
were  reported, fift een of these SAE s were assessed as being not relat ed to study product. One 
SAE was consider ed to be  relat ed: acute inferi or myoca rdial infarction. Two AES I s were  
reported in this c linical trial: psori asiform dermatitis and  celiac di sease (both ass essed as not 
related to study product because both disorders pre -existed to vaccination, but both disorders 
received the diagnosis after vaccination ). 
The current monovalent split IIV was derived from the influenza virus A/Hong Kong/125/2017 
(H7N9). The manufacturing process for the productio n of this investigational A/H7N9 vaccine 
is similar to the process used to produce the licensed Influenza Virus Vaccine Fluzone® family 
of products. As such, the safety profile of the candidate A/H7N9 vaccine should be similar to 
the current Fluzone® vacci ne.  
 
 
 
 
 
 
 
 
  
The potent
ial risks to su bjects are an ticipat ed to be sim ilar to those observed  for S anofi P asteur’s 
unadjuv anted licensed  inter-pandemic (seasonal ) IIVs  (Fluzone® and Fluzone® High-Dose), thei r 
unadjuv anted licensed  2009 A/H1N1 and  A/H5N1 monoval ent IIVs, and for previously 
conducted 2013 H7N9 IIV administered with and without AS03 and MF59 (see the Sanofi Pasteur Investigator’s Brochure  Investigational Pandemic Influenza Virus vaccines, Monovalent 
A/Shanghai/2/2013 (H7N9) product code 504, Monovalent A/Hong Kong/125/2017 (H7N9) 
product code 504, Monovalent A/Indonesia/05/2005 (H5N1) product code 458, Monovalent 
A/Vietnam/1203/2004 (H5N1) product code 399, Monovalent A/Bar- Headed Goose/Qinghai 
Lake/1A/2005 (H5N1) product code 458, Version Number 1.0, January 2018). 
Occasionally, adult recipients of unadjuvanted licensed, IIVs may develop influenza- like 
reactions , such as fever, feverishness ( chills/shivering/sweating), fatigue (tired ness), malaise 
(general unwell feeling), myalgia (body aches/muscular pain), arthralgia (joint pain), headache, 
and/or nausea. Some subjects may develop reactions at the injection site, including pruritus 

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
32 (itching), ecchymosis (bruising), erythema (redness), induration (hardness), swell ing, pain, 
and/or tenderness. Most of these reactions peak in intensity in the first 24 hours after vaccination 
and disappear without treatment within 1 or 2 days. Analgesics (e.g., acetaminophen, ibuprofen, 
or similar non -steroidal anti- inflammatory drugs  (NSAIDs)) and rest may generally relieve or 
lessen these reactions.  Bruising can sometimes occur due to the vaccination procedure. 
In addition, post- marketing surveillance indicates autoimmune disorders as potential risks for 
pandemic vaccines based on those identified for the seasonal IIVs; these may also include , but 
are not limited to, neuritis, convulsions, severe allergic reactions, syncope, encephalitis, 
thrombocytopenia, vasculitis, and Guillain- Barré syndrome.  Reports of these reactions were rare; 
however, exact incidence rates cannot be precisely calculated.   
Acute and potentially life -threatening allergic reactions (i.e., anaphylaxis) are also possible.  
These reactions occur in about 1 in 4 million people given a vaccination. These reactions can 
manifest as  skin rash (hives), swelling around the mouth, throat, or eyes  (angioedema) , difficulty 
breathing  (bronchospasm), a fast pulse (tachycardia) , or decrease in  blood pressure 
(hypotension). If these reactions occur, they can usually be stopped by the administration of 
emergency medications by the study personnel. As with any vaccine or medication, there is a 
very small chance of a death, although researchers do not expect this to occur. 
During the swine influenza (H1N1) vaccine campaign of 1976, some recipients developed a 
paralytic illness called Guillain -Barré syndrome (GBS). GBS  is an acute inflammatory 
neuropathy characterized by weakness, hyporeflexia or areflexia, and elevated protein 
concentrations in cerebrospinal fluid. The rate of GBS was significantly increased in individuals 
receiving the 1976 swine influenza (H1N1) vaccine at about 1 per 100,000 vaccine recipients. This syndrome has not been seen consistently with other influenza vaccines. Most persons who 
develop GBS recover completely,  although the recovery period may be as little as a few weeks 
or as long as a few years.  About 30% of those with GBS still have residual weakness after 3 
years and about 3% may suffer a relapse of muscle weakness and tingling sensations many years 
after th e initial attack.  Intensive surveillance of GBS after administration of IIVs since 1976 has 
shown a slight increase in risk over background cases (more than one additional case of GBS per 
million persons) following vaccination, typically with onset within 6 weeks after vaccination [60]. Interestingly, although vaccination rates have increased in the last 10 years , the numbers of 
reported cases of vaccine -associated GBS have declined [61]. A recent study in Canada showed 
that the 2009 H1N1 vaccine was associated with a small but significant risk of GBS in persons 50 years and older [62]. An active, population-based surveillance study conducted in the United States during the 2009-2010 influenza season found less than 1 excess GBS case per million 
doses of 2009 H1N1 vaccine administered – a rate similar to that associated with some 
previously administered annual influenza vaccines [63-65]. Another study using the Medicare system showed an elevated risk of GBS  with 2009 monovalent H1N1  vaccination (incidence rate 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
33 ratio = 2.41, 95% confidence interval: 1.14, 5.11; attributable risk = 2.84 per million doses 
administered, 95% confidence interval: 0.21, 5.48) [66]. An international collaboration study 
also supported a conclusion of an association between 2009 H1N1 vaccination and GBS [67]. It 
is unknown if the administration of the monovalent inactivated influenza 2017 H7N9 virus vaccine to be used in this clinical trial will result in an increased incidence of  GBS  as the 
mechanism leading to this AE has not been completely elucidated.  
As of November 22, 2015 ( per the manufacturer’s IB  dated February 2016), data are available 
for 56 GSK sponsored clinical trials of AS03-adjuvanted monovalent pandemic vaccines 
manufactured by GSK.  More than 18,000 adult (age ≥18 years) and 6,900 pediatric (6 months to 
17 years old) clinical trial participants have received at  least one dose of a GSK -manufactured, 
AS03 -adjuvanted monovalent pandemic influenza vaccine. Clinical d ata collected by GSK as of 
November 22, 2015, suggest that inactivated monovalent (pre)pandemic influenza virus antigens 
adjuvanted with AS03 have gener ally acceptable safety and benefit/risk profile s, though the 
incidence rates of solicited local and systemic AEs are higher with AS03-adjuvanted antigens 
than with antigen alone, a licensed IIV3 , or placebo. Some unsolicited AEs  (e.g., insomnia, 
dizziness, cystitis) were associated with a  higher relative r isk among H5N1/AS03 recipients in 
contrast to Fluarix
® or placebo recipients.  
The information and guidance that follow are based on pre- clinical and clinical study results for 
GSK-manufactured AS03- adjuvanted monovalent pandemic vaccines, post -marketing safety 
surveillance data seen with unadjuvanted, IIV3s  and (in the case of the H1N1 vaccines) post-
marketing safety surveillance data seen to date for both Pandemrix™ and Arepanri x™ H1N1  
vaccines . 
The reactogenicity profile in humans of GSK- manufactured  AS03 -adjuvanted vaccines is 
primarily  associated with the adjuvant. The incidence and severity  of injection site redness, 
swelling, and pain at the injection site in recipients of AS03 -adjuvanted vaccines are increased 
relative to monovalent pandemic influenza antigen alone, a licensed  IIV3, or placebo.  There is no 
increase in injection site and systemic  reactogenicity  events in  recipients of AS03-adjuvanted 
vaccines  after  a second dose of vaccine relative to the first when given 21 days  apart.  In young 
children (6 months to 6 years old), increased frequency of fever  has been observed following a 
heterologous booster dose of adjuvanted vaccine administered 6 months after the primary  series.  
As of November 22, 2015, there has been no evidence in clinical trials to support a conclusion 
that any potential immune -mediated disease or group of diseases was causally related to an AS03 -
adjuvanted vaccine.  There have been no deaths in GSK clin ical trials of AS03 -adjuvanted 
pandemic influenza vaccines assessed as related  to study vaccine . A total of 1,428 non- fatal SAEs 
have been reported for adult subjects as of November 22, 2015. Fifteen of these events were deemed related to vaccination by th e Investigator or GSK.  Of these, six occurred in recipients of 
an adjuvanted H1N1 vaccine: asthma, herpes zoster, hepatic enzyme increased, and pain in 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
34 extremity, polymyalgia rheumatic, and thrombocytopenia. Three occurred in recipients of 
unadjuvanted H1N 1 vaccine:  alanine aminotransferase increased, hypersensitivity, and multiple 
sclerosis.  One SAE classified as related (myalgia) occurred in a subject who received a control 
product. Four SAEs classified as related occurred in recipients of an adjuvanted H5N1 vaccine: 
autoimmune hepatitis, angina pectoris, pulmonary embolism, and non- Hodgkin’s lymphoma.  One 
SAE classified as related (lobar pneumonia) occurred in a recipient of an unadjuvanted H5N1 
vaccine. Overall, the reactogenicity and safety profile of AS03 -adjuvanted pandemic vaccines is 
acceptable and no safety concerns have been identified in clinical trials.  
Narcolepsy is a chronic sleep disorder with a background incidence rate, based on US data, of 
approximately 1.37 per 100,000 per year, with a peak onset between 10 and 19 years of age in 
some datasets.  Narcolepsy, when associated with cataplexy is seen almost exclusively in 
individuals who  are HLA DQB1 *0602 allele carriers [68]. An autoimmune etiology has been 
proposed. In the post-marketing period for adjuvanted H1N1 pandemic vaccines, several 
epidemiological studies conducted in several countries independently of GSK reported an 
increased risk of narcolepsy with or without cataplexy in subjects who were vaccinated with  
Dresden -manufactured H1N1 ( Pandemrix ™ H1N1 ) vaccine during the 2009- 2010 season. These 
studies have described an absolute risk increase of narcolepsy of approximately 1.4 to 8 additional cases per 100,000 vaccinated children/adolescents, and approximately one additional case per 100,000 vaccinated adults compared to background rates of 0.12 to 0.79 per 100,000 
children/adolescents per year and 0.67 to 1.10 per 100,000 adults per year. The observed temporal 
association between narcolepsy  and vaccination with Pandemrix ™ H1N1 is not fully understood, 
and further research  to evaluate the association between narcolepsy and Pandemrix ™ H1N1, and 
other possible contributory factors to the development of narcolepsy during the 2009- 2010  
pandemic,  such as genetic and environmental factors, is being conducted.  A GSK-supported 
study was conducted in Quebec, Canada, to assess the risk of narcolepsy associated with Arepanrix H1N1, using various index dates, risk periods, observation periods, and 
epidemiological designs. Overall, GSK considers that there is no strong evidence of an 
association between Q -Pan-H1N1 and narcolepsy in Quebec.  Recently, the CDC conducted a 
study to assess trends in narcolepsy incidence rates before and after 2009 H1N1 influenza (pH1N1) vaccination campaigns and to evaluate the risk of narcolepsy following adjuvanted 
pH1N1 vaccines. Results of the incidence rates analysis indicated no change in narcolepsy rates 
between the period before wild-type pH1N1 virus circulation and the period after the start of pH1N1vaccination campaigns in any countries except Sweden, the first signaling country, and Taiwan, where incidence began to increase upon wild-type pH1N1 virus circulation. In the case-
control analysis, no association was observed for AS03-adjuvanted pH1N1 vaccine and 
narcolepsy in children or adults, and in the case- coverage analysis no association was observed 
for narcolepsy in children, the only age groups studied. However, the data for the AS03-
adjuvanted pH1N1 vaccine, Pandemrix™, were limited. (20th Annual Conference on Vaccine 
Research,  April 24-26th, 2017, Abstract S6- 1). 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
35 No post- marketing data are available for AS03 administered in combination with any GSK -
manufactured H5N1, H7N1, H7N9, or H9N2 antigen. However, millions of doses of GSK-
manufactured H1N1 antigens, combined with AS03, were administered in the context of the 2009/10 pandemic response. In addition to the adverse reactions reported in clinical trials, the following have been reported during post- marketing experience with Pandemrix ™ (H1N1) and 
Arepanrix ™ (H1N1):  
• Immune system disorders 
o Rare: anaphylaxis, allergic reactions  
• Nervous system disorders o Rare: febrile convulsions (in subjects below 20 years of age), somnolence **, 
Guillain -Barré syndrome* 
*Spontaneous reports of Guillain-Barré syndrome have been received following 
vaccination with Arepanrix™ (H1N1); however, a causal association between vaccination and Guillain-Barré syndrome has not been established. Data  from a post-
marketing epidemiological study in Canada indicate a small but significant increased relative risk o f Guillain -Barré syndrome of 1.80 (95% CI, 1.63-4.62) in the 56-day 
period following vaccination with Arepanrix™ (H1N1, in persons 50 years of age and older). The number of GBS cases attributable to vaccination was approximately 
2 per 1 million doses. 
**reported in patients with narcolepsy and as a temporary event following 
vaccination 
o Very  rare
1: narcolepsy with or without cataplexy  
1Frequency based on estimated  attributable risk from  epidemiological studies in 
several European countries. 
• Skin and subcutaneous tissue disorders 
o Rare: angioedema, generalized skin reactions, urticaria  
• General disorders and administration site conditions o Rare: injection site reactions (such as inflammation, mass, ecchymosis)  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
36 From post- marketing surveillance with interpandemic (seasonal) trivalent vaccines, the following 
additional AE s have been reported: 
• Blood and lymphatic system disorders 
o Transient thrombocytopenia 
• Nervous system disorders o Neuralgia, convulsions  
o Neurological  disorders, such as encephalomyelitis, neuritis, and Guillain -Barré 
syndrome 
• Vascular disorders  
o Vasculitis with transient renal involvement  
As of November 22, 2015, the available data for women who become pregnant during clinical 
trials of AS03 -adjuvanted (pre) pandemic influenza vaccines do not suggest any causal 
relationship between adverse pregnancy outcomes and receipt of an AS03-adjuvanted vaccine. 
However, there is no available data related to the risks of exposure to H7N9 vaccines 
administered with o r without AS03 upon pregnancy and pregnancy outcomes. 
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law.  However, there is a chance that 
unauthorized pe rsons will see the subject ’s PHI.  All study records will be kept in a locked file 
cabinet or maintained in a locked room at the participating VTEU sites.  Electronic files will be 
password- protected.  Only people who are involved in the conduct, oversight, monitoring, or 
auditing of this trial will be allowed access to the PHI that is collected.  Any publications from 
this trial will not use information that will identify subjects by name.  Organizations that may 
inspect and/or copy research records maintained  at the participating VTEU sites for quality 
assurance and data analysis include groups such as the local Institutional Review Board (IRB) , 
NIAID , and the FDA. 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov , as required by 
US Law.  This web site will not include information that can identify subjects.   
There may be other risks, discomforts, or side effects  that are unknown at this time. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
37 2.3.2 Known Potential Benefits  
There are no known benefits attributable to the receipt of the 2017 H7N9 IIV with or without 
AS03 adjuvant. Vaccination using the 2017 H7N9 IIV with or without AS03 adjuvant may or 
may not provide protection against a serious disease with the influenza 2017 H7N9  virus, should 
the participant be exposed . The duration of any such protection is currently unknown. The 2017 
H7N9  IIV with or without AS03 adjuvant is not expected to offer protection against circulating 
seasonal influenza viruses. There may be pandemic preparedness benefits to society in the future 
if the vaccine and adjuvant s being evaluated in this clinical trial prove to be sufficiently safe and 
immunogenic and can be employed if a need for widespread influenza 2017 H7N9 vaccination 
occurs.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
38 3 STUDY OBJECTIVES  AND OUTCOME MEASURES  
3.1 Study Objectives  
3.1.1 Primary  
Safety : 
• To assess the safety and reactogenicity following receipt of two doses of 2017 H7N9 IIV 
administered intramuscularly at different dosages approximately 21 days apart given with 
or without AS03 adjuvant  
Immunogenicity : 
• To assess the serum hemagglutination inhibition (HAI) and neutralizing (Neut) antibody 
responses following receipt of two doses of 2017 H7N9 IIV administered intramuscularly 
at different dosages approximately 21 days apart with or without AS03 adjuvant, stratified by age of recipient.  
3.1.2 Secondary   
Safety:  
• To assess unsolicited non-serious adverse events (AEs) following receipt of two doses of 
a 2017 H7N9 IIV administered IM at different dosages approximately 21 days a part with 
or without AS03 adjuvant  
• To assess medically -attended adverse events (MAAEs) including new-onset chronic 
medical conditions (NOCMCs), potentially immune- mediated medical conditions 
(PIMMCs), and all serious adverse events (SAEs) following receip t of two doses of a 
2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with 
or without AS03 adjuvant  
Immunogenicity : 
• To assess the serum HAI and Neut antibody responses approximately 7 and 21 days following receipt of a single dose, and approximately 7 days following receipt of two 
doses of 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with or without AS03 adjuvant, stratified by age of recipient. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
39 3.1.3 Exploratory 
Immunogenicity:  
• To assess the effect s of age, sex, body mass index, and prior receipt of seasonal influenza 
vaccine(s) on serum HAI and Neut antibody responses following receipt of two doses of 
a 2017 H7N9 IIV administered IM at different dosages approximately 21 days apart with 
or without AS03 adjuvant. 
• To assess, in at least a subset of samples, the cross -reactivity of serum HAI and Neut 
antibody responses to antigenically drifted  variants of influenza A/H7 viruses following 
receipt of two doses of a 2017 H7N9 IIV administered intramuscular ly at different 
dosages approximately 21 days apart with or without AS03 adjuvant, stratified by age of 
recipient .  
• To assess the durability of serum HAI and Neut antibody responses at approximately 180 days following receipt of two doses of 2017 H7N9 IIV administered intramuscularly at 
different dosages approximately 21 days apart with or without AS03 adjuvant, stratified by age of recipient.   
• 
To assess the NA content of the 2017 H7N9 IIV and determine the serum antibody responses to 
NA following receipt o f 2017 H7N9 IIV.  
3.2 Study Outcome Measures  
3.2.1 Primary  
Safety:  
• Occurrence of study vaccine- related serious adverse events (SAEs) from the time of the 
first study vaccination through approximately 12 months after the last study vaccination. 
• Occurrence of solicited  injection site and systemic reactogenicity events from the time of 
each study vaccination through 7 days after each study vaccination. 
• Occurrence of clinical safety laboratory adverse events from the time of each study 
vaccination through approximately 7 days after each study vaccination.  
Immunogenicity:  
• For HAI and Neut antibodies , percentage of subjects achieving seroconversion against 
the influenza 2017 H7N9 study vaccine strain (defined as either a pre- vaccination titer 
<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a minimum 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
40 four-fold rise in post- vaccination titer) at approximately 21 days after the second study 
vaccination (Study Day 43). 
• For HAI and Neut antibodies , percentage of subjects achieving titer ≥1:40 against the 
influenza 2017 H7N9 study vaccine strain at approximately 21 days after the second 
study vaccination (Study Day 43). 
• Geometric Mean Titers (GMTs) of serum HAI and Neut antibodies against the influenza 
2017 H7N9 vaccine strain at approximately 21 days after the second study vaccination 
(Study Day 43) .  
3.2.2 Secondary  
Safety:  
• Occurrence o f study vaccine-related unsolicited non-serious AEs from the time of each 
study vaccination through approximately 21 days after each study vaccination. 
• Occurrence of all unsolicited adverse events, regardless of the assessment of seriousness 
or relatedness , from the time of each study vaccination through approximately 21 days 
after each study vaccination.  
• Occurrence of MAAEs, including NOCMCs, and PIMMCs from the time of the first 
study vaccination through approximately 12 months after the last study vaccination. 
• Occurrence of all serious adverse events (SAEs), regardless of the assessment of 
relatedness, from the time of the first vaccination through approximately 12 months after the last study vaccination.  
Immunogenicity : 
• For HAI and Neut antibodies , percentage of subjects achieving seroconversion against 
the influenza 2017 H7N9 vaccine strain at approximately 7, 21, and 28 days after the first 
study vaccination (Study Days 8, 22, 29). 
• For HAI and Neut antibodies , percentage of subjects achieving titers  of 1:40 or greater 
against the influenza 2017 H7N9 vaccine strain at  baseline and approximately 7, 21, and 
28 days after the first study vaccination (Study Days 8, 22, 29). 
• GMTs of serum HAI and Neut antibodies against the influenza 2017 H7N9 vaccine virus 
at baseline and approximately 7, 21, and 28 days after the first study vaccination (Study 
Days 8, 22, 29).  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
41 3.2.3 Exploratory 
Immunogenicity:  
• For HAI and Neut antibodies , percentage of subjects achieving seroconversion and the 
Geometric Mean Titers  of serum HA I antibody  against the 2017 H7N9 study vaccine 
strain approximately 21 and 180 days after the second study vaccination (Study Days 43 
and 202), stratified by age, sex, body mass index, and prior receipt of seasonal influenza 
vaccine(s).  
• For HAI and Neut antibodies , for at least a subset of subjects, percentage achieving 
seroconversion, percentage with titer ≥1:40, and Geometric Mean Titers against antigenically drifted variants of influenza A/H7 viruses at baseline and approximately 21 
and 180 days after the second study vaccination (Study Day 43 and 202). 
• For HAI and Neut antibodies, percentage of subjects achieving seroconversion, 
percentage with titer ≥1:40, and Geometric Mean Titers against the 2017 H7N9 study vaccine strain at approximately 180 days after the second study vaccination (Study Day 
202). 
• Percentage of subjects with detectable levels of serum N9 NA specific antibody elicited by 2017 H7N9 vaccination, and the correlation of the NA content of 2017 H7N9 IIV with the elicited NA specific antib ody responses at baseline and approximately 8 and 21 days 
after the first study vaccination (Study Day 1, 9 and 21) and 8, 21 and 180 days after the second study vaccination (Study Day, 29, 43 and 202). 
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
42 4 STUDY DESIGN  
This is a randomized, double-blinded, Phase II study in males and non-pregnant females, who 
are in good health, aged 19 years and older. This clinical trial is designed to assess the safety, 
reactogenicity, and immunogenicity of a pre-pandemic 2017 monovalent inactivated influenza A/H7N9 virus vaccine (2017 H7N9 IIV),), manufactured by Sanofi Pasteur , administered at 
different dosages given 1) with AS03 adjuvant and Phosphate Buffered Saline ( PBS) diluent 
[manufactured by GlaxoSmithKline (GSK) and Sanofi Pasteur, respectively], (3.75 mcg of HA per dose), 2) with AS03 adjuvant (7.5 mcg and 15 mcg HA per dose),), or 3) without adjuvant (15 mcg and 45 mcg of HA per dose). The 2017 H7N9 IIV was manufactured using a reverse 
genetics -derived reassortant candidate vaccine virus IDCDC RG56B (H7N9), containing the HA 
and NA from low pathogenic influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, 
NP, M and NS from A/Puerto Rico/8/1934 (H1N1). 
Subjects who are in good health and meet all eligibility criteria (including an erythrocyte 
sedimentat ion rate [ESR], urine or serum pregnancy test, history and physical exam) within 28 
days prior to the first vaccination or on the day of, but prior to, first vaccination, will be 
randomized into one of 5 study groups, stratified by age as shown in Table 1. Baseline clinical 
safety laboratories will be drawn prior to the first vaccine dose and will not be used to screen 
subjects for eligibility . 
Reactogenicity will be measured by the occurrence of solicited injection site and systemic 
reactions from the time of each study vaccination through 7 days after each study vaccination. 
Unsolicited non- serious AEs will be collected from the time of each study vaccination through 
approximately 21 days after each study vaccination. SAEs, MAAEs, including NOCMCs, and 
PIMMCs,  will be collected from the time of the first study vaccination through approximately 12 
months after the last study vaccination. Clinical laboratory evaluations for safety will be 
performed on venous blood collected prior to each study vaccination and approximately 7 days 
after each study vaccination.  
Immunogenicity testing will include performing HAI and Neut antibody assays against the 2017 
H7N9 vaccine virus on serum samples obtained i mmediately prior to each study vaccination 
(Days 1 and approximately Day 22), approximately 7 days after each study vaccination (Days 8 
and 29), and approximately 21 and 180 days after the second study vaccination (Days 43 and 202). 
Novel methods for ident ifying and assessing alternative correlates of protection against influenza 
infection are needed.  To assess the NA specific antibody response to vaccination, it is first 
necessary to determine the NA content of inactivated influenza vaccine; this assay is  under 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
43 development.  If successful, the NA content in a dosage specific manner can be correlated to the 
N9 NA-specific antibody responses elicited by the 2017 H7N9 IIV. 
Subjects who have not received licensed 2017-2018 seasonal trivalent or quadrivalent inactivated 
influenza vaccine (IIV3 or IIV4, including high dose vaccine for the elderly) prior to being 
enrolled in the study may receive it anytime following completion of the Day 43 study visit or 
upon early termination.  
For additional details on study procedures and evaluations and study schedule by study 
visits/days , see Sections 7 and 8 and  Appendix A : Schedule of Study Procedures and 
Evaluations. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
44 5 STUDY ENROLLMENT AND  WITHDRAWAL 
Approximately 400 (up to 420) individuals 19-64 years old, and approximately 240 (up to 300) 
greater than or equal to ( ≥) 65 years old, males and non -pregnant females, who are in good 
health by history and meet all eligibility criteria , will be enrolled at up to 9 VTEU sites 
participating in this trial. The target population should reflect the community at large at each of 
the participating VTEU sites.  Estimated time to complete enrollment in this trial is 
approximately  12 weeks.  Information regarding th is trial may be provided to potential subjects 
who have previously participated in vaccine trials conducted at the participating VTEU sites.  
Other forms and/or mechanisms of recruitment may also be used.  The local Institutional Review 
Board ( IRB) will approve all materials prior to use.  
Subject Inclusion and Exclusion Criteria must be assessed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-investigator.  
No exemptions are gran ted on Subject Inclusion or Exclusion Criteria in DMID -sponsored 
studies. Questions about eligibility should be directed toward the DMID Medical Officer. 
5.1 Eligibility Criteria  
5.1.1 Subject Inclusion Criteria  
Subjects eligible to participate  in this trial must meet all of the following inclusion criteria: 
1. Provide written informed consent prior to initiation of any study procedures. 
2. Are able to understand and comply with planned study procedures and be available for all study visits.  
3. Are males or non -pregna nt females, 19 years of age and older, inclusive. 
4. Are in good health
1. 
1As determined by medical history and  physical examination to evaluate acute or currently ongoing chronic medical 
diagnoses or conditions, defined as those that have been present for at  least 90 days, which would affect the assessment 
of the safety of subjects or the immunogenicity of study vaccinations.  Chronic medical diagnoses or conditions should 
be stable for the last 60 days  (no hospitalizations, ER, or urgent care for condition and no adverse symptoms that need 
medical intervention such as medication change/supplemental oxygen) . This includes no change in chronic prescription 
medication, dose, or frequency as a result of deterioration of the chronic medical diagnosis or condition in the 60 days 
prior to enrollment.  Any prescription change that is due to change of health care provider, insurance company, etc., or 
that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this  
inclusion criterion.  Any change in prescription medication due to improvement  of a disease outcome, as determined by 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
45 the site principal investigator or appropriate sub-investigator, will not be considered a deviation of this inclusion 
criterion.  Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator 
or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity  and do not indicate a worsening of medical diagnosis or condition. Similarly, medication changes 
subsequent to enrollment and study vaccination are acceptable provided there was no deterioration in the subject’s chronic medical condition that necessitated a medication change , and there is no additional risk to the subject or 
interference with the evaluation of responses to study vaccination.  Note: Topical, nasal, and inhaled medications (with 
the exception of inhaled corticosteroids as outlined in the Subject Exclusion Criteria (see Section 5.1.2 ), herbals, 
vitamins, and supplements are permitted.  
5. Oral temperature is less than 100 .0°F.  
6. Pulse is 47 to 100 bpm, inclusive. 
7. Systolic blood pr essure is 85 to 150 mm Hg, inclusive (subjects <65 years of age), 85 to 
160 mmHg, inclusive (subjects > 65 years of age). 
8. Diastolic blood pressure is 55 to 95 mmHg, inclusive. 
9. Erythrocyte sedimentation rate (ESR) is less than 30 mm per hour. 
10. Women of childbearing potential2 must use an acceptable contraception method3 from 30 
days before first study vaccination until 60 days after last study vaccination. 
2Not sterilized via tubal ligation, bilateral oophorectomy, salpingectomy , hysterectomy, or successful Essure® 
placement (permanent, non-surgical, non- hormonal sterilization) with documented radiological confirmation test at 
least 90 days after the procedure, and still menstruating or < 1 year of the last menses if menopausal.  
3Includes, , non-male sexual relationships, abstinence  from sexual intercourse with a male partner,  monogamous 
relationship with vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving 
the first study vaccination, barrier methods such as condoms or diaphragms with spermicide or foam, effective 
intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, injectables , or oral contraceptives 
(“the pill”).  
11. Women of childbearing potential must have a negative urine or serum pregnancy test 
within 24 hours prior to study vaccination. 
5.1.2 Subject Exclusion Criteria  
Subjects eligible to participate in this trial must not meet any of the following exclusion criteria:  
1. Have an acute illness4, as determined by the site principal  investigator or appropriate sub-
investigator, within 72 hours prior to study vaccination. 
4An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion 
of the site principal investigator or appropri ate sub -investigator, the residual symptoms will not interfere with the 
ability to assess safety parameters as required by the protocol.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
46 2. Have any medical disease or condition that, in the opinion of the site principal 
investigator or appropriate sub-invest igator, is a contraindication to study participation5. 
5Including acute or chronic medical disease or condition, defined as persisting for at least 90 days , that would place 
the subject at an unacceptable risk of injury, render the subject unable to meet t he requirements of the protocol, or may 
interfere with the evaluation of responses or the subject’s successful completion of this trial. 
3. Have immunosuppression as a result of an underlying illness or treatment, a recent 
history or current use of immunosuppressive or immunomodulating disease therapy.  
4. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination. 
5. Have known active neoplastic disease or a history of any hematologic malignancy.  Non-
melanoma , treated,  skin cancers are permitted.  
6. Have known human immunodeficiency virus ( HIV), hepatitis B, or hepatitis C infection.  
7. Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene- based 
adjuvants, or other components of the study vaccine. 
8. Have a history of severe reactions following previous immunization with licensed or unlicensed influenza vaccines.  
9. Have a personal or family history of narcolepsy.  
10. Have a history of Guillain -Barré syndrome.  
11. Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.  
12. Have a history of PIMMCs
6 
6Refer to Appendix  B: List of Potentially Immune -Mediated Medical Conditions.  
13. Have a history o f alcohol or drug abuse within 5 years prior to study vaccination. 
14. Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other psychiatric 
diagnosis that may interfere with subject compliance or safety evaluations.  
15. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement 
for danger to self or others within 10 years prior to study vaccination. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
47 16. Have taken oral or parenteral (including intra -articular) corticosteroids of any dose within 
30 days prior to study vaccination. 
17. Have taken high -dose inhaled corticosteroids7 within 30 days prior to each study 
vaccination.  
7High -dose defined as per age as using inhaled high dose per reference chart https://www.nhlbi.nih.gov/health-
pro/guidelines/current/asthma -guidelines/quick -reference-html#estimated -comparative -daily -doses   
18. Received a licensed live vaccine within 30 days prior to the first study vaccination, or 
plan to receive a licensed live vacci ne within 30 days before or after each study 
vaccination.  
19. Received or plan to receive a licensed , inactivated , vaccine ( excluding all flu vaccines ) 
within 14 days before or after each study vaccination.  
20. Received or plan to receive an inactivated seasonal flu vaccine within  21 days before or 
after each study vaccination.  
21. Received immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90 days prior to each  study vaccination. 
22. Received an experimental agen t
8 within 30 days prior to the first study vaccination, or 
expect to receive an experimental agent9 during the 13- month trial-reporting period. 
8Including vaccine, drug, biologic, device, blood product, or medication.  
9Other than from participation in this  trial.  
23. Are participating or plan to participate in another clinical trial with an interventional agent
10 that will be received during the 13- month trial-reporting period. 
10Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication.  
24. Received or plan to receive an influenza A/H7 vaccine11 or have a history of influenza 
A/H7 subtype infection .  
11And assigned to a group receiving influenza A/H7 vaccine, does not apply to documented placebo recipients.  
25. Have traveled to mai nland China and had substantial12 direct contact with live or freshly 
slaughtered poultry or pigeons within the past five years . 
12substantial contact is defined as visited a poultry farm and/or a live poultry market.  
26. Occupational exposure to or substanti al direct physical contact13 with birds in the past 
year and through the 21 days after the second study vaccination. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
48 13Exposure to free range chickens in the yard is exclusion ary. Casual contact with birds at petting zoos or county or 
state fairs or having  pet birds does not exclude subjects from study participation.  
27. Female subjects who are breastfeeding or plan to breastfeed at any given time from the 
first study vaccination until 30 days after the last study vaccination.  
28. Plan to travel outside the US (continental US, Hawaii, and Alaska) from enrollment 
through 21 days after the second study vaccination. 
5.2 Treatment Assignment Procedures  
5.2.1 Enrollment and Randomization Procedures  
Per ICH guideline E6: Good Clinical Practice (GCP), screening records will be kept at each participating VTEU site to document the reason why an individual was screened, but failed trial entry criteria.  The reasons why individuals failed screening will be recorded in the Statistical and 
Data Coordinating Center’s (SDCC) AdvantageEDC
SM (Electronic Data Capture System) . 
Once consented and upon entry of demographic data and confirmation of eligibility for this  trial, 
the subject will be enrolled , randomly assigned to 1 of 5 treatment groups . All subjects will 
receive 2 vaccinations; the same dose will be given to the subject at both the first and second 
vaccination. Subjects will be randomized with allocation 2:2:2:1:1  into 5 groups , stratified by 
site and age ( see Table 1) to receive IM 2017 H7N9 IIV at 3.75 mcg, 7.5 mcg  or 15 mcg at Days 
1 and 22 wit h AS03 adjuvant or 15 mcg or 45 mcg at Days 1 and 22 administered without 
adjuvant. 
Enrollment of subjects will be done online using the enrollment module of AdvantageEDCSM. 
The randomization code will be prepared by statisticians at the SDCC and included in the 
enrollment module for th is trial.  AdvantageEDCSM will assign each subject to a treatment arm 
after the demographic and eligibility data have been entered into the system.  A designated 
individual at each participating VTEU site will be provided with a code list for emergency 
unblinding purposes, which will be kept in a secure place. Instructions for use of the enrollment module are included in the AdvantageEDC
SM User’s 
Guide. Manual back -up procedures and instructions are provided for use in the event that a 
participating VTEU site temporarily loses access to the Internet or the online enrollment system 
is unavailable.  
Over -enrollment is allowed to account for subjects who do not receive the full schedule of study 
vaccinations , as shown in Table 1. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
49 5.2.2 Masking Procedures  
This is a double-blind clinical trial. 
Subjects, investigators, study personnel performing any study- related assessments following 
study vaccine administration  are blinded to study treatment. Laboratory personnel performing 
HAI and  Neut antibody assays will receive serum samples  blinded to subject ID number and 
sample visit number . 
The randomization scheme will be generated by the SDCC and provided to unblinded study 
personnel (i.e., research pharmacist s performing study vaccination  preparation s and unblinded 
study vaccine administrator s) at the participating VTEU sites.  
The unblinded study vaccine administrator is a study personnel member credentialed  to 
administer vaccines and may also participate in dose preparation, but will not be involved in study- related assessments or have subject contact for data collection following study vaccine 
administration.  
The Data and Safety Monitoring Board ( DSMB ) may receive data in aggregate and presented by 
treatment arm. The DSMB may also be provided with expected and observed rates of the 
expected AEs in an unblinded fashion, and may request the treatment arm be unblinded for an 
individual subject if required for safety assessment. The DSMB will review grouped and unblinded data in the closed session only. 
5.2.3 Reasons for Withdrawals and Discontinuation of Treatment 
Subjects may voluntarily withdraw their consent for trial participation at any time and for any 
reason, without penalty. 
A subject may withdraw or be withdrawn from this  trial for any of the following reasons: 
• Medical disease or condition, or any new clinical finding for which continued 
participation, in the opinion of the site principal investigator or appropriate sub-investigator, would compromise the safety of the subject, or would interfere with the subject's successful completion of this  trial, or would interfere with the evaluation of 
responses (for example, has baseline significant laboratory abnormalities).  
• Subject no longer meets eligibility criteria  (see Section 5.1). N ote: Medication changes  in 
the 60 days prior to enrollment , as specified in Subject Inclusion Criterion #4, are 
exclusionary for receipt of the first study vaccin ation only. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
50 • As deemed necessary by the site principal investigator or appropriate sub- investigator for 
noncompliance or other reasons. 
• Subject withdrawal of consent. 
• Subject l ost to follow-up. 
• Termination of this  trial. 
• New information becomes available that makes further participation unsafe. 
The second study vaccination will not be administered to a subject if any of the following criteria 
are met : 
• Medical condition or medication change for which continued participation, in the opinion 
of the site principal investigator or appropriate sub-investigator, would pose a risk to the 
subject or would be likely to confound interpretation of the results. 
• Presence of signs or symptoms that could confound or confuse assessment of study vaccine reactogenicity.  For s ubjects with injection site or systemic signs or symptoms , or 
with an acute illness, including an oral temperature greater than or equal to 100°F, the second  study vaccination should be postponed/deferred until signs, symptoms , or acute 
illness  have resolved , or are improving as further specified below, and if within the 
acceptable protocol-specified window for that visit (Day 22+7).). No exceptions to the protocol-specified window will be made . Note for afebrile, acute illness only:  If a 
subject is afebrile, his/her acute illness is nearly resolved with only minor residual 
symptoms remaining, this occurs within the acceptable protocol- specified  window for 
that visit (Day 22+7) , and , in the opinion of the site principal investigator or appropriate 
sub-investigator, the residual symptoms will not interfere with the ability to assess safety 
parameters as required by the protocol, the subject may receive the second  study 
vaccination  without further approval from the DMID Medical Officer. No exceptions to 
the protocol-specified window will be made. Grade 3 solicited or unsolicited AE that is 
ongoing, whether or not it is improved or resolving.  
• Any unresolved or continuing Grade 2 AE that has not decreased in severity to Grade 1 
or less.   
• An unresolved or continuing Grade 1 AE is permissible following the documented determination by the site PI or appropriate sub-investigator, that it would not render study 
vaccination unsafe or interfere with the evaluation of responses. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
51 • Grade 3 solicited or unsolicited AE  that occurs without alternative etiology in the 8 days 
following the first study vaccination.  
• Grade 3 clinical safety laboratory value (according to the toxicity table, Section 9.2.3) 
that does not decrease to Grade 2 or less prior to the second  study vaccination. Any 
clinical safety laboratory parameter may be re- evaluated only once at the central (clinical) 
laboratory in order to assess eligibility prior to the second study vaccination. If the 
clinical safety laboratory value decreases to Grade 2 or less, the subject may receive the 
second study vaccination. The second study vaccination should be scheduled to occur 
within the acceptable protocol-specified window for that visit (Day 22+7 days post first 
study vaccination). No exceptions to the protocol- specified window will be made . 
• New onset of illness or condition that meets the Subject E xclusion C riteria  (see Section 
5.1.2). 
• Hospitalization that occurs before administration of the second study vaccination.  
• Subject no longer meets eligibility criteria  (see Section 5.1). Note: Medication changes 
subsequent to the first study vaccination are not exclusionary for receipt of the second 
study vaccination provided there was no deterioration in the subject’s chro nic medical 
condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccination. 
• As deemed necessary by the site principal investigator or appropriate sub- investigator for 
noncompliance or other reasons. 
• Subject  refusal of further study vaccination. 
• Subject withdrawal of consent. 
• Subject l ost to follow-up. 
• Termination of this  trial. 
• New information becomes available that makes further participation unsafe. 
5.2.4 Handling of Withdrawals and Discontinuation of Treatment  
The primary reason for withdrawal from this  trial will be recorded on the Study Status data 
collection form. Subjects will be encouraged to complete the Early Termination Visit.  The Early 
Termination Visit procedures are listed in  Section 8.2.11. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
52 Although subjects are free to withdraw at any time or may be withdrawn by the site principal 
investigator or appropriate sub- investigator at any time  (see Section 5.2.3), those subjects who 
receive only one dose of study vaccine will be encouraged to remain in this trial for follow -up 
safety assessments (may be conducted by phone call rather than in person) continuing through 
approximately 12 months after the ir last study vaccination . These subjects will also be 
encouraged to provide a venous blood sample for immunogenicity assays at approximately 21 
days and 180 days after the ir last study vaccination , if applicable. See the protocol -specific 
Manual of Procedures (MOP) for alternate follow -up requirements. 
Every attempt will be ma de to follow all AEs, including solicited injection site and systemic 
reactions, unsolicited non-serious AEs , SAEs , MAAEs , including NOCMCs , and  PIMMCs, 
ongoing at the time of early withdrawal through resolution as per applicable collection times 
defined for the specific type of AE. 
In the case of subjects who fail to appear for a follow-up safety assessment, extensive effort (i.e., three documented contact attempts via phone calls made on separate occasions and followed by a 
certified letter) will be made to locate or recall them, or at least to determine their health status.  
These efforts wil l be documented in the subject’s study records.  
Subjects who withdraw, or are withdrawn or terminated from th is trial, or are lost to follow -up 
after signing the informed consent form, randomization, and receipt of study vaccine will not be 
replaced.   
5.2.5 Termination of Study  
Although the sponsor has every intention of completing this  trial, it reserves the right to 
terminate this  trial at any time for clinical or administrative reasons.  Reasons for termination 
include, but are not limited to, study closure due to DSMB review  and recommendation  and at 
the discretion of DMID. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
53 6 STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT 
6.1 Study Produc t Description  
2017 H7N9 IIV 
Sanofi Pasteur  has developed a monovalent 2017 H7N9 IIV  manufactured from a reverse 
genetics -derived reassortant virus containing the HA and NA from influenza A/Hong 
Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 
(H1N1) . The manufacturing process for the production of this monovalent 2017 H7N9 IIV is 
similar to the manufacturing process used to produce the licensed IIV Fluzone® family of 
products.  
 
 
 
 
 
PBS Diluent 
The PBS  diluent was  produced in accordance with the commercial process utilized in 
manufacture of  PBS buffer/diluent for the formulation of Fluzone®, influenza virus 
vaccine. 
AS03 Adjuvant [Adjuvant System AS(03)] 
 
6.1.1 Ac
quisition  
2017 H7N9 IIV will be provided by Sanofi Pasteur  under contract to BARDA/DHHS . 
The PBS diluent will be provided by Sanofi Pasteur under contract to BARDA/DHHS.  
AS03 adjuvant will be provided by GSK under contract to BARDA/DHHS . 

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
54 Upon request by DMID, 2017 H7N9 IIV, PBS diluent, and AS03  adjuvant will be transferred to 
the following address: 
DMID Clinical Materials Services  Contract  
Fisher BioServices  
20439 Seneca Meadows Parkway 
Germantown, MD 20876 
 
 
   
Sterile empty vials will be obtained by the DMID Clinical Materials Services (CMS ), Fisher 
BioServices . 
2017 H7N9 IIV, PBS diluent, AS03 adjuvant, and sterile empty vials for study vaccine 
preparation will be provided through the DMID CMS  to the participating VTEU sites prior to the 
start of this  trial upon request and with prior approval from DMID. Should the site principal 
investigator require additional 2017 H7N9 IIV, PBS diluent, AS03 adjuvant, or sterile e mpty 
vials during this trial, further instructions are provided in the protocol- specific MOP.  
6.1.2 Formulation, Storage, Packaging, and Labeling 
2017 H7N9 IIV 
Investigational influenza virus A/Hong Kong vaccine (H7N9), a monovalent type A inactivated 
vaccine for IM use, is a sterile suspension prepared from pandemic influenza virus candidate 
vaccine propagated in embryonated chicken eggs. The vaccine contains no preservative (thimerosal) . No components of this vaccine contain latex. It  is essentially clear and  slightly 
opalescent in color and supplied in single-dose glass vials . The vials must be stored at 2°C to 
8°C (36°F to 46°F). Do not freeze.  Vials will be provided with latex -free stoppers . 
 
  
  
  

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
55 Specific mixing instructions are included in the MOP to achieve specific dosages.  
PBS Diluent 
 
 
It is
 
essentially clear and slightly opalescent in color and must be stored at 2°C to 8°C (36°F to 46°F). 
Vials will be provided with latex -free stoppers . 
AS03 Adjuvant [Adjuvant System (03)] 
The AS03 adjuvant is supplied as a preservative -free, oil-in-water , whitish to yellowish 
homogenous milky liquid emulsion presented in a 3 mL Type I, single -use glass vials.  The vials 
must be stored at 2°C to 8°C (36°F to 46°F).  Do not freeze. Vials  will be provided with latex -
free stoppers.  
Each of these study products will be labeled according to manufacturer specifications and include the statement “Caution: New Drug Limited by Federal Law to Investigational Use.”  
Further details are included in the respective, applicable Investigator’s Brochures for the 2017 
H7N9 IIV, AS03 adjuvant, as well as in the protocol -specific MOP.  
Sterile empty vials will be provided with latex -free stoppers . 
6.1.3 Study Product Storage and Stability  Procedures  
The temperature of the storage unit must be manually recorded daily (excluding non-business 
days and holidays as applicable) and continuously monitored and  recorded during the duration of 
this trial per the participating VTEU site standard operating procedures  (SOPs) , and 
documentation will be maintained.  If the temperature fluctuates outside of the required range, the 
affected study product(s) must be quarantined at the correct storage temperature and labeled as 
‘Do Not Use’ (until further notice). The research pharmacist must alert the site principal 
investigator and study coordinator, if the temperature fluctuates outside of the required range. In 
the event the temperature fluctuates outside of the required range, including accidental deep-freezing or disruption of the cold chain, the affected study product(s) must not be administered. 
The site principal investigator or responsible person should immediately contact the DMID Product Support Team at DMIDProductSupportTeam@niaid.nih.gov for further instructions 
before any additional study vaccinations are administered . Based on the information collected, 
DMID and/or the manufacturer will determine whether the affected study product(s) can be used. 

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
56 If it cannot be used, the site will receive specific instructions on how to return the affected study 
product(s) to the DMID CMS  or destroy it on site.    
6.2 Dosage, Preparation , and Administration of Study Intervention/ 
Investigational Product  
See the protocol- specific MOP Appendi ces for detailed information on the preparation, labeling, 
storage, and administration of study vaccine for each treatment arm. Study vaccine preparation will be performed by the participating VTEU site research pharmacist  on the same day of study 
vaccine admi nistration . 
Visually inspect the 2017 H7N9 IIV, PBS diluent and  AS03 adjuvant upon receipt and prior to 
use. If the study product(s) appear (s) to have been damaged, contaminated or discolored, contain 
visible particulate matter   or if there are any concer ns regarding its integrity,  do NOT use the 
affected study product(s). The affected study product(s) must be quarantined at 2°C to 8°C (36°F 
to 46°F) and  labeled  as ‘Do Not Use’ (until further notice) . The site principal investigator or 
responsible person should immediately contact the DMID Product Support Team at 
DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical Project Manager for further 
instructions before any additional study vaccinations are a dministered . Based on the information 
collected, DMID and/or the manufacturer will determine whether the affected study product(s) can be used.  If it cannot be used, the site will receive specific instructions on how to return the 
affected study product(s) to the DMID CMS  or destroy it on site.  If the 2017 H7N9 IIV , PBS 
diluent or the AS03 adjuvant is  unusable, study personnel will use another vial  from the study 
supply. Replacement vials  may be requested by contacting DMID.  Additional instructions for 
quarantine and DMID c ontact information are provided in the protocol- specific MOP.  
For those doses that must be admixed with AS03 , visually inspect the 2017 H7N9 IIV /PBS 
diluent plus adjuvant admixture prior to use. The admixture will be milky in appearanc e. If it 
appears to have been damaged, contaminated or  discolored, contain visible particulate matter, or 
if there are any concerns regarding its integrity, do NOT use it. The affected 2017 H7N9 
IIV/PBS diluent plus adjuvant admixture must be quarantined at room temperature  and labeled 
as ‘Do Not Use’ (until further notice).  The site principal investigator or responsible person 
should immediately contact the DMID Product Support Team at 
DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical Project Manager  for further 
instructions before any additional study vaccinations are administered. Based on the information 
collected, DMID and/or the manufacturer will determine whether the 2017 H7N9 IIV /PBS 
diluent plus adjuvant admixture can be used.  If it cannot be used, the site will receive specific 
instructions on how to send the 2017 H7N9 IIV/PBS diluent plus adjuvant admixture to the DMID CMS  or destroy it on site.  If the 2017 H7N9 IIV/PBS diluent plus adjuvant admixture is 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
57 unusable, the participating VTEU site s’ research pharmacist will prepare another vial.  Additional 
instructions for quarantine and DMID contact information are provided in the protocol- specific 
MOP.  
For those doses that must be admixed with AS03 , the 2017 H7N9 IIV/PBS diluent plus adjuvant 
admi xture , once mixed, must be stored at room temperature in an upright position and must be 
used within 8 hours.  Gently invert the final mixed vial 5 to 7 times immediately before the 
single dose is withdrawn.  Do not shake the final mixed vial.  Only one dose should be 
withdrawn from the final mixed vial.  
Once mixed, the A/H7N9 unadjuvanted vaccine admixture for the 45 mcg/dose study group 
(Group 5) mu st be stored at 2°C to 8°C (36°F to 46°F) and must be used within 8 hours. 
Study vaccine administration will be performed by an unblinded study personnel member who is credentialed  to administer vaccines  and may also participate in dose preparation, but will not be 
involved in study-related assessments or have subject contact for data collection following stud y 
vaccine administration . Each dose of study vaccine will be administered via a single IM injection 
given in the deltoid muscle of the subjects’ preferred arm. The site of injection (right or left arm) will be recorded on the appropriate data collection form. Aseptic technique will be used for the 
withdrawal and administration of each dose of study vaccine using a disposable sterile needle 
appropriate in length for each subject and a disposable sterile 1-mL syringe. See the protocol-specific MOP for informa tion on how to administer IM injections. Each dose of study vaccine 
must be administered within 30 minutes of drawing into the syringe (not to exceed 8 hours total since admixing time) , and the prepared syringe must be stored at room temperature until 
admi nistered.  
Dose calculations are based on the actual HA content per 0.5 mL. Each 0.5 mL dose of AS03 
adjuvanted study vaccine contains one 0.25 mL dose of AS03 adjuvant. 
6.3 Modification of Study Intervention/Investigational Product for a 
Subject  
There will be  no dose modifications. If a subject’s second study vaccination is deferred, it should 
be rescheduled to occur within the acceptable protocol-specified window for that visit (Day 22+7 
days post first study vaccination). No exceptions to the protocol- specif ied window will be made. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
58 6.4 Accountability Procedures for the Study Intervention/ 
Investigational Product  
After receipt of the 2017 H7N9 IIV , PBS diluent, AS03 adjuvant, and sterile empty vials, the site 
principal investigator is responsible for study product distribution and disposition, and has 
ultimate responsibility for study product accountability.  The site principal investigator may 
delegate to the participating VTEU site s’ research pharmacist responsibility for study product 
accountability.  The participating VTEU site s’ research pharmacist will be responsible for 
maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study product (s). The study product 
accountability records and dispensing logs will also capture vial numbers, including final mixed vial number, date of study vaccine preparation/administration, time of study vaccine preparation, expiration of study vaccine preparation, time study vaccine is drawn into the syringe, and amount of study vaccine withdrawn for administration. Time of study vaccine administration to the 
subject will be captured on the appropriate data collection form. All study product (s), including 
the amount of 2017 H7N9 IIV, AS03 adjuvant, and admixture, whether administered or not, 
must be documented on the appropriate study product accountability record or dispensing log. 
The sponsor's monitoring staff will verify the participating VTEU sites’ study product 
accountability records and dispensing logs per the site monitoring plan. 
Used and unused vials of 2017 H7N9 IIV, PBS diluent, AS03 adjuvant, and admixture will be 
retained  until monitored and released for disposition as applicable. This can occur on an ongoing 
basis for used vials of 2017 H7N9 IIV, PBS diluent, AS03 adjuvant, and admixture. Used vials of A/H7N9 vaccine, PBS diluent, AS03 adjuvant and admixture may be destroyed in accordance with site -specific SOPs following each monitoring visit where Study  Product Accountability is 
monitored, and resolution of any discrepancies. Final disposition of the unused 2017 H7N9 IIV, 
PBS diluent, AS03 adjuvant, and sterile empty vials will be determined by DMID and 
communicated to the participating VTEU sites by the  DMID Clinical Project Manager.  
6.5 Assessment of Subject Compliance with Study Intervention/  
Investigational Product  
Study product will be administered to subjects by an unblinded study vaccine administrator via IM injection at all dosing times according to s ubject treatment assignment and as described in 
Section 6.2. Thus, subject compliance is not anticipated to be an issue. Deviations from the dose 
schedule may only occur as described in Section 6.3.
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
59 6.6 Concomitant Medications/Treatments  
Administration of any medications, therapies, or vaccines will be recorded on the appropriate 
data collection  form.  Concomitant medications will include all current medications and 
medications taken in the 60 days  prior to signing the informed consent form thro ugh 
approximately  21 days after the last  study vaccination  or early termination  (if prior to 21 days 
after the last study vaccination) , whichever occurs first. Medications reported in the electronic 
case report form (eCRF) are limited to those taken within 30 days prior to the first study 
vaccination through approximately 21 days after the last study vaccination. Prescription and over-the- counter drugs will be in cluded as well as herbals, vitamins , and supplements. In 
addition, receipt of non- study influenza vaccines will be solicited through approximately 180 
days after the last study vaccination , and reported in the eCRF. Use of a new medication should 
prompt evaluation for the occurrence of an y MAAE, including a new diagnosis of chronic 
medical disease or condition.  
Medications that might interfere with the evaluation of the investigational product(s) should not be used during the trial-reporting period (approximately 12 months after the last study vaccination) unless clinically indicated as part of the subject’s health care. Medications in this 
category include the prohibited medications per  the Subject E xclusion C riteria (see Section 
5.1.2). In addition, the site principal investigator or appropriate sub-investigator may identify other medications that should not be used due to a risk to subject safety or assessme nt of 
reactogenicity and immunogenicity . 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
60 7 STUDY PROCEDURES AND  EVALUATIONS 
7.1 Clinical Evaluations  
Complete medical history will be obtained by interview of subjects  at the  screening visit 
(optional) or on Day 1 prior to the first study vaccination . Subjects will be queried regarding a 
history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, 
cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic system, 
nervous system, blood, lymph nodes, endocrine system, musculoskeletal system, skin, and 
genital/reproductive tract.  A history of any allergies, cancer, immunodeficiency, psychiatric 
illness, substance abuse, and autoimmune disease will be solicited. Subjects will also be queried regarding a personal history and family history of narcolepsy. At follow -up visits after the first 
study vaccination, an interim medical history will be obtained by interview of subjects noting any changes since the previous clinic visit or contact . The interim medica l history should include 
an assessment for new medical conditions and symptoms suggestive of PIMMCs. 
Concomitant medications will be collected as described in Section 6.6. 
At the  screening visit (optional) or the baseline visit (Day 1) a physical examination  will be 
performed on all subjects to include the following organs and organ systems: including skin, head and neck, lungs, heart, liver, spleen, extremities, lymph nodes, and nervous system, by a 
study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site 
principal investigator or sub- investigator.  At follow-up visits afte r the first stud y vaccination , a 
targeted physical examination may be performed , if indicated based on the subject’s interim 
medical history,  by a study clinician licensed to make medical diagnoses and listed on the Form 
FDA 1572 as the site principal investigator or sub- investigator . Targeted physical examination s 
should also include an assessment for signs suggestive of PIMMCs. 
Vital signs (o ral temperature, pulse, and blood pressure) will be collected at the screening visit  
(optional) and prior to each study vaccination (Days 1 and 22). Vital signs assessed on Day 1 
prior to the first study vaccination will be considered as baseline. Subjects  must not eat or drink 
anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. 
Height and weight will be collected at the screening visit (optional) or on Day 1 prior to the first 
study vaccination for the calculation of Body Mas s Index ( BMI ). 
Reactogenicity assessments will include an assessment of solicited AEs occurring from the time  
of each study vaccination through Day 8 after each study vaccination, which includes an 
assessment of injection site reactions including pruritus (itching), ecchymosis (bruising), 
erythema (redness), induration (hardness), swelling, pain, and tenderness as well as systemic 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
61 reactions including fever, feverishness ( chills/shivering/sweating), fatigue (tired ness), malaise 
(general unwell feeling), myal gia (body aches/muscular pain exclusive of the injection site), 
arthralgia (joint pain exclusive of the injection site), headache, and nausea. Pre-administration 
reactogenicity assessments will be performed prior to each study vaccination to establish 
baseline, then the study vaccination will be given. 
Subjects will be observed in the clinic for at least 20 minutes after each study vaccination . The 
study vaccination site will be examined , post- administration reactogenicity assessments will be 
performed,  and any AE/SAEs will be recorded on the appropriate data collection form prior to 
discharge from the clinic.  The study vaccination site will also be examined approximately 7 days 
after each  study vaccination. 
All subjects will complete a subject memory aid from the time  of each study vaccination through 
7 days after each study vaccination.  Subject memory aids will be reviewed with the subjects for 
AEs (solicited injection site and systemic reactions  and unsolicited  AEs ) approximately 3 and 7 
days after each study vaccination via phone call (Day 4) and clinical visit (Day 8). 
7.2 Laboratory Evaluations  
7.2.1 Clinical Laboratory Evaluations 
Urine or serum pregnancy tests will be performed locally  by site laboratory at the screening visit 
(optional) and within 24 hours prior to each study vaccination on all women of childbearing 
potential.  Results must be negative and known prior to randomization on Day 1 and 
administration of each study vaccination to be eligible for participation in this trial and receipt of 
each study  vaccination . Erythrocyte sedimentation rate (ESR) will be collected from each subject 
at screening (optional) (within 28 days prior to the first study vaccination) or on Day 1 prior to 
study vaccination  to confirm trial eligibility . To be eligible for par ticipation in this trial and 
receipt of the first study vaccination , the subject’s ESR  evaluation must be confirmed to meet the 
eligibility criteria as outlined in the Subject Inclusion Criteria (see Section 5.1.1).  
• The ESR evaluation will be performed locally by the  site.  A venous blood sample 
(approximately 4 mL) will be collected from each subject at the baseline visit.  
Clinical safety laboratory parameters  (WBC,  Hgb, PLT, ALT, T. Bili, Cr ) will be collected from 
each subject  prior to each study  vaccination and approximately 7 days after each study 
vaccination. These evaluations will be performed by the central (clinical) laboratory.  Venous 
blood samples (approximately 10 mL) will be collected  for these safety labs.  The results from the 
clinical safety laboratory parameters collected on Day 1 will not be available or reviewed prior to 
study vaccination, and will serve as a safety baseline assessmen t only. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
62 The volume of venous blood to be collected for ESR as well as clinical safety laboratory 
evaluations is presented in Table 2. 
7.2.2 Special Assays or Procedures  
Immunogenicity  
Assays to determine serum levels of HAI and Neut antibodies will be performed at Southern  
Research . Venous blood samples (approximately 10 mL) for antibody assays will be collected 
from each subject immediately prior to each study vaccination (Day 1  and approximately Day 
22) and, approximately 7 days after each study vaccination (approximately Day 8 and Day 29), 
and approximately 21 days  and 180 days after the second study vaccination (approximately Day s 
43 and 202). Subjects who withdraw early will have HAI and Neut antibody assays run on 
available sera.  
Venous blood samples (10 mL) will also be collected for future use at the same time points. Sites 
may elect to allow subjects to consent to study participation but to have the option to opt out of 
the collection of the future use samples, or may include collection of future use samples as a condition of study participation and not allow the opt out option.  
The assays for determination of the NA content and antibodies to the NA are under development. 
If successful, the correlation of NA content in the 2017 H7N9 IIV with elicited N9 NA specific 
serum antibody responses may be assessed; no additional venous blood will be collected from subjects.  2017 H7N9 IIV and Adjuvant will be shipped from the DMID CMS  to the NA content 
assay designated laboratory for NA content assessment. Any laboratory involved with the determination of NA content or NA specific antibody responses will remain blinded to the HAI and Neut antibodies results performe d at Southern Research.  
Samples for interim immunogenicity assessments  (for HAI and Neut antibody assays) will be 
shipped from the DMID CMS  to Southern Research for post- study vaccination immunogenicity 
assessment at Visit 03, 06, and 07 once available for the first 25 subjects per adjuvanted 
treatment arm and 13 subjects per unadjuvanted treatment arm in the 19- 64 year -old age stratum  
and the first 15 subjects per adjuvanted treatment arm and 8 subjects per unadjuvanted treatment arm with in the ≥65 year-old age stratum. Following the last subject’s Visit 7, samples for all 
subject s for visits through Visit 7 (Day 43) will be shipped to Southern Research for the final 
HAI and Neut analysis. For subjects included in the interim assessments  new samples will be 
shipped and tested for the final analysis.  Following the last subject’s visit 10, samples f rom all 
subjects for visit 10 (Day 202) will be shipped to Southern Research for the final HAI and Neut analysis . 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
63 The volume of venous blood to be collected for immunogenicity assays and future research is 
presented in Table 2. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
64 Table 2: Venipuncture Volumes (mL):  
Study Visit 
Number  
V00 
V01 
V03 
V04 
V06 
V07 
V10 
Total 
(mL)  Study Day post 
first study 
vaccination  
Screening 
(Optional)   
D -28 to -1 
Enrollment 
and Dose 1  
D1 
D8+2d  
 D22+7d  
D29 
D43 
D202  
Study Day post 
second study 
vaccination  
 
 
 
Dose 2  
D1 
D8±3d 
D22+7d  
D181±14d  
Study Vaccination   X  X     
ESR 4^ 4^*      4  
Clinical Baseline 
and Safety 
Laboratory 
Evaluations~   
10† 10 10† 10   
40  
Immunogenicity 
Assays    10† 10 10† 10 10 10 60 
Serum Sample for 
Future Research#  10† 10 10† 10 10 10 60 
Total (mL)  (0) 4 (34) 30 30 30 30 20 20 164 
^ Drawn up to 28 days prior to  study vaccination. Results must be known and confirmed to meet the eligibility 
criterion prior to randomization and first study vaccination.    
~ Includes WBC, Hgb, PLT, ALT, T. Bili, C r. 
# Sites may elect to allow subjects to consent to study participation but to have the option to opt out of the collection 
of the future use samples, or may include collection of future use samples as a condition of study participation and 
not allow the opt out option.  
† All blood drawn immediately prior to study vaccination.  
* Not required if done at the optional screening visit  
7.2.3 Specimen Preparation, Handling, and Shipping  
7.2.3.1 Instruction s for Specimen Preparation, Handling , and Storage  
Instructions for specimen preparation, handling, and storage are included in the central (clinical) 
laboratory manual and protocol- specific MOP as appropriate.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
65 7.2.3.2 Specimen Shipment  
Specimen shipment will occur at intervals during the course of this trial following all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the central (clinical) laboratory manual and protocol- specific MOP as appropriate.  
Specimens for  safety laborato ry evaluations will be shipped from the participating VTEU sites to 
the central (clinical) laboratory.  
Specimens for HAI and Neut antibody assays will be shipped from the participating VTEU sites to the DMID CMS , and then provided by the DMID CMS  to Southern Research in a blinded 
manner.  
Specimens for the NA antibody assays will be shipped from the participating VTEU sites to the DMID CMS , and then provided by the DMID CMS  to the NA antibody assay laboratory once it 
has been identified. 
Further instru ctions for specimen shipment are included in the central (clinical) lab oratory 
manual and protocol- specific MOP, as appropriate. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
66 8 STUDY SCHEDULE  
Complete study schedule details listed by type of visit are described below.  Refer also to 
Sections 4 and 7 and Appendix A : Schedule of Study Procedures and Evaluations. 
8.1 Screening (Optional) and Enrollment Visit s 
8.1.1 Visit 00, Screening Clinic Visit (Optional) (Day -28 to -1) 
• Subjects will be provided with a description of this trial (purpose and study procedures) 
and asked to read and sign the informed consent form. The informed consent form will be signed prior to performing any study procedures, including administration of the first study vaccination. 
• Demog raphic information will be obtained by interview of subjects. 
• Eligibility criteria will be reviewed with subjects.  
• Complete medical history will be obtained by interview of subjects to ensure eligibility . 
• All concomitant medications taken within 60 days pr ior to signing the informed consent 
form  will be reviewed with subjects  to determine stability of chronic diseases and 
eligibility . Medications reported in the eCRF are limited to those taken within 30 days 
prior to the first study vaccination.  
• Subject receipt of licensed seasonal influenza vaccine over the previous two seasons, what type (inactivated or live attenuated), and approximate date of vaccination will be recorded on the appropriate data collection form, if known. Prior receipt of licensed season al influenza vaccine is not exclusionary, as long as it has been administered within 
the allowable window (see Section 5.1.2).  
 
• Subject receipt of non-seasonal influenza vaccines, including those that are experimental, 
what type (inactivated or live attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be recorded on the appropriate DCF, if known. Prior receipt of non- seasonal influenza vaccines are not exclusionary, except influenza A/H7 
vaccines (see Section 5.1.2).  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained to 
ensure eligibility prior to first study vaccination. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
67 • Height and weight will be collected for the calculation of BMI. 
• A physical examination will be performed on all subjects to include the following organs 
and organ systems: skin, head and neck, lungs, heart, liver, spleen, extr emities, lymph 
nodes, abdomen, g eneral appearance,  musculoskeletal   and nervous system and as 
assessment for signs suggestive of a PIMMC, by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or 
sub-investigator . 
• A urine or serum pregnancy test may be performed on all women of childbearing 
potential. Results must be negative to ensure eligibility.  
• Approximately 4 mL of venous blood will be collected for ESR, and performed locally by the site. The ESR value must be confirmed as less than 30 mm per hour prior to randomization and first study vaccination. 
8.1.2 Visit 01 Day 01, Enrollment (for subjects previously screened at Day -28 to - 1) 
and First Vaccination (Dose 1), Clinic Visit   
• Subje ct’s willingness to participate will be reconfirmed and documented in the subject’s 
study records prior to performing any further study procedures, including administration 
of the first study vaccination.  
• Eligibility criteria, including results of the ESR  will be reviewed .  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases,  and symptoms suggestive of PIMMCs, will be obtained by interview of 
subjects  prior to the study vaccination and any changes since the previous clinic visit or 
contact  will be noted . 
• All concomitant medications will be reviewed with subjects prior to the first study 
vaccination  for accuracy and completeness . Any new concomitant medications taken 
since the screening visit will be reviewed with subjects and assessed for continued eligibility prior to the first study vaccination .  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained to 
ensure eligibility prior to first study vaccination. Vital signs assessed on Day 1 prior to 
the first study vaccination will be considered as baseline. Subjects must not eat or drink 
anything hot or cold, or smoke within 10 minutes prior to taking ora l temperature.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
68 • A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed prior to the first study vaccination, if indicated based on review of complete medical history and any updates obtained by interview of subjects 
since the screening visit , by a study clinician licensed to make medical diagnoses and 
listed on the Form FDA 1572 as the site principal investigator or sub- investigator . 
• A urine or serum pregnancy test will be performed within 24 hours prior to the first study 
vaccination on all women of childbearing potential. Results must be negative and known 
prior to randomization and first study vaccination. 
• Subjects will be enrolled in AdvantageEDC
SM and assigned randomly to a treatment arm  
prior to the first study vaccination.  
• Pre-administration reactogenicity assessments will be performed prior to the first study 
vaccination to establish baseline.  
• Approximately 10 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline serum antibody assays. 
• Approximately 10 mL of venous blood will be collected immediately prior to the first study vaccination for baseline clinical safety labs ( WBC, Hgb, PLT, ALT, T. Bili, Cr ), 
and performed by the central (clinical) laboratory . The results from this blood draw will 
not be available or reviewed prior to study vaccination, and will serve as a safety baseline assessment only.  
• Approximately 10 mL of venous blood will be collected prior to study vaccination for 
future research from subjects who consent to collection of serum for future use , either by 
signing an informed consent form that includes collection of future use samples as a 
condition of study participation or by indicating that they opt in to sample collection for 
future use if the informed consent form allows the option to choose that option. 
• Subjects will then receive a single dose of study vaccine via IM injection into the deltoid muscle of the preferr ed arm. The site of injection (right or left arm) and time of 
administration will be recorded on the appropriate data collection form. Subjects will be observed in the clinic for at least 20 minutes after the first study vaccination. The first 
study vaccin ation site will be examined, post- administration reactogenicity assessments 
will be performed, and any AE/SAEs will be recorded on the appropriate data collection 
form  prior to discharge from the clinic.  
• Subjects will be provided with a memory aid and other study- related materials to record 
daily oral temperature, solicited injection site and systemic reactions, any unsolicited 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
69 AEs, and concomitant medications. Subjects will be encouraged to take their ora l 
temperature around the same time each day. Subjects must not eat or drink anything hot 
or cold, or smoke within 10 minutes prior to taking oral temperature. Subjects will be instructed on how to use their memory aid and how to measure and record AEs prior to discharge from the clinic. Subjects will be instructed to notify the study center if they 
develop any severe reactions after the first study vaccination. If the site principal 
investigator or appropriate sub-investigator deems the reaction severe enough, further instructions will be given to the subject on the proper course of action, including a return to the clinic for immediate evaluation if appropriate.  
8.1.3 Visit 01, Day 1, Enrollment /Baseline  (for subjects not previously screened at Day 
-28 to -1) and First Study Vaccination (Dose 1) , Clinic Visit  
• Subjects will be provided with a description of this trial (purpose and study procedures) and asked to read and sign the informed consent form. The informed consent form will be signed prior to performing any study procedures, including administration of the first study vaccination. 
• Demographic information will be obtained by interview of subjects. 
• Complete medical history will be  obtained by interview of subjects prior to the first study 
vaccination to ensure eligibility . 
• All concomitant medications taken within 60 days prior to signing the informed consent 
form will be reviewed with subjects . Medications reported in the eCRF are limited to 
those taken within 30 days prior to the first study vaccination. 
• Subject receipt of licensed seasonal influenza vaccine over the previous two seasons, 
what type (inactivated or live attenuated), and approximate date of  vaccination will be 
recorded on the appropriate data collection form, if known. Prior receipt of licensed 
seasonal influenza vaccine is not exclusionary, as long as it has been administered within the allowable window (see Section 5.1.2). Subject receipt of non- seasonal influenza 
vaccines, including those that are experimental, what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known. Prior receipt of non- seasonal influenza 
vaccines are not exclusionary, except influenza A/H7 vaccines (see Section 5.1.2).  
• Vital signs, including oral temperature, pulse, and blood pressure , will be obtained to 
ensure eligibility prior to first study vaccination. Vital signs assessed on Day 1 prior to 
the first study vaccination will be considered as baseline.  Subjects must not eat or drink 
anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
70 • Height and weight will be collected prior to the first study vaccination for the calculation 
of BMI.  
• A physical examination will be performed on all subjects to include the following organs 
and organ systems: skin, head and neck, lungs, heart, liver, spleen, extremities, lymph 
nodes, abdomen, g eneral appearance, musculoskeletal  and nervous system and as 
assessment for signs suggestive of a PIMMC, by a study clinician licensed to make 
medical diag noses and listed on the Form FDA 1572 as the site principal investigator or 
sub-investigator . 
• Approximately 4 mL of venous blood will be collected for ESR, and performed locally 
by the site. The ESR value must be confirmed as less than 30 mm per hour prior to 
randomization and first study vaccination. 
• Eligibility criteria, including results of ESR evaluation, will be reviewed with subjects 
prior to the first study vaccination to ensure continued eligibility. 
• A urine or serum pregnancy test will be performed within 24 hours prior to the first study vaccination on all women of childbearing potential. Results must be negative and known 
prior to randomization and first study vaccination. 
• Subjects will be enrolled in AdvantageEDC
SM and assigned randomly to a treatment arm 
prior to the first study vaccination.  
• Pre-administration reactogenicity assessments will be performed prior to the first study 
vaccination to establish baseline.  
• Approximately 10 mL of venous blood will be collected immediately prior to the firs t 
study vaccination for baseline serum antibody assays. 
• Approximately 10 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline clinical safety labs ( WBC, Hgb, PLT, ALT, T. Bili, Cr), 
and performed by the central  (clinical) laboratory . The results from this blood draw will 
not be available or reviewed prior to study vaccination, and will serve as a safety baseline 
assessment only.  
• Approximately 10 mL of venous blood will be collected prior to study vaccination for 
future research  from subjects who consent to collection of serum for future use, either by 
signing an informed consent form that includes collection of future use samples as a condition of study participation or by indicating that they opt in to sample collection for 
future use if the informed consent form allows the option to choose that option. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
71 • Subjects will then receive a single dose of study vaccine via IM injection into  the deltoid 
muscle of the preferred arm.  The s ite of injection (right or left arm)  and time of 
administration will be recorded on the appropriate data collection form. Subjects will be 
observed in the clinic for at least 20 minutes after the first study vaccination.  The first 
study vaccination site will be examined , post- administration reactogenicity assessments 
will be performed , and any AE/SAEs will be recorded on the appropriate data collection 
form  prior to discharge from the clinic. 
• Subjects will be provided with a memory aid and other study- related materials to record 
daily oral te mperature, solicited injection site and systemic reactions , any unsolicited 
AEs, and concomitant medications. Subjects  will be encouraged to take their oral 
temperature around the same time each day.  Subjects must not eat or drink anything hot 
or cold, or smoke within 10 minutes prior to taking oral temperature. Subjects will be 
instructed on how to use the ir memory aid and how to measure and record AEs prior to 
discharge from the clinic.  Subjects  will be instructed to notify the study center if they 
develop any severe reactions after the first study vaccination.  If the site principal 
investigator or appropriate sub-investigator deems the reaction severe enough, further instructions will be given to the subject on the proper course of action, including a return to the clinic for immediate evaluation if appropriate.  
8.2 Follow -up Visits 
Follow-up visits are scheduled in reference to study vaccination dates as indicated for each visit window. 
8.2.1 Visit 02, Day 4, Memory Aid Review, Phone Call 
(Window: Day 4±1 day post first study vaccination) 
Study personnel will contact subjects by phone to solicit any AE/SAE, medical history,  and 
concomitant medication information (including solicitation for receipt of any non- study 
influenza vaccines , including those that are experimental, what type (inactivated or live 
attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected.) and review information on their memory aid. Based on the information, subjects may be asked to return to 
the clinic for evaluation.  
  
8.2.2 Visit 03, Day 8, Clinic Visit  
(Window: Day 8+2 days po st first study vaccination) 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
72 • Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases,  and symptoms suggestive of PIMMCs, will be obtained by interview of 
subjects  and any changes since the previous clinic visit or contact  will be noted . 
• Memory ai d information will be reviewed with subjects.  
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines , including those that are e xperimental, what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected.) will be 
recorded on the appropriate data collection form. 
• All AE/SAEs will be recorded on the appropriate data collection form.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator or sub-investigator. 
• The first study vaccination site  will be examined . 
• Approximately 10 mL of venous blood will be collected for safety lab s, WBC, Hgb, PLT, 
ALT, T. Bili, Cr, and performed by the central (clinical) laboratory. 
• Approximately 10 mL of venous blood will be collected for serum  antibody assays.  
• Approximately 10 mL of venous blood will be collected for future research from subjects who consent to collection of serum for future use, either by signing an informed consent 
form that includes collection of future use samples as a condition of study participation or 
by indicating that they opt in to sample collection for future use if the informed consent 
form allows the option to choose that option. 
8.2.3 Visit 04, Day 22, Second Study Vaccination (Dose 2), Clinic Visit 
(Window: Day 22+7 days post first study vaccination) 
• Eligibility criteria will be reviewed with subjects  prior t o the second  study vaccination  to 
ensure continued eligibility . 
• For a subject to receive the second study vaccination, refer to section 5.2.3  for second 
vaccination eligibility criteria .   
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
73 • Interim medical history, including an assessment for new medical conditions stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  prior to the second study vaccination and any changes since the previous clinic 
visit or contact  will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines , including those that are experimental, what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected. Prior receipt of 
non-seasonal influenza vaccines are not exclusionary, except influenza A/H7 vaccines 
(see Section 5.1.2) will be recorded  on the appropriate data collection form prio r to the 
second study vaccination. 
• All AE/SAEs will be recorded on the appropriate data collection form.  
• Vital signs, including oral temperature, pulse, and blood pressure, will be obtained prior to the second study vaccination. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. Note: Vital signs are not required for subjects who are discontinued from receipt of the second study vaccination and are being followed for safety.  
• A targeted physical  examination , including an assessment for signs suggestive of 
PIMMCs, may be performed prior to the second study vaccination, if indicated based on review of interim medical history , by a study clinician licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-investigator . 
• A urine or serum pregnancy test will be performed within 24 hours prior to the second study vaccination on all women of childbearing potential. Results must be negative and known prior the second study vaccination. 
• Pre-administration reactogenicity assessments will be performed prior to the second study 
vaccination to establish baseline.  
• Approximately 10 mL of venous blood will be collected for safety labs WBC, Hgb, PLT, ALT, T. Bili, Cr, and performed by the central (clinical) laboratory. 
• Approximately 10 mL of venous blood will be collected immediately prior to the second 
study vaccination for serum  antibody assays. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
74 • Approximately 10 mL of venous blood will be collected immediately prio r to the second 
study vaccination for future research  from subjects who consent to collection of serum 
for future use , either by signing an informed consent form that includes collection of 
future use samples as a condition of study participation or by indicating that they opt in to 
sample collection for future use if the informed consent form allows the option to choose 
that option. 
• Subjects will then receive a single dose of study vaccine via IM injection into  the deltoid 
muscle of the preferred arm.  The second study vaccination may be given in the same 
preferred arm as long as there is no interference with the reactogenicity assessment.  The 
site of injection (right or left arm) and time of administration will be recorded on the 
appropriate data collect ion form. Subjects will be observed in the clinic for at least 20 
minutes after the second study vaccination. The second study vaccination site will be 
examined , post- administration reactogenicity assessments will be performed , and any 
AE/SAEs will be reco rded on the appropriate data collection form prior to discharge from 
the clinic.  
• Subjects will be provided with a memory aid and other study- related materials to record 
daily oral temperature, solicited injection site and systemic reactions, any unsolicited 
AEs, and concomitant medications. Subjects will be encouraged to take their oral 
temperature around the same time each day.  Subjects must not eat or drink anything hot 
or cold, or smoke within 10 minutes prior to taking oral temperature. Su bjects will be 
instructed on how to use the ir memory aid and how to measure and record AEs prior to 
discharge from the clinic.  Subjects will be instructed to notify the study center if they 
develop any severe reactions after the second  study vaccination. I f the site principal 
investigator or appropriate sub-investigator deems the reaction severe enough, further 
instructions will be given to the subject on the proper course of action, including a return 
to the clinic for immediate evaluation if appropriate.  
8.2.4 Visit 05, Day 25, Memory Aid Review, Phon e Call  
(Window: Day 4+1 day post second study vaccination) 
Study personnel will contact subjects  by phone to solicit any AE/SAE , medical history,  and 
concomitant medication information (including solicitation for receipt of any non- study 
influenza vaccines , including those that are experimental, what type (inactivated or live 
attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected.) and review 
information on their memory aid. Based on the information, subjects may be asked to return to the clinic for evaluation.  Note: For subjects who are di scontinued from the receipt of the second 
study vaccination, AEs will be limited to SAEs, MAAEs, including NOCMCs, and PIMMCs. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
75 8.2.5 Visit 06, Day 29, Clinic Visit  
(Window: Day 8+2 days post second study vaccination) 
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases,  and symptoms suggestive of PIMMCs, will be obtained by interview of 
subjects  and any changes since the previous clinic visit or contact  will be noted. 
• Memory aid information will be reviewed with subjects.  
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines , including those that are experimental, what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate dat e of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected.) will be 
recorded on the appropriate data collection form. 
• All AE/SAEs will be recorded on the appropriate data collection form. Note: for subjects 
who discontinued from the receipt of the second study vaccination, AEs will be limited to 
SAEs, MAAEs, including NOCMCs, and PIMMCs. 
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based o n review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator or sub-investigator. 
• The second study vaccination site will be examined.  
• Approximately 10 mL of venous blood will be collected for safety labs WBC, Hgb, PLT, 
ALT, T. Bili, Cr, and performed by the central (clinical) laboratory. 
• Approximately 10 mL of venous blood will be collected for serum  antibody assays.  
• Approximately 10 mL of venous blood will be collected for future research  from subjects 
who consent to collection of serum for future use, either by signing an informed consent 
form that includes collection of future use samples as a condition of study participation or 
by indicating that they opt in to sample collection for future use if the informed consent 
form allows the option to choose that option. 
8.2.6 Visit 07, Day 43, Clinic Visit 
(Window: Day 22+7 days post second study vaccination)  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
76 • Interim medical history, including an assessment for new medic al conditions , stability of 
chronic diseases,  and symptoms suggestive of PIMMCs, will be obtained by interview of 
subjects  and any changes since the previous clinic visit or contact  will be noted. 
• All concomitant medications (including solicitation for rec eipt of any non-study influenza 
vaccines , including those that are experimental, what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected.) will be 
recorded on the appropriate data collection form. 
• All AE/SAEs will be recorded on the appropriate data collection form. Note: for subjects 
who discontinued from the receipt of the second study vaccination, AEs will be limite d to 
SAEs, MAAEs, including NOCMCs, and PIMMCs. 
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator or sub-investigator. 
• Approximately 10 mL of venous blood will be collected for HAI and Neut antibody 
assays.   
• Approximately 10 mL of venous blood will be collected for fut ure research  from subjects 
who consent to collection of serum for future use, either by signing an informed consent 
form that includes collection of future use samples as a condition of study participation or 
by indicating that they opt in to sample collec tion for future use if the informed consent 
form allows the option to choose that option. 
8.2.7 Visit 08, Day 82, Safety Follow- up, Phone Call  
(Window: Day 61±7 days post second study vaccination) 
Subjects will be contacted by phone to query for safety events an d solicitation for receipt of any 
non-study influenza vaccines , including those that are experimental, what type (inactivated or 
live attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination 
will be recorded on the appropriate DCF, if known and not previously collected. Adverse events limited to MAAEs including NOCMCs , PIMMCS , and SAEs that have occurred since the 
previous clinic visit or contact  will be solicited. Based on the information, subjects may be asked 
to return to the clinic for evaluation. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
77 8.2.8 Visit 09, Day 142, Safety Follow- up, Phone Call  
(Window: Day 121±14 days post second study vaccination) 
Subjects  will be contacted by phone to query for safety events  and solicitation for receipt of any 
non-study influenza vaccines, including those that are experimental, what type (inactivated or 
live attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination 
will be record ed on the appropriate DCF, if known and not previously collected. Adverse events 
limited to MAAEs including NOCMCs , PIMMCs,  and SAEs that have occurred since the 
previous clinic visit or contact  will be solicited. Based on the information, subjects may be asked 
to return to the clinic for evaluation. 
8.2.9 Visit 10, Day 202, Safety Follow- up, Clinic Visit  
(Window: Day 181±14 days post second study vaccination) 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic medical diseases,  and symptoms suggestive of PIMMCs, will be obtained by 
interview of subjects and any changes since the previous clinic visit or contact  will be 
noted. 
• Receipt of any non -study influenza vaccines , including those that are experimental, what 
type (inactivated or live attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be recorded on the appropriate DCF, if known and 
not previously collected will be solicited.  
• Adverse events limited to MAAEs includin g NOCMCs , PIMMCs, and SAEs that have 
occurred since the previous clinic visit or contact  will be solicited   
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator or sub-investigator. 
• Approximately 10 mL of venous blood will be collected for serum  antibody assays.  
• Approximately 10 mL of venous blood will be collected for future research from subjects 
who consent to collection of serum for future use, either by signing an informed consent form that includes collection of future use samples as a condition of study participation or by indicating that they opt in to sample collection for future use if the informed consent 
form allows the option to choose that option.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
78 8.2.10 Visit 11, Day 387, Safety Follow- up, Phone Call  
(Window: Day 366±14 days post second study vaccination) 
Subjects will be contacted by phone to query for safety events. AEs  limited to MAAEs including 
NOCMCs , and PIMMCS, and SAEs that have occurred since the previous clinic visit or contact  
will be solicited . Based on the information, subjects may be asked to return to the clinic for 
evaluation. 
8.2.11 Early Termination Visit (if needed)  
The following activities will be performed at the early termination visit on subject s who 
withdraw, or are withdrawn or terminated from this  trial: 
• Interim medical history, including an assess ment for new medical conditions and 
symptoms suggestive of PIMMCs, will be obtained by interview of subjects and any 
changes since the previous clinic visit or contact  will be noted. 
• Memory aid information will be reviewed with subjects (if within 7 days after the last 
study vaccination). 
• All concomitant medications will be recorded on the appropriate data collection form (if 
within  21 days after the last study vaccination).  Receipt of any non -study influenza 
vaccine, including those that are experimental,  what type (inactivated or live attenuated), 
what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be 
recorded on the appropriate DCF, if known and not previously collected will be recorded if within  180 days after the second study vaccination. 
• All AE/SAEs will be recorded on the appropriate data collection form. AEs will be 
limited to SAEs , MAAEs , including NOCMCs , and PIMMCs that have occurred since 
the previous clinic visit or contact will be solicited  (if after 21 days after last study 
vaccination).   
• Vital signs, including oral temperature, pulse, and blood pressure, may be obtained if 
indicated.  Subjects must not eat or drink anything hot or cold, or smoke within 10 
minutes prior to taking oral temper ature.  
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site principal investigator or sub-investigator. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
79 • The study vaccination site will be examined (if within 7 days after the last study 
vaccination).  
• Post- administration reactogenicity assessments will be performed (if within 7 days after 
the last study vaccination). 
• Approximately 10 mL of venous blood will be collected for WBC, Hgb, PLT, ALT, T. 
Bili, C r, and performed by the central (clinical) laboratory (if within  7 days after the last 
study vaccination). 
• Approximately 10 mL of venous blood will be collected for serum  antibody assays (if 
within  21 days after the last  study vaccination).  
• Approximately 10 mL of venous blood will be collected for future research (if within 21 
days after the last study vaccination)  from subjects who consent to collection of serum for 
future use, either by signing an informed consent form that includes collection of future use samples as a condition of study participation or by indicating that they opt in to 
sample collection for future use if the informed consent form allows the option to choose 
that option.  
8.2.12 Unscheduled Visit (if needed)  
Unscheduled visits may occur at any time during this  trial. Any of th e following activities may 
be performed:  
• Interim medical history, including an assessment for new medical conditions and symptoms suggestive of PIMMCs, will be obtained by interview of subjects and any 
changes since the previous clinic visit or contact  will be noted (if indicated).  
• Memory aid inf ormation will be reviewed with subjects  (if within 7 days after the last 
study vaccination). 
• All concomitant medications will be recorded on the appropriate data collection form (if 
within  21 days after the last study vaccination).  Receipt of any non -study influenza 
vaccine, including those that are experimental, what type (inactivated or live attenuated), what subtype (e.g., A/H3, A/H5, A/H9) and approximate date of vaccination will be recorded on the appropriate DCF, if known and not previously collected will be recorded 
if within180 days after the second study vaccination. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
80 • All AE/SAEs will be recorded on the appropriate data collection form. AEs will be 
limited to SAEs , MAAEs , including NOCMCs , and  PIMMCs if after 21 days after the 
last study vaccination.  
• Vital signs, including oral temperature, pulse, and blood pressure, may be obtained if 
indicated.  Subjects must not eat or drink anything hot or cold, or smoke within 10 
minutes prior to taking oral temperature.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site principal investigator or sub-inves tigator.  
• The study vaccination site will be examined (if within 7 days after the last study 
vaccination).  
• Post- administration reactogenicity assessments will be performed (if within 7 days after 
the last study vaccination ). 
• Approximately 10 mL of venous blood will be collected for WBC, Hgb, PLT, ALT, T. Bili, Cr, and performed by the central (clinical) laboratory ( if indicated ). 
• Approximately 10 mL of venous blood will be collected for serum  antibody assays (if 
within 21 days after the last study vaccinatio n). 
• Approximately 10 mL of venous blood will be collected for future research  from subjects 
who consent to collection of serum for future use (if within 21 days after the last study 
vaccination) , either by signing an informed consent form that includes collection of 
future use samples as a condition of study participation or by indicating that they opt in to sample collection for future use if the informed consent form allows the option to choose that option. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
81 9 ASSESSMENT OF SAFETY  
9.1 Specification of Safety Parameters  
Safety will be assessed by the frequency and severity of:  
1. SAEs  occurring from the time of the first study vaccination through approximately 12 
months after the last study vaccination.  
2. Solicited AEs – reactogenicity events occurring from the time  of each study vaccination 
through 7 days after each study vaccination: 
a) Injection site reactions including pruritus, ecchymosis, erythema, induration/swelling, 
pain, and tenderness. 
b) Systemic reactions including  fever, feverishness, fatigue, malaise, myalgia, arthralgia, 
headache, and nausea.  
3. Clinical safety laboratory AEs occurring from the time of each study vaccination through 
approximately 7 days after each study vaccination.  Parameters to be evaluated include 
WBC, Hgb, PLT, ALT, T. Bili, Cr. 
4. Unsolicited  AEs  –non-serious AEs  occurring from the time of each study vaccination 
through approximately 21 days  after each  study vaccination . 
5. MAAEs , including NOCMCs , and PIMMCs occurring from the time of the first study 
vaccination through approximately 12 months after the last study vaccination.  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1 Adverse Events  
Adverse Event (AE):  (ICH) E6 defines an AE as any untoward medical occurrence in a patient 
or clinical investigation subject administered a pharmaceutical product regardless of its causal 
relationship to the study treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product.  The occurrence of an AE may come to the attention 
of study personnel during study visits and interviews of a study recipient presenting for medical 
care, or upon review by a study monitor. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
82 AEs, including solicite d injection site and systemic (subjective and quantitative) reactions, not 
meeting the protocol-defined crite ria for SAEs  will be captured on the appropriate data collection 
form and eCRF. Information to be collected for unsolicited non-serious AEs include s event 
description, date of onset, licensed study clinician’s assessment of severity and relationship to 
study product and alternate etiology (if not related to study product) (assessed only by those with 
the training and authority to make a diagnosis and listed on the Form FDA 1572 as the site 
principal investigator or sub-investigator), date of resolution of the event, seriousness, and outcome. AEs occurring during the trial collection and reporting period will be documented 
appropriately regardless of relationship. AEs will be followed through resolution. 
Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases, it will be recorded as an AE.  
AEs must be graded for severity and assessed for relationship to study product (see definitions below). AEs  characterized as intermittent require documentation of onset and duration of each 
episode. The start and stop date of each reported AE will be recorded on the appropriate data collection form and eCRF. 
FDA defines an AE as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related. 
New -Onset Chronic Medical  Conditions (NOCMCs) : NOCMCs  are defined as any new ICD -
10 diagnosis that is applied to the subject during the duration of the study, after receipt of the 
study agent, that is expected to continue for at least 3 months and requires continued health care intervention. 
Medically -Attended Adverse Events (MAAEs): For each unsolicited AE experienced, the 
subject will be asked if he/she had received medical attention, defined as hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel for any reason. AEs characterized by such unscheduled medical care will be designated as MAAEs.  
Potentially Immune- Mediated Medical Conditions (PIMMCs):  PIMMCs  constitute a group 
of AEs that includes diseases which are clearly autoimmun e in etiology and other inflammatory 
and/or neurologic disorders which may or may not have autoimmune etiologies. PIMMCs currently in effect are presented in Appendix B : List of PIMMCs. 
Severity of Event:  AEs will be assessed by a licensed study clinician  listed on the Form FDA 
1572 as the site principal investigator or appropriate sub-investigator using a protocol-defined grading system (see Section s 9.2.2 and 9.2.3).  For events not included in the protocol-defined 
gradi ng system, the following guidelines will be used to quantify severity: 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
83 • Mild (Grade 1): Events require minimal or no treatment and do not interfere with the 
subject’s  daily activities.  
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with 
therapeutic measures.  Moderate events may cause some interference with functioning and 
daily activities.  
• Severe (Grade 3) : Events interrupt the subject’s daily activities  and may require systemic 
drug therapy or other treatment. Severe events are usually incapacitating.  
Relationship to Study Product:  The licensed study clinician’s  assessment of an AE's 
relationship to study product is part of the documentation process, but it is not a factor in 
determining what is or is not reported in this  trial. If there is any doubt as to whether a clinical 
observation is an AE, the event should be reported. The relationship to study product must be 
assessed for AEs using the terms: related or not related.  In a clinical trial, the study product must 
always be suspect.  To help assess, the following guidelines are used: 
• Related  – There is a reasonable possibility that the study product caused the AE . 
Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study product and t he AE. 
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event. 
9.2.2 Reactogenicity  
Reactogenicity events are AEs that are common and known to occur following administration of  
this type of study vaccine . The following Toxicity Grading Scales will be used to grade solicited 
local (injection site) and systemic ( subjective and quantitative) reactions: 
Injection Site Reactogenicity  Grading  
Injection Site Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the 
injection site 
(spontaneous discomfort)  Subject is aware of pain , 
but it does not interfere 
with daily activity , and 
no pain medication is 
taken  Subject is aware of pain; 
there is interference with 
daily activity  or it 
requires repeated use of a 
non-narcotic pain reliever  
for >24 hours  Subject is aware of pain , 
and it prevents daily 
activity  or requires any use 
of a narcotic pain reliever  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
84 Injection Site Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Tenderness – hurts only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
interfe res with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Pruritus (Itching)  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activ ity 
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness)/Swelling*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
* Will also be measured in mm but size will not be used as halting criteria.  
 
Ecchymosis, erythema, and induration/swelling as analyzed by measurement will be graded as 
follows: 
Local (Injection Site) Reactogenicity  Measurements  
Local (Injection Site) Reaction  Small  Medium  Large  
Ecchymosis (Bruising)*  <20 mm 20 mm – 50 mm >50 mm 
Erythema (Redness)*  <20 mm 20 mm – 50 mm >50 mm 
Induration (Hardness)/Swelling*  <20 mm 20 mm – 50 mm >50 mm 
* Will not be used as halting criteria.  
Subjective Systemic Reactogenicity  Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(Chills/ Shivering/Sweating)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
85 Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fatigue (Tired ness) No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Malaise (General Unwell 
Feeling)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular Pain)*  No interference 
with daily activity  Some inter ference with 
daily activity  Significant interference, 
prevents daily activity  
Arthralgia (Joint Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Headache No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Nausea  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
* Not at injection site.  
 
Oral temperature# will be graded as follows: 
Quantitative Systemic Reactogenicity  Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* - oral† 38.0°C – 38.4°C  
100.4°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0 °F 
# Oral temperature  assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
* A fever can be considered not related to the study product if an alternative etiology can be documented.  
† Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature . 
9.2.3 Additional Adverse Event Severity Grading  
For Individuals 19-64 years of age, pulse and blood pressure# will be graded as follows: 
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute 45 – 46 40 – 44 <40 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
86 Tachycardia - beats per minute 101 – 130 131 – 155 >155  
Hypotension (systolic) mm Hg 80 – 84 75 – 79 <75 
Hypotension (diastolic) mmHg  50 – 54 45 – 49 <45 
Hypertension (systolic) mm Hg 151 – 155 156 – 160 >160  
Hypertension (diastolic) mm Hg 96 – 100 101 – 105 >105  
# Pulse and blood pressure assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
87  
For Individuals >65 years of age, pulse and blood pressure# will be graded as follows:  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia - beats per minute 45 – 46 40 – 44 <40 
Tachycardia - beats per minute 101 – 130 131 – 155 >155  
Hypotension (systolic) mm Hg  80 – 84 75 – 79 <75 
Hypotension (diastolic) mm Hg  50 – 54 45 – 49 <45 
Hypertension (systolic) mm Hg  161 – 165 166 – 170 >170  
Hypertension (diastolic) mm Hg  96 – 100 101 – 105 >105  
# Pulse and blood pressure assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
88 Clinical safety laboratory results# will be graded as follows: 
Clinical Safety Laboratory Adverse Event Grading# 
Hematology  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC 103/µL (Decrease)  2.5 – 3.9 1.5 – 2.4 <1.5 
WBC 103/µL (Increase)  10.6 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL (Decrease) (Female)  10.1 – 11.4 8.5 – 10 <8.5 
Hgb g/dL (Decrease) (Male)  11.0 – 12.4 9.5 – 10.9 <9.5 
Platelets 103/µL (Decrease)  125 – 139 100 – 124 <100  
Platelets 103/µL (Increase)  416 – 550 551– 750 >750  
    
Chemistry  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
ALT IU/L (Increase) (Female) 44 – 100 101 – 200 >200  
ALT IU/L (Increase) (Male)  61 – 138 139 – 275 >275  
Total Bilirubin mg/dL (Increase) – 
when accompanied by any increase in 
ALT 1.30 – 1.59 1.60 – 1.80 >1.80 
Total Bilirubin mg/dL (Increase) – 
when ALT is normal  1.30 – 1.89 1.90 – 2.40 >2.40 
Creatinine mg/dL (Increase) 
(Female)  1.1 – 1.7 1.8 – 2.0 >2.0 
Creatinine mg/dL (Increase) (Male)  1.4 – 1.7 1.8 – 2.0 >2.0 
# Clinical laboratory evaluations assessed on Day 1 prior to the first study vaccination  will be considered as 
baseline.  
9.2.4 Serious Adverse Events  
Serious Adverse Event (SAE) : An AE  or suspected adverse reaction is considered “serious” if, 
in the view of either the site principal investigator or sponsor, it results in any of the following 
outcomes: 
• Death,  
• A life-threatening AE*, 
• Inpatient hospitalization or prolongation of existing hospitalization,  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
89 • A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or 
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical 
judgment they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
* Life -threate ning AE. An AE  is considered “life- threatening” if, in the view of either the site 
principal investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.  It does not include an AE  that, had it occurred in a more severe form, might have caused 
death.  
SAEs will be: 
• Assessed for severity and relationship to study product and alternate etiology (if not 
related to study product) by a licensed study physician listed on the Form FDA 1572 as 
the site principal investigator or su b-investigator. 
• Recorded on the appropriate SAE form and eCRF. 
• Followed through resolution by a licensed study physician listed on the Form FDA 1572 
as the site principal investigator or sub -investigator. 
• Reviewed and evaluated by an Independent Safety Mon itor (ISM)  (as deemed necessary) , 
the DSMB  (periodic review unless related), DMID, and the IRB. 
9.2.5 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
The site principal investigator or appropriate sub-inves tigator is responsible for recording  all 
AE/SAEs that are observed or reported during this  trial, regardless of the relationship to study 
product. AE/SAEs , abnormal laboratory test values, or abnormal clinical findings will be 
collected, assessed, documented, reported, and followed appropriately, using a local laboratory 
as necessary . In determining eligibility, refer to section 5.2.3 and the protocol- specific MOP.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
90 9.3 Reporting Procedures  
Solicited injection site and systemic reactogenicity events will be documented and reported from 
the time of each study vaccination through 7 days after each study vaccination . 
Clinical safety laboratory AEs will be documented and reported from the time of each study 
vaccination through approximately 7 days after each study vaccination.  
Unsolicited non-serious AEs will be documented and reported from the time of each study 
vaccination through approximately 21 days  after each  study vaccination. 
SAEs , MAAEs , including NOCMCs , and PIMMCs  will be documented and reported from the 
time of the first study vaccination through approximately 12 months after the last  study 
vaccination . 
9.3.1 Serious Adverse Events  
Any AE that meets a protocol- defined serious criterion must be submitted immediately (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group at the 
following address:  
DMID Pharmacovigilance Group 
Clinical Research Operations and Management Suppo rt (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20817, USA 
 
 
 
In addition to the SAE form, selected SAE data fields must also be entered into 
Advanta
geEDCSM. Please see the protocol -specific MOP for details regarding this procedure. 
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance Group and should be provided as soon as possible. 
The site will send a copy of the SAE report (s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group. The DMID Medical Monitor and DMID 
Clinical Project Manager will be notified of the SAE  by the DMID Pharmacovigilance Group.  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and 
potential impact on study subject safety and protocol conduct. 

DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
91 At any time after completion of this  trial, if the site principal inve stigator or appropriate sub-
investigator becomes aware of an SAE that is suspected to be related to study product, the site 
principal investigator or appropriate sub-investigator will report the event to the DMID 
Pharmacovigilance Group.  
9.3.2 Regulatory Reporti ng for Studies Conducted Under DMID -Sponsored IND  
Following notification from the site principal investigator  or appropriate sub- investigator , 
DMID, the Investigational New Drug (IND) sponsor, will report any suspected adverse reaction that is both serious and unexpected. DMID will report an AE as a suspected adverse reaction 
only if there is evidence to suggest a causal relationship between the drug and the AE . DMID 
will notify FDA and all participating site principal investigators (i.e., all principal investigators to whom the sponsor is providing drug under its IND(s) or under any principal investigator’s IND(s)) in an IND safety report of potential serious risks from clinical trials or any other source, 
as soon as possible, but in no case later than 15 calendar days after the sponsor determines that 
the information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected fatal or life- threatening suspected adverse reaction as soon as possible, 
but in no case later than 7 calendar days after the sponsor’s initial receipt of the information.  
Relevant follow up information to an IND safety report will be submitted as soon as the information is available.  Upon request from FDA, DMID will submit to FDA any additional data 
or information that the agency deems necessary, as soon as possible, but in no case later than 15 
calendar days after receiving the request.  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least an nually in a summary format.  
9.3.3 Reporting of Pregnancy 
Pregnancies occurring in study subjects will be reported via AdvantageEDC
SM on the Pregnancy 
Report form.  No further study vaccinations will be administered to pregnant subjects, but with 
the subject’s per mission  all protocol- required  venous blood samples will be obtained and the 
subject will continue to be followed for safety for the duration of this  trial. Efforts will be made 
to follow all pregnancies reported during the course of this trial to pregnancy outcome pending the subject’s permission. 
9.4 Type and Duration of Follow -up of Subjects after Adverse Events  
AEs will be collected , assessed,  and followed through resolution from the time of each study 
vaccination through approximately 21 days  after each study vaccination. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
92 SAEs , MAAEs , including NOCMCs , and  PIMMCs  will be collected , assessed,  and followed 
from the time of the first study vaccination through  resolution even if this extends beyond the 
trial-reporting period (approximately 1 2 months after the last  study vaccination). 
Resolution of an AE/SAE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations, and outcomes will be recorded on the appropriate data collection form.  
9.5 Halting Rules  
Further enrollment and study vaccinations will be halted for DSMB review/recommendation if 
any of the following are reported:  
• Any subject experiences ulceration, abscess, or necrosis at the injection site related to 
study product administration. 
• Any 2 or more subjects experience laryngospasm, bronchospasm, or anaphylaxis within 1 
day after administration of study product that is considered related to study product. 
• Three or more subjects experience generalized urticaria (defined as occurring at more than two body parts) within 3 days after administration of study product that is 
considered related to study product. 
• Any subject experiences a study vaccine -related SAE from the time of the first study 
vaccination through the subject’s last study visit.  
• Any subject experiences acute weakness of limbs and/or cranial nerve innervated muscles 
(description of potential signal of GBS ) after administration of study product. 
• Any subject develops a PIMMC  after administration of study product. 
This trial will also be halted for DSMB review/recommendation if, within 7 days after 
administration of either study vaccination, any of the following occurs within the AS0 3-
adjuvanted treatment arms or within the two unadjuvanted treatment arms.  
 
• 7% or more of subjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to both vaccine administration, across all groups, 
experience the same severe (Grade 3) study vaccine-r elated injection site reaction.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
93 Ecchymosis, erythema, and induration/swelling will also be measured in mm but size will 
not be used as halting criteria.  
• 7% or more of subjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to both vaccine administration, across all groups, 
experience the same severe (Grade 3) study vaccine- related subjective systemic reaction, 
for which the severity (grade) is corroborated by study personnel. 
• 7% or more of subjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to both vaccine administration, across all groups, 
experience the same severe (Grade 3) study vaccine- related quantitative systemic 
reaction.  
• 7% or more of subject s (with a minimum of 3 subjects)  who received at least one dose of 
study vaccine to date, cumulative to both vaccine administration, across all groups, 
experience the same severe (Grade 3) study vaccine- related clinical safety laboratory AE. 
Grading scales  for solicited injection site and systemic (subjective and quantitative) reactions are 
included in Section 9.2.2. 
Grading scales for clinical safety laboratory AEs are included in Section 9.2.3. 
If any of the halting rules are met following any subject receipt of any study vaccination, then 
this trial will not continue with the remaining enrollments  or study vaccinations without a review 
by and recommendation from the DSMB  to proceed. 
DMID retains the authority to suspend additional enrollment and study interventions/ administration of study product during the entire trial, as applicable.  
The DMID Medical Monitor is empowered to stop enrollment and study vaccinations if AEs that meet the halting criteria are reported . 
9.6 Safety Oversight  
9.6.1 Independent Safety Monitor (ISM)  
The ISM is a physician with relevant  expertise whose primary responsibility is to provide 
independent safety monitoring in a timely fashion. For this trial an ISM is not required . 
However, at each participating VTEU site , and at the request of DMID, in real time, the principal 
investigator should be able to identify an independent physician to function as an ad hoc ISM. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
94 That person should have the privileges to examine the subject, review the subject’s medical and 
study records, and provide an independent medical assessment and recommendatio n to DMID.  
9.6.2 Data and Safety Monitoring Board (DSMB) 
Safety oversight will be co nducted by a DSMB  that is an independent group of experts that 
monitors subject safety and advises DMID. The DSMB members will be separate and 
independent of study personnel part icipating in this trial and should not have scientific, financial 
or other conflict of interest related to this  trial. The DSMB  will consist of members with 
appropriate expertise to contribute to the interpretation of the data from this trial.  The DSMB 
will operate under the rules of a DMID- approved charter that will be written at the organizational 
meeting of the DSMB. Procedures for DSMB reviews/meetings will be defined in the charter. 
Reports may include enrollment and demographic information, medical history, concomitant medications, physical assessments, clinical laboratory values, dosing compliance, and solicited 
and unsolicited AE/SAEs, HAI and Neut antibody assay results. The DSMB will review SAEs 
on a regular basis and ad hoc during this trial. The DMID Medical Monitor and the ISM (as 
deemed necessary) will be responsible for reviewing SAEs in real time.  
The DSMB  will conduct the following reviews: 
• Bi-monthly safety data reviews (including monthly safety data and cumulative safety 
data) until the last subject completes the visit that occurs approximately 21 days after the 
last study vaccination.  
• Interim analysis of serum antibody responses comparing venous blood samples collected 
at baseline, Visit 03, Visit 06, and Visit 07 for 25 subje cts per adjuvanted treatment arm 
and 13 subjects per unadjuvanted treatment arm within the 19- 64year -old stratum, and 
the first 15 subjects per adjuvanted treatment arm and 8 subjects per unadjuvanted treatment arm within the ≥65 year-old stratum. These re view s may be conducted as part 
of the scheduled monthly reviews or as the data become available. Reports will include data summarized by unblinded treatment arm, but the presentation will be in a format that 
prevents inadvertent unblinding of any individua l subjects.  
• Data review 9 days after all subjects have received Dose 2 (complete study visit number 
V06). This review may be conducted as part of the scheduled monthly reviews.  
• Ad hoc when a halting rule is met or DMID/DSMB chair may convene an ad hoc me eting 
if there are immediate concerns regarding observations during the course of this trial. 
• Final review meeting  may be held  6 to 8 months after clinical database lock to review the 
cumulative unblinded safety and immunogenicity data for this trial. If a final review 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
95 meeting is held, the data will be provided in a standard summary format. The DSMB may 
be asked to provide recommendations in response to questions posed by DMID. 
Additional data may be requested by the DSMB, and interim statistical reports may be generated 
as deemed necessary and appropriate by DMID. The DSMB may receive data in aggregate and presented by treatment arm. The DSMB may also be provided with expected and observed rates 
of the expected AEs in an unblinded fashion, and may reque st the treatment assignment be 
unblinded for an individual subject if required for safety assessment. The DSMB will review 
grouped and unblinded data in the closed session only. As an outcome of each review/meeting, the DSMB will make a recommendation as t o the advisability of proceeding with study 
vaccinations (as applicable), and to continue, modify, or terminate this trial. 
The DSMB  will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB . At this time, each data element that the DSMB  needs to 
assess will be clearly defined.  Procedures for DSMB  reviews/meetings will be defined in the 
charter.  The DSMB  will review applicable data to include , but not limited to , study progress and 
participant, clinical, safety and reactogenicity data . Reports may include enrollment and 
demographic information, medical history, concomitant medications, physical assessments , 
clinical laboratory values, dosing compliance, and solicited and unsolicited AE/SAEs , HAI and 
Neut antibody assay results . 
DMID or the DSMB  chair may convene the DSMB  on an ad hoc basis according to protocol 
criteria or if there are immediate concerns regarding observations during the course of this  trial. 
The DMID Medical Monitor is empowered to stop enrollment and study vaccinations if AEs that 
meet the halting criteria are reported.  The DMID Medical Monitor and the ISM (as deemed 
necessary) will be responsible for reviewing SAEs in real time.  The DSMB  will review SAEs on 
a regular basis and ad hoc during this  trial. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
96 10 CLINICAL MONITORING  
10.1 Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subjects’  protections, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations, and that this  trial is 
conducted in accordance with the protocol, protocol-specific MOP and applicable sponsor 
standard operating procedures. DMID, the sponsoring agency, or its designee will conduct site-
monitoring visits as detailed in the clinical monitoring plan.  
Site visits will be made at standard intervals as defined by DMID and may be made more 
frequently as directed by DMID.  Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, informed consent forms, medical and laboratory reports, and protocol and GCP compliance.  Site monitors will have access to each participating 
VTEU  site, study personnel, and all study documentation according to the DMID -approved site 
monitoring plan. Study monitors will meet with site principal investigators to discuss any problems and actions to be taken and document visit findings and discussions. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
97 11 STATISTICAL CONSIDERATIONS 
11.1 Introduction  
The goal of this clinical trial is to assess in healthy adults ages 19 – 64 and in healthy adults ages 
≥65 the safety, reactogenicity, and immunogenicity of a 2017 H7N9 IIV manufactured by Sanofi 
Pasteur administered intramuscularly at different dosages (3.75 mcg , 7.5 mcg and 15 mcg of HA 
per dose) given with AS03 adjuvant manufactured by GSK approximately 21 days apart, and two 
dose levels ( 15 or 45 mcg) administered without adjuvant approximately 21 days apart. These 
treatment arms are included to allow evaluation of antigen dosage as well as the potential of the 
adjuvant to enhance the immune response to the 2017 H7N9 IIV. 
11.2 Study Hypotheses  
This Phase II study is not designed to test a formal null hypothesis. Rather, it is intended to obtain sufficient data to obtain meaningful estimates of the immune response induced by this vaccine and to uncover any safety issues that occur at a sufficient ly high rate that they might be 
observed in a study of this size. The sample size facilitates formal testing of selected hypothese s 
as discussed in Section 11.4.3, along with the probability of observing safety outcomes and the 
precision of immunogenicity outcomes. 
11.3 Study Outcome Measures  
Please refer to study outcome measures in Section 3.2. 
11.4 Sample Size Considerations  
Please refer to study design outlined in Section 4. 
11.4.1 Study Population  
The study population for this clinical trial includes males and non-pregnant females, aged 19 
years and older, who are in good health and meet all eligibility criteria. The subjects will be recruited from the general population at the participating VTEU sites that have substantial experience conducting large influenza vaccine studies.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
98 11.4.2 Subject Enrollment and Follow -up 
Based on the accrual rate s observed in similar studies, it seems reasonable to expect that the 
participating VTEUs will be able to enroll this trial in a timely fashion. In previous DMID trials 
of A/H7N9 vaccines, 5 VTEUs recruited 975 healthy adults ages 19-64 in 10 weeks, and 10 
VTEU sites ( or sub-contracted sites) recruited 479 healthy adults ≥65 years old in 14 weeks. 
Prior experience suggests up to 5% of subjects ages 19 – 64, and 12% of subjects ages ≥65 may be excluded from the per protocol analysis for the primary immunogenicity outcome either because they did not receive the second study vaccination, were lost- to-follow-up, or because 
they had a protocol deviation requiring their exclusion from the per protocol analysis.  
Within the 19- 64 years age stratum, o ver enrollment up to 5% is allowed, to ensure a minimum 
of n=100 per adjuvanted treatment arm and n = 50 per unadjuvanted treatment arm are available 
for the primary immunogenicity analysis . Within the ≥65 years treatment arm a minimum of 60 
subjects are planned to enroll in each  adjuvanted treatment arm and a minimum of 30 subjects 
are planned  to enroll in each unadjuvanted treatment arm to ensure at least 50 subjects in each 
adjuvanted arm and 25 subjects in each unadjuvanted arm are available for analysis of the 
primary immunog enicity endpoint . Enrollment within this age stratum may continue up to 
approximately 75 subjects per adjuvanted arm and approximately  38 subjects per unadjuvanted 
arm. 
Follow-up will consist of 2 segments. The first encompasses the core data for this tria l and will 
consist of results for all study visits through approximately 21 days after the last study 
vaccination. The second segment consists of a 6-month immunogenicity assessment and follow-
up safety assessments through approximately 12 months after the last study vaccination. 
11.4.3 Sample Size  
This study is planned to enroll a minimum of  160 subjects in each adjuvanted treatment arm (100 
in 19- 64 years age stratum , 60 in ≥65 years stratum), and 80 subjects in each unadjuvanted 
treatment arm (50 in 19 -64 years  age stratum, 30 in ≥65 years stratum) . The sample size for this 
study was selected to obtain preliminary estimates in a time critical manner. While this study is 
not designed to test any specific null hypothesis, the following tables illustrate the precis ion and 
power that is available for select estimates and comparisons of interest.  
 
Table 3 indicates the probability of observing one or more safety events, such as solicited 
injection site or systemic reactogenicity events or  an unsolicited non- serious AE of a particular 
type for a single adjuvanted treatment arm/stratum (N = 60, or 100 ), for a single adjuvanted 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
99 treatment arm combined over age strata (N=160), for all subjects receiving unadjuvanted vaccine 
(N = 160), and for all subjects receiving adjuvanted vaccine (N = 480). 
Table 3: Power (%) to Detect Safety Events:  
Event  
Frequency  N = 60  N = 100 N = 160 N = 480 
≥10%  
Very Common  >99 >99 >99 >99 
≥1%  
Common  45 63 80 >99 
≥0.1%  
Uncommon  6 10 15 38 
≥0.01%  
Rare  <1 1 2 5 
Binomial confidence intervals (CI) are widest (have the least precision) when the response rate is 
50%. Table 4 is presented to indicate the worst case scenario for pr ecision of observed exact 
(Clopper- Pearson) binomial confidence intervals. 
Table 4: Precision of Binomial Confidence Intervals: 
N 95% CI  
60 37-63 
100 40-60 
160 42-58 
480 45-55 
Table 5 illustrates the minimum detectable differences in the proportion of subjects responding 
(e.g., attaining seroconversion or a titer ≥1:40) between two adjuvanted treatment arms within 
each stratum using a two -sided Likelihood Ratio Test and alpha = 0.05. 
Over enrollment is allowed as described in Section 11.4.3, to ensure a minimum of n=100 per 
adjuvanted treatment arm in the 19 -64 years age stratum, therefore power calculations will 
assume n=100 per group. Based on previous DMID A/H7N9 trials it is expected 5% of enrolled  
subjects in this stratum may be excluded from analysis of the primary endpoint. In the event that 
only 100 subjects are actually enrolled in a treatment arm, the small dropout rates anticipated 
would have a minimal impact on the calculations below.  
Within the ≥65 years treatment arm a dropout rate of up to 12% is expected based on previous 
DMID trials in this population, so a minimum of 60 subjects are planned to enroll in each treatment arm to ensure at least 50 are available for analysis of the primary immunogenicity endpoint. 
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
100 Table 5: Minimum Detectable Difference in Proportion Responders with 80% Power  
Assumed Proportion of subjects with titer 
≥40 in comparator arm 19-64 years stratum  
(N = 100) ≥65 years stratum  
(N = 50) 
0.40 0.19 0.27 
0.50 0.19 0.27 
0.60 0.18 0.25 
0.70 0.16 0.21 
0.80 0.13 0.16 
0.90 0.08 0.10 
Per FDA guidance, for differences in HAI antibody response rates, the lower confidence limit on 
the appropriate point estimate excluding equality (i.e., 0 for the difference parameter) may be 
sufficient to demonstrate the added value of the adjuvant. Table 6 and  Table 7 show the lower 
bound of the 95% confidence interval for the difference in the proportion responders between the 
adjuvanted and unadjuvanted arms (e.g. 15 mcg + AS03 minus 45 mcg unadjuvanted) assuming 
the proportion of responders in the unadjuvanted arm is 0.10 and considering a range for the 
proportion of responders in the adjuvanted arm ranges from 0.50 to 0.90.  
Table 6: Lower Confidence bound2 for difference in proportion of responders  
between Adjuvanted (N = 100) and unadjuvanted (N = 50) arms, 19- 64 years stratum  
Adjuvanted Arm Unadjuvanted  
Arm Difference  Lower Confidence 
Bound 
0.50 0.10 0.40 0.26 
0.60 0.10 0.50 0.36 
0.70 0.10 0.60 0.46 
0.80 0.10 0.70 0.56 
0.90 0.10 0.80 0.67 
 
Table 7: Lower Confidence bound2 for difference in proportion of responders  
between Adjuvanted (N = 50) and unadjuvanted (N = 25) arms, ≥65 years stratum  
Adjuvanted Arm Unadjuvanted  
Arm Difference  2:1 Allocation  
NUA=25 
0.50 0.10 0.40 0.19 
0.60 0.10 0.50 0.29 
0.70 0.10 0.60 0.39 
0.80 0.10 0.70 0.49 
0.90 0.10 0.80 0.60 
2. Farrington- Manning confidence limits.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
101 11.5 Planned Interim Analyses  
Interim analyses will only be used to terminate this trial in the event that unanticipated safety 
events deemed to be of sufficient concern require such action by the sponsor. These assessments 
will not be made on the basis of testing a formal statistical hypothesis; therefore, p- value 
adjustment will not be made to any analyses. A DSMB will be convened by DMID to review 
study progress and participant, clinical, safety, and reactogenicity and immunogenicity data as 
described in Section 9.6.2. 
An interim analysis of immunogenicity is planned, as described in Section 11.5.2, which includes a series of Expedited Interim Immunogenicity Reports of serum HAI and Neut antibody 
responses. This information will be reviewed due to the extraordinary need to inform public health decision makers in their preparations for their response to a potential 2017 A/H7N9 pandemic. Although interim immunogenicity results will not be used to make decisions concerning the conduct of this trial, they may be used to make decisions on activities external to 
this trial, e.g., designing future trials of the 2017 H7N9 IIV with and without AS03 adjuvant in 
other age groups. 
Additionally, a preliminary report of safety and immunogenicity data through Day 202, including 
a set of “topline” immunogenicity  and safety  tables produced on an expedited timeline, may  be 
prepared as described in section 11.6; though this report will be released while subjects remain in 
the trial for long -term safety follow -up, it will be consider ed the final analysis of these data.  
Emergent public health needs may dictate additional interim safety, reactogenicity, and/or immunogenicity analyses be performed on available information at any time during the trial. If 
this occurs, immunogenicity data will be analyzed as results are available from the central immunogenicity laboratory.  
11.5.1 Interim Safety Review  
An interim safety review  may include enrollment and demographic information, medical history, 
concomitant medications, physical assessments , clinical laboratory values, dosing compliance, 
and solicited and unsolicited AE/SAEs.  Additional data may be requested by the DSMB, and 
interim statistical reports may be generated as deemed necessary and appropriate by DMID.  The 
DSMB may receive data in aggregate and presented by treatment arm. The DSMB may also be 
provided with expected and observed rates of the expected AEs in an unblinded fashion, and may 
request the treatment assignment  be unblinded for an individual subject if required for safety 
assessment . The DSMB will review grouped and unblinded data in the closed session only. The 
DSMB will meet and review this data at scheduled time points or ad hoc as needed during this  
trial as defined in the DSMB charter.  As an outcome of each review/meeting,  the DSMB will 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
102 make a recommendation as to the advisability of proceeding with study vaccinations (as 
applicable), and to continue, modify, or terminate this  trial. 
Additionally, this  trial will be monitored to determine if any of the halting rules described in 
Section 9.5 are met.  
11.5.2 Interim Immunogenicity Review  
There is no plan to halt this trial prior to full enrollment and completion of all follow -up visits 
based on interim immunogenicity results.  
A series of E xpedited Interim Immunogenicity Reports of HAI and Neut  serum antibody 
responses comparing venous blood samples collected at baseline (D1), Visit 03 (D8), Visit 06 
(D29), and Visit 07 (D43) is planned. Reports will include HAI and Neut results for 
approximately  25 subjects per adjuvanted treatment arm and 13 subjects per unadjuvanted 
treatment arm within the 19-64year -old stratum and the first 15 subjects per adjuvanted treatment 
arm and 8 subjects per unadjuvanted treatment arm within the ≥65 year-old stratum. Reports will be prepared following each post-vaccination visit. This information will be reviewed due to the extraordinary need to inform public health decision makers in their preparations for their response to a potential 2017 A/H7N9 pandemic. These data will be archived by the SDCC, but 
will not be part of the final clinical database for this study, nor will they be made available to the 
clinical investigators for publication.  
Immune responses will be summarized in terms of strain -specific 2017 A/H7N9 HAI and Neut 
antibody titers and the rela tionship to study vaccine dosage and adjuvant use. It is anticipated 
that all analyses will be carried out in parallel for both assays , but reports may be prepared 
separately for HAI and Neuts if results are available on different timelines.  Interim analys es will 
focus on rates of titers ≥1:40, seroconversion (defined as either a pre-vaccination titer <1:10 and 
a post- vaccination titer ≥1:40 or a pre- vaccination titer ≥1:10 and a minimum four-fold rise in 
post- vaccination titer) and Geometric Mean Titers (G MTs), along with corresponding 95% 
confidence intervals. No formal hypothesis testing will be included in the interim analysis. 
Immunogenicity reports will be provided by the SDCC to the DMID Scientific Lead and Clinical 
Project manager, and the DSMB. Reports will include data summarized by unblinded treatment arm, but the presentation will be in a format that prevents inadvertent unblinding of any individual subject. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
103 11.6 Final Analysis Plan  
Clinical, safety, and reactogenicity data through approximately 180 da ys after the second study 
vaccination will represent the primary clinical database for this trial. Once the last subject 
completes the visit that occurs approximately 180 days after the last study vaccination, the 
primary clinical database may be cleaned, monitored, and locked, and all serum samples will be 
sent for vaccine-strain HAI and Neut antibody assays. Unblinded analyses of safety reactogenicity , and primary and secondary immunogenicity data are planned. A preliminary 
report may be prepared by the S DCC after the primary clinical database is locked  and all HAI 
and Neut data through 180 days after the last study vaccination are received .  
Regardless of whether a preliminary report is prepared, a “topline” subset of the immunogenicity and safety tables will be provided to DMID  on an expedited timeline following database lock, 
concurrently with preliminary report or CSR generation. These analyses may be made available 
to the sponsor for planning subsequent trials and to the lead principal investigator  for 
publication. These analyses will not be used to make any decisions concerning the conduct of this trial. As it is anticipated that subjects may  remain in long term safety follow -up at the time 
of these analyses, blinded investigators and DMID medical monitors not involved in  the analysis , 
publication, or clinical study report preparation will be responsible for assessing SAEs and MAAEs including PIMMCs and new onset chronic medical conditions until all subjects have completed the final follow -up visit. All  analyses of data included in the topline and preliminary 
report for early release will be considered the final analysis of these data, and also included in the 
final clinical study report (CSR).  
Analysis of exploratory immunogenicity endpoints may be performed and released as the data 
are available from the research  laboratory. Any such analyses would be considered the final 
analysis for the endpoint, and included in the CSR. The final CSR will be completed after  the 
last subject’s last visit is completed,  and the final clinical database including all long term safety 
follow-up data is cleaned, monitored and locked. Additional exploratory immunogenicity 
endpoint data not available at the time of CSR preparation may be included in an addendum to 
the CSR.  
A formal statistical analysis plan will be developed and finalized prior to unblinding for any 
interim analysis , which defines the analyses to be included in the Expedited Interim 
Immunogenicity Reports, P reliminary report, and the final CSR. 
11.6.1 Analysis Populations 
The Safety Analysis population includes all subjects who received at least one dose of study vaccine.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
104 The modified intent- to-treat ( mITT) population includes all subjects who received at least one 
dose of study vaccine and contributed both pre- and at least one post-study vaccination venous 
blood samples for immunogenicity testing (HAI or Neut antibody assays) for which valid results were reported. For analyses using the mITT population, subjects will be grouped based on randomized treatment arm .  
The per protocol (PP) population includes all subjects in the mITT subset with the following exclusions: 
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits subsequent to major protocol deviations, such a s: 
• Second study vaccination not received,  
• Second study vaccination received out of window, 
• Receipt of non- study licensed live vaccine within 30 days before or after each study 
vaccination,  
• Receipt of non- study licensed inactivated vaccine within 14 days before or after 
each study vaccination,  
• Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days before 
or after each study vaccination.  
• Data from any visit that occurs substantially out of window. 
For analyses using the PP population, subjects will be grouped based on study vaccinations 
received.  
11.6.2 Safety Data 
Summaries and analysis of safety data will be presented for the Safety Analysis Population. All summaries and analyses will be presented for all subjects, and by age stratum.  
Solicited AEs will be summarized by severity for each day after each study vaccination (Days 1 -
7 post each study vaccination) and as the maximum severity over all 8 days. Additionally, 
solicited AEs will be analyzed by taking the most severe response over the follow-up period, 
dichotomizing into a binary variable (none versus mild, moderate, or severe) and using standard techniques, such as exact confidence intervals, to summarize the proportion of subjects reporting 
each symptom, any injection site symptom, and a ny systemic symptom. Summaries of solicited 
AEs will be presented separately for each study vaccination as well as overall study vaccinations 
by treatment arm. The proportion of subjects reporting symptoms may be compared between 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
105 treatment arms using Chi-square or Fisher’s exact test. The proportion of subjects reporting 
solicited symptoms between the different study vaccinations (i.e., first and second) will be 
compared using McNemar’s test.  
Unsolicited AEs will be coded by Medical Dictionary for Regulator y Activities (MedDRA) for 
preferred term and system organ class (SOC). The numbers of SAEs, MAAEs, including NOCMCs, and PIMMCs are likely to be small in this trial and will be reported by detailed 
listings showing the event description, MedDRA
 preferred  term and SOC, relevant dates (study 
vaccinations and AEs), severity, relatedness, and outcome for each event. Non-serious 
unsolicited AEs will be summarized as number and percentage of subjects reporting at least one 
event in each MedDRA preferred term a nd SOC, cross tabulated by severity and relationship to 
study product. Additionally, the proportion of subjects and exact 95% confidence intervals of AEs in aggregate and by MedDRA
 categories will be computed.  
Clinical laboratory data will be summarized b y severity for each visit and as the maximum over 
all post-study vaccination visits. Graphical presentations may include box plots. 
11.6.3 Immunogenicity  Data   
Summaries and analysis of immunogenicity data will be presented for the m ITT and PP 
populations. 
Immune responses in terms of strain- specific 2017 H7N9 HAI and Neut antibody titers will be 
summarized by treatment arm at each time point. Analyses will include percentage of subjects 
with a titer ≥1:40, percentage of subjects achieving seroconversion (defined as either a pre-
vaccination titer <10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a 
minimum four -fold rise in post-vaccination antibody titer), and GMTs along with corresponding 
95% confidence intervals. Descriptive summary stat istics will be provided for all assays and time 
points. The correlation between HAI and Neut antibody titers will be evaluated. Plots such as reverse cumulative distributions or longitudinal presentations of GMTs will be presented. 
Additionally, the immune response, as described above, will be summarized by available 
covariates, such as age, sex, body mass index, and prior receipt of seasonal influenza vaccine(s), and these covariates may be considered statistical modeling.  As an exploratory analysis, model s 
will be developed to evaluate the relationship between dosage and adjuvant on immune response. 
For example, logistic regression may be used to examine the relationship of proportion of 
responders with dosage and adjuvant , and available covariates may be considered for inclusion in 
the model. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
106 Additionally, N9 NA specific antibody assays are in development.  If successful, N9 NA specific 
responses may be assessed at baseline, and 8, 29, 43 and 202 after receipt of the first study 
vaccination.  For each time point summaries will include percentage of subjects with detectable 
N9 NA response (to be defined in SAP based following assay development and selection) and GMTs along with corresponding 95% confidence intervals. Descriptive summary statistics will 
be provided for all assays and time points. The correlation of N9 NA response with HAI and 
Neut antibody titers will be evaluated, and plots such as reverse cumulative distributions or longitudinal presentations of GMTs will be presented. 
Further, a determination of the NA content of the 2017 H7N9 IIV is planned, and if successful 
may be used to correlate the N9 NA elicited antibody responses to the NA content of the 2017 
H7N9 IIV. Detectable NA antibody responses and GMTs will be summarized stratified by NA content, and statistical modeling may be used to examine the relationship of NA response with 
NA vaccine content, HA antigen dosage, and adjuvant.  
At least a subset of samples will also be tested for cross -reactive serum HAI and Neut antibody 
responses to antigenically drifted variants of influenza A/H7 viruses. Strain -specific results will 
be summarized using descriptive statistics  as described above, correlations with 2017 H7N9 
responses, and association with study vaccine dose and adjuvant. Further immunogenicity testing and/or analyses may be carried out in the future based upon 
subjects’ prior receipt of non- seasonal influenza vaccines, including type (inactivated or live 
attenuated), what subtype (e.g. A/H3, A/H5, A/H9) and approximate date of vaccination. 
11.6.4 Missing Values and Outliers  
All attempts will be made to collect all data per protocol. As missing data are expected to be 
minimal, no imputation will be performed for missing values. Any data point that appears to be 
erroneous or inexplicable based on clinical judgment will be investigated as a possible outlier. If 
data points are identified as outliers, sensitivity analyses will be performed to examine the impact of including or excluding the outliers. Any substantive differences in these analyses will 
be reported. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
107 12 DATA COLLECTION FORM S AND ACCESS TO 
SOURCE DATA/DOCUMENT S 
Each participating VTEU site will maintain appropriate medical and research records for this 
trial, in compliance with ICH E6, Section 4.9, and regulatory and institutional requirement s for 
the protection of confidentiality of subjects. Each participating VTEU site will permit authorized 
representatives of the DMID, its designees, and appropriate regulatory agencies to examine (and when required by applicable law, to copy) clinical tria l records for the purposes of quality 
assurance reviews, audits, monitoring and evaluation of the study safety and progress.  These 
representatives will be permitted access to all source data, which include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions 
certified after verification as being accurate and complete, microfiches, photographic negatives, 
microfilm or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the 
laboratories, and medico- technical departments involved in the trial.  Source data are all 
information, original records of clinical findings, observa tions, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial. 
Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records 
from the subject’s primary care provider is not required.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
108 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each  participating VTEU site 
is responsible for conducting routine quality assurance (QA) and quality control (QC) activities 
to internally monitor study progress and protocol compliance. Each participating site principal 
investigator will provide direct access to all study- related sites, source data/data collection forms, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local 
and regulatory authorities. Each  site principal investigator will ensure all study personnel are 
appropriately trained and training documentation is current and maintained on site. 
The SDCC will implement QC procedures beginning with the data entry system and generate 
data QC checks that will be run on the database. Any missing data or data anomalies will be 
communicated to the participating VTEU site (s) for clarification and resolution. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
109 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1 Ethical Standard  
The site principal investigator will ensure that this trial is conducted in full conformity with 
principles of the Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 
and 56, and ICH E6; 62 Federal Regulations 25691 (1997), if applicable. The site principal 
investigator’s  institution will hold a current F ederalwide Assurance (FWA) issued by the Office 
of Human Research Protection (OHRP) for federally funded research. 
14.2 Institutional Review Board  
Prior to enrollment of subjects into this trial, the  protocol and informed consent form will be 
reviewed and approved by the appropriate IRB listed on its  FWA.  
The responsible official for the IRB will sign the IRB letter of approval of the protocol prior to 
the start of this trial and a copy will be provide d to DMID.  The IRB FWA number will be 
provided to DMID. 
Should amendments to the protocol be required, the amendments will be written by the sponsor 
and provided to the site principal investigator for submission to the IRB. 
14.3 Informed Consent Process  
14.3.1 Informe d Consent  
The site principal investigator will choose subjects in accordance with the eligibility criteria detailed in Section 5.1. Before any study procedures are performed , subjects must sign an ICF 
that complies with the requirements of 21 CFR Part 50 and 45 CFR 46 and the local IRB. Study personnel may employ IRB-approved recruitment efforts prior to obtaining study consent ; 
however, before any study procedures a re performed to determine protocol eligibility an ICF 
must be signed.  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial  participation.  Before any study procedures 
are performed  subjects will receive a comprehensive explanation  of the proposed study 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
110 procedures and study interventions/products. This will include the nature, risks and possible 
benefits  of th is trial, alternate therapies, any known AEs,  the investigational status of the study 
interventions/products, and the other elements that are part of obtaining proper informed consent. 
Subjects  will also receive a detailed explanation of the proposed use and disclosure of their 
protected health infor mation, including specifically their serum samples.  Subjects  will be 
allowed sufficient time to consider participation in this  research trial, after having the nature, 
risks, and possible benefits of th is trial explained to them, and have the opportunity to discuss 
this trial with their family, friends , or legally authorized representative, or think about it prior to 
agreeing to participate.  
ICFs  describing in detail the study interventions/products, study procedures, risks, and possible 
benefits will be  given to subjects.  The ICF must not include any exculpatory statements.  ICFs  
will be IRB -approved and subjects  will be asked to read and review the appropriate document. 
Upon reviewing the appropriate document, the site principal investigator (or designee ) will 
explain this  research trial to subjects  and answer any questions that may arise. Subjects must sign 
the ICF, and written documentation of the informed consent process is required prior to starting 
any study procedures being done specifically for  this trial, including determining eligibility and 
administering study product. 
By signing the ICF, subjects agree to complete all study procedures required by this trial, unless 
the subject withdraws voluntarily, or is withdrawn or terminated from this trial for any reason.  
The rights and welfare of subjects will be protected by emphasizing to subjects that the quality of 
their medical care will not be adversely affected if they decline to participate in or withdraw from this trial.  
DMID will provide the site principal investigator, in writing, any new information that 
significantly impacts the subject’s risk of receiving the investigational products. This new information will be communicated by the site principal investigator to subjects who consent to 
participate in this  trial in accordance with IRB requirements.  The ICF will be updated and 
subjects will be re -consented per IRB requirements, if necessary.  Subjects  will be given a copy 
of all ICFs  that they sign. 
14.4 Exclusion of Women, Minorities, and Child ren (Special Populations)  
This trial will be inclusive of all subjects age 19 and above who meet the Subject I nclusion 
Criteria  (see Section 5.1.1) and do not meet the Subject Exclusion C riteria  (see Section 5.1.2), 
regardless of religio n, sex, or ethnic background. Adults aged 18 are excluded because the CDC -
recommended adult immunization schedule considers adults as age 19 and above, and therefore this is the subject population chosen for this study [69]. Should the outcome of this trial be 
deemed acceptable, additional trials may be initiated including those in other populations. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
111 It is unknown if the 2017 H7N9 IIV with or without AS03 adjuvant poses any risks to an unborn 
child. As of November 22, 2015 (per the most current version of the manufacturer’s IB), the 
available data for women who become pregnant during clinical trials of AS03-adjuvanted (pre) 
pandemic influenza vaccines do not sugges t any causal relationship between adverse pregnancy 
outcomes and receipt of an AS03- adjuvanted vaccine.  Women of childbearing potential who are 
not steriliz ed via tubal ligation , bilateral oophorectomy , salpingectomy,  hysterectomy,  or 
successful Essure® placement (permanent, non-surgical, non- hormonal sterilization) with 
documented radiological confirmation test at least 90 days after the procedure , and still 
menstruating or <1 year of the last menses if menopausal  must agree to practice highly effective 
contraception that may include, but not limited to,  non- male sexual relationships,  abstinence 
from  sexual  intercourse with a male partner, monogamous relationship with a vasectomized 
partner  who has been vasectomized for 180 days or more prior to the subje ct receiving the first 
study vaccination, barrier methods such as condoms or diaphragms with spermicide or foam,, effective intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, 
injectables, or oral contraceptives (“the pill”) , with use of a highly effective method of 
contraception for a minimum of 30 days prior to study product exposure and agree to practice 
highly effective contraception for the duration of study product exposure, including 60 days after 
their last study vaccina tion. A highly effective method of contraception is defined as one that  
results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. In 
addition to contraceptive use, all women of childbearing potential will be required to have a negative urine or serum pregnancy test within 24 hours prior to each study vaccination. If a 
female subject becomes pregnant while participating in this trial, we will ask her permission to follow-up with her about her health and the health of her baby through pregnancy outcome. 
Children will not be included in this trial as presently there are no safety or efficacy data in 
adults. 
14.5 Subject Confidentiality  
Subject confidentiality is strictly held in trust by the site principal investigators, other study 
personnel, the sponsor, and their agents. The confidentiality includes documentation, investigation data, subject’s clinical information and all other information generated during participation in the study. No information concerning the study or the data generated from the 
study will be released to any unauthorized third parted without prior written approval of the 
DMID and the subject.  Subject confidentiality will be maintained when study results are published or discussed in conferences. The study monitor or other authorized representatives of the sponsor or government regulatory agencies may inspect all documents and records required 
to be maintained by the investigator, including but not limited to, medical records (office, clinic, 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
112 or hospital) and pharmacy records for the subjects in this study. The clinical study site will 
permit access to such records.  
To protect privacy, we have received a Certificate of Confidentiality.  With this Certificate, the 
researchers cannot be forced to release inf ormation that may identify the research subject, even 
by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or 
other proceedings.  The researchers will use the Certificate to resist any demands for information 
that would identify the subject, except as explained below. 
The Certificate cannot be used to resist a demand for information from personnel of the United 
States Government that is used for auditing or evaluation of federally funded projects, like this 
study, or for information that must be released in order to meet the requirements of the Federal 
Food and Drug Administration (FDA). 
A Certificate of Confidentiality does not prevent the subject from voluntarily releasing 
information about themselves or their involvement in this research.  If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the Certificate to withhold that information.   
The Certificate of Confidentiality does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research 
project regarding matters that must be legally reported including: child and elder abuse, sexual abuse, or wanting to harm themselves or others.   
 
   
14.6 Study Discontinuation  
If this trial is discontinued, subjects, who  have signed  the informed consent form and are 
randomized and vaccinated, will continue to be followed for safety for the duration of the 
prescribed safety follow -up period. No further study vaccinations will be administered.  
14.7 Costs, Subject Compensation, and Research Related Injuries  
There is no cost to subjects for taking part in this trial. 
Subjects may be compensated for their participation in this trial. Compensation will be in 
accordance with the local IRB’s policies and procedures, and subject to IRB approval. 
If it is determined by the participating VTEU site and the site principal investigator that an injury 
occurred to a subject as a direct result of the tests or treatments that are done for this trial, then 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
113 referrals to appropriate health care facilities will be provided to the subject.  Study personnel will 
try to reduce, control, and treat any complications from this trial. Immediate medical treatment 
may be provided by the participating VTEU site, such as giving emergency medications to stop 
immediate allergic reactions to the study vaccin e. No financial compensation will be provided to 
the subject by the participating VTEU site for any injury suffer ed due to participation in this 
trial. 
For this protocol, the study products (monovalent inactivated influenza 2017 H7N9 virus vaccine 
manufactured by Sanofi Pasteur and adjuvant (AS03) manufactured by GSK), are covered under the Public Readiness and Emergency Preparedness Act (PREP Act) , as described in Section 
2.1.1. 
14.8 Future Use of Stored Specimens  
Residual samples/specimens are those that are left over after the study has been completed. Subjects may be asked for permission to keep any remaining (residual) clinical samples (serum) 
derived from venous blood samples for possible use in future research studies, such as examining additional immunological assessments or testing for antibodies against other viruses or bacteria, 
or the retention of those samples for possible future use may be a condition of study 
participation . Residual clinical samples for future use will be stored indefinitely at a central 
clinical storage facility  and may be shared for purposes other than per protocol analysis with 
investigators at the participating VTEU site and with other investigators at other institutions  once 
the clinical study report has been finalized . 
Other blood samples are being collected during the study specifically for future use , from 
subjects who consent to collection of those specimens either by signing an informed consent 
form that includes collection of future use samples as a condition of study participation or by 
indicating that they opt in to sample collection for future use if the informed consent form allows 
the option to choose that option. It is anticipated that up to ten 0.5 mL aliquots of serum from 
each extra 10 mL venous blood sample  will be available specifically for the purpose of future 
research, including but not limited to non -traditional immune assay development, assessing 
innate immune factors , and the ability of H7 vaccine-induced antibodies to cross- react with other 
influenza viruses. These future research  clinical samples will be stored indefinitely at a central 
clinical storage facility.  
Unlike residual samples, samples/specimens collected during the study solely for the purpose of future research  may be requested from DMID and shipped from the DMID CAR at any time.  
The samples (residual and the extra venou s blood sample collected solely for future use) will not 
be sold or used directly for production of any commercial product. No genetic tests will be 
performed on samples. Each sample will be encoded (labeled) only with a barcode and a unique 
tracking numbe r to protect subject confidentiality.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
114 There are no benefits to subjects in the collection, storage and subsequent use of their specimens  
for future research . Reports about future research done with subjects’ samples will NOT be  kept 
in their health records. 
Subjects  who are provided the option to decide if residual samples may be retained for possible 
future use or if other blood specimens may be collected specifically for future use may change 
those decisions at any time by notifying the study doctors or nurses in writing.  However, if the 
subject originally consents to future us e of residual samples or collection of samples specifically 
for future use, and subsequently changes his/her decision, any data from a previously collected 
sample may still be used for this research.  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
115 15 DATA HANDLING AND RE CORD KEEPING  
The site principal investigator is responsible to ensure the accuracy, completeness, legibility, and 
timeliness of the data reported.  
Data collection forms w ill be derived from the eCRF and provided by the SDCC to record and 
maintain data for each subject enrolled in th is trial. All data collection forms should be 
completed in a neat, legible manner to ensure accurate interpretation of data.  Black or blue ink is 
required to ensure clarity of reproduced copies.  When making a change or correction, cross out 
the original entry with a single line and initial and date the change.  Do not erase, overwrite, or 
use correction fluid or tape on the original. 
Data reported  in the eCRF derived from the data collection forms should be consistent with the 
data collection forms or the discrepancies should be explained. 
The sponsor and/or its designee will provide guidance to the site principal investigators and other 
study personnel on making corrections to the data collection forms and eCRF. 
15.1 Data Management Responsibilities  
All data collection forms and laboratory reports must be reviewed by the clinical team and data 
entry personnel, who will ensure that they are accurate and complete.  AEs  must be recorded on 
the appropriate data collection form, assessed for severity and relationship, and reviewed by the 
site principal investigator or appropriate sub- investigator.  
Data collection is the responsibility of the study personnel at each  participating VTEU site under 
the supervision of the respective site principal investigator. During this  trial, the site principal 
investigator must maintain complete and accurate documentation for this  trial. 
The SDCC for this trial will be responsible for data management, quality review, analysis, and 
reporting of the study data. 
15.2 Data Capture Methods 
Clinical ( including , but not limited to,  AE/SAEs, concomitant me dications, medical history, 
physical assessments , and clinical laboratory values ), reactogenicity and immunogenicity data 
will be entered  into a 21 CFR  11-compliant Internet Data Entry System provided by the SDCC.  
The data system includes password protection and internal quality checks, such as automatic 
range checks, to identify data th at appear inconsistent, incomplete, or inaccurate. Clinical and 
reactogenicity data will be entered directly from the data collection forms completed by the study 
personnel. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
116 15.3 Types of Data  
Data for this trial will include clinical, safety , and outcome measures (e.g ., clinical  laboratory 
values , reactogenicity  and immunogenicity data). 
15.4 Timing/Reports  
A series of Expedited Interim Immunogenicity Reports of HAI and Neut serum antibody 
responses comparing venous blood samples collected at baseline (D1), Visit 03 (D8), Visit 04 
(D22), Visit 06 (D29), and Visit 07 (D43) is planned. Reports will include HAI and Neut results 
for approximately 25 subjects per adjuvanted treatment arm and 13 subjects per unadjuvanted treatment arm within the 19 -64year -old stratum and the first 15 subjects per adjuvanted treatment 
arm and 8 subjects per unadjuvanted treatment arm within the ≥65 year-old stratum. Reports will be prepared following each post-vaccination visit. 
Clinical, safety and reactogenicity data through approximately 180 days after the second study 
vaccination will represent the primary clinical database for this trial. Once the last subject 
completes the visit that occurs approximately 180 days after the last study vaccination, the 
primary clinical database may be cleaned, monitored and locked. Unblinded analyses of safety, 
reactogenicity, and primary and secondary immunogeni city data is planned. A preliminary report 
may be prepared by the SDCC after the primary clinical database is locked  and all HAI and Neut 
data through 180 days after the last study vaccination are received .  
Regardless of whether a preliminary report is prepared, a “topline” subset of the immunogenicity 
and safety tables will be provided to DMID on an expedited timeline following database lock, 
concurrently with preliminary report or CSR generation. These analyses may be made available 
to the sponsor for planning subsequent trials and to the lead principal investigator  for 
publication. These analyses will not be used to make any decisions concerning the conduct of this trial.  As it is anticipated that subjects may  remain in safety follow -up for 12 months after last 
study vaccination at the time of these analyses, each site will have at least one investigator 
blinded to perform safety assessments. In addition, blinded investigators and medical monitors not involved in the analysis , publication, or clinical study report preparation  will be responsible 
for assessing SAEs and MAAEs including PIMMCs and new onset chronic medical conditions until all subjects have completed the final follow -up visit. All analyses of data included in the 
topline and preliminary report for early release will be considered the final analysis of these data, and also included in the final clinical study report (CSR). 
Analysis of exploratory immunogenicity endpoints may be performed and released as the data is 
available from the central clinical laboratory. An y such analyses would be considered the final 
analysis for the endpoint, and included in the CSR. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
117 The final CSR will be completed  after the last subject’s last visit is completed, and the final 
clinical database including all long- term safety follow -up data is cleaned, monitored and locked. 
Additional exploratory immunogenicity endpoint data not available at the time of CSR 
preparation may be included in an addendum to the CSR. 
Additional statistical reports may be generated as deemed necessary and appropriate by DMID.  
Safety and immunogenicity summary reports may be generated for the DSMB . 
After the final CSR  is complete, and upon request and DMID approval, the SDCC will provide 
the participat ing VTEU sites with a summary of results by treatment arm  and/or subject 
treatment assignments.  In this regard, the participating VTEU sites requesting such information 
to share with study subjects must do so in compliance with their respective IRB guidelines. 
15.5 Study Records Retention  
Study records and reports including, but not limited to , eCRFs, source documents, ICFs , and 
study drug disposition records shall be maintained for 2 years after a marketing application is 
approved for the drug for the indication for which it is being investigated; or, if no application is 
to be filed or if the application is not approved for the drug, until 2 years after the investigation is 
discontinued and the FDA has been  notified. Informed consent forms for future use will be 
maintained as long as the sample exists.  
The participating VTEU  sites must contact DMID for authorization prior to the destruction of 
any study records.   
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
118 16 PROTOCOL DEVIATIONS  
A protocol deviation is any noncompliance with the study protocol, GCP, or protocol- specific 
MOP requirements.  The noncompliance may be either on the part of the subject, the site 
principal investigator, or other study personnel. As a result of deviations, corrective actions are 
to be developed by the site and implemented promptly. 
These practices are consistent with ICH E6:  
4.5 Compliance with Pro tocol, Sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, Section 5.1.1 
5.20 Noncompliance, Sections 5.20.1, and 5.20.2 
It is the responsibility of the site principal investigator and other study personnel to use 
continuous vigilance to identify and report deviations within five working days of identification 
of the protocol deviation, or within five working days of the scheduled protocol-required activity.  All deviations must be promptly reported to DMID, via the SDCC’s Adva ntageEDC
SM. 
All protocol deviations, as defined above, must be addressed in study subject data collection forms.  A completed copy of the DMID Protocol Deviation Form must be maintained in the 
Regulatory File as well as in the subject's chart.  Protocol devi ations must be sent to the local IRB 
per its guidelines. The site principal investigator and other study personnel are responsible for 
knowing and adhering to their IRB requirements. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
119 17 PUBLICATION POLICY  
All investigators funded by the NIH must submit or have submitted for them to the National 
Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/ ) an electronic 
version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than 12 months after the official date of publication. The NIH Public 
Access Policy  ensures the public has access to the published results of NIH funded research. It 
requires investigators to submit final peer- reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central upon acceptance for publication. Further, the policy stipulates that these papers must be accessible to the public on PubMed Central no later than 12 
months after publication.  
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/ 
• NIH Office of Extramural Research ( OER ) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm 
As of January 2018, all clinical trials supported by the NIH must be registered on ClinicalTrials.gov, no later than 21 days after the enrollment of the first subject. Results of all 
clinical trials supported by the NIH, generally, need to be submitted no later than 12 months 
following the primary completion date. A delay of up to 2 years is available for trials that meet 
certain criteria and have applied for certification of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTria ls.gov. 
For this trial the responsible party is DMID  which will register the trial and post results.   
The responsible party does not plan to request certification of delayed posting. 
Refer to:  
• Public Law 110-85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-149 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
120 18 LITERATURE REFERENCES 
 
1. Centers for Disease, C. and Prevention, Emergence of avian influenza A(H7N9) virus 
causing severe human illness - China, February-April 2013. MMWR Morb Mortal Wkly 
Rep, 2013. 62(18): p. 366-71. 
2. Fouchier, R.A., et al., Avian influenza A virus (H7N7) associated with human 
conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci 
U S A, 2004. 101(5): p. 1356-61. 
3. Lindstrom, S., et al., Human infections with novel reassortant influenza A(H3N2)v 
viruses, United States, 2011. Emerg Infect Dis, 2012. 18(5): p. 834-7. 
4. Peiris, M., et al., Human infection with influenza H9N2. Lancet, 1999. 354 (9182): p. 916-
7. 
5. Perez -Padilla, R., et al., Pneumonia and respiratory failure from swine-origin influenza A 
(H1N1) in Mexico.  N Engl J Med, 2009. 361(7): p. 680-9. 
6. Subbarao, K., et al., Characterization of an avian influenza A (H5N1) virus isolated from 
a child with a fatal respiratory illness.  Science, 1998. 279(5 349): p. 393-6. 
7. Oxford, J.S., Influenza A pandemics of the 20th century with special reference to 1918: 
virology, pathology and epidemiology. Rev Med Virol, 2000. 10(2): p. 119-33. 
8. Patriarca, P.A. and N.J. Cox, Influenza pandemic preparedness plan for the United 
States. J Infect Dis, 1997. 176 Suppl 1: p. S4-7. 
9. Galasso, G.J., F.J. Tyeryar, Jr., and J.R. La Montagne, Overview of clinical trials of 
influenza vaccines, 1976.  J Infect Dis, 1977. 136 Suppl : p. S425-8. 
10. La Montagne, J.R., et al., Summ ary of clinical trials of inactivated influenza vaccine - 
1978. Rev Infect Dis, 1983. 5(4): p. 723-36. 
11. Couch, R.B. and J.A. Kasel, Immunity to influenza in man. Annu Rev Microbiol, 1983. 
37: p. 529-49. 
12. Couch, R.B., et al., Antibody correlates and predictors of immunity to naturally 
occurring influenza in humans and the importance of antibody to the neuraminidase. J 
Infect Dis, 2013. 207(6): p. 974-81. 
13. Memoli, M.J., et al., Evaluation of Antihemagglutinin and Antineuraminidase Antibodies 
as Corre lates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge 
Model. MBio, 2016. 7(2): p. e00417-16. 
14. Ennis, F.A., et al., Correlation of laboratory studies with clinical responses to A/New 
Jersey influenza vaccines.  J Infect Dis, 1977. 136 S uppl : p. S397-406. 
15. Gross, P.A., et al., Immunization of elderly people with high doses of influenza vaccine. J 
Am Geriatr Soc, 1988. 36 (3): p. 209-12. 
16. Keitel, W.A., et al., High doses of purified influenza A virus hemagglutinin significantly 
augment serum and nasal secretion antibody responses in healthy young adults. J Clin 
Microbiol, 1994. 32(10): p. 2468-73. 
17. Matzkin, H. and E. Nili, Accidental tenfold overdose of influenza vaccine: a clinical and 
serological study. Isr J Med Sci, 1984. 20(5): p. 411-5. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
121 18. Mostow, S.R., et al., Inactivated vaccines. 1. Volunteer studies with very high doses of 
influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J, 1973. 49(569): 
p. 152-8. 
19. Palache, A.M., et al., Antibody response after influenza immunization with various 
vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine, 1993. 11(1): p. 3-9. 
20. Remarque, E.J., et al., Improvement of the immunoglobulin subclass response to 
influenza vaccine in elderly nursing-home residents by the use of high- dose vaccines.  
Vaccine, 1993. 11(6): p. 649-54. 
21. Ruben, F.L. and G.G. Jackson, A new subunit influenza vaccine: acceptability compared 
with standard vaccines and effect of dose on antigenicity. J Infect Dis, 1972. 125(6): p. 
656-64. 
22. Ruben, F.L., C.W. Potter, and C.H. Stuart- Harris, Humoral and secretory antibody 
responses to immunization with low and high dosage split influenza virus vacci ne. Arch 
Virol, 1975. 47(2): p. 157-66. 
23. Keitel, W.A., et al., Increasing doses of purified influenza virus hemagglutinin and 
subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol, 1996. 3(5): p. 507-10. 
24. Couch, R.B., et al., A randomized clinical trial of an inactivated avian influenza A 
(H7N7) vaccine.  PLoS One, 2012. 7(12): p. e49704. 
25. Treanor, J.J., et al., Safety and immunogenicity of an inactivated subvirion influenza A 
(H5N1) vaccine.  N Engl J Med, 2006. 354(13 ): p. 1343-51. 
26. Atmar, R.L. and W.A. Keitel, Adjuvants for pandemic influenza vaccines. Curr Top 
Microbiol Immunol, 2009. 333: p. 323-44. 
27. Bresson, J.L., et al., Safety and immunogenicity of an inactivated split-virion influenza 
A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 2006. 367(9523): p. 1657-64. 
28. Keitel, W.A., et al., Safety and immunogenicity of an inactivated influenza A/H5N1 
vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis, 2008. 198(9): p. 1309-16. 
29. Carmona, A., et al., Immunogenicity and safety of AS03-adjuvanted 2009 influenza A 
H1N1 vaccine in children 6-35 months. Vaccine, 2010. 28(36): p. 5837-44. 
30. Diez -Domingo, J., et al., Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 
(Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J, 2010. 29(6): p. e35-46. 
31. Lero ux-Roels, I., et al., Antigen sparing and cross-reactive immunity with an adjuvanted 
rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet, 
2007. 370(9587): p. 580-9. 
32. McElhaney, J.E., et al., AS03-adjuvanted versus non-adjuvanted inactivated trivalent 
influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.  Lancet Infect Dis, 2013. 13(6): p. 485-96. 
33. Vogel, F.R., et al., Emulsion-based adjuvants for influenza vaccines. Expert Rev 
Vaccines , 2009. 8(4): p. 483-92. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
122 34. Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in 
Finland 
National Narcolepsy Task Force.  National Institute for Health and Welfare (THL) Finland. 35. A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix – a first and preliminary report. 
36. Choe, Y.J., G.R. Bae, and D.H. Lee, No association between influenza A(H1N1)pdm09 
vaccination and narcolepsy in South Korea: an ecological study. Vaccine, 2012. 30(52): p. 7439-42. 
37. Dauvilliers, Y., et al., Increased risk of narcolepsy in children and adults after pandemic 
H1N1 vaccination in France. Brain, 2013. 136(Pt 8): p. 2486-96. 
38. Eurosurveillance editorial, t., Swedish Medical Products Agency publishes report from a 
case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy.  Euro Surveill, 2011. 16(26).  
39. Miller, E., et al., Risk of narcolepsy in children and young people receiving AS03 
adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ, 2013. 346: p. f794. 
40. Montplaisir, J., et al., Risk of narcolepsy associated with inactivated adjuvanted (AS03) 
A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One, 2014. 9 (9): p. 
e108489. 
41. Nohynek, H., et al., AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase 
in the incidence of childhood narcolepsy in Finland. PLoS One, 2012. 7(3): p. e33536. 
42. O'Flanagan, D., et al., Investigation of an association between onset of narcolepsy and 
vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill, 2014. 19(17): p. 15-25. 
43. Wijnans, L., et al., The incidence of narcolepsy in Europe: before, during, and after the 
influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine, 2013. 31(8): p. 1246-54. 
44.  A Phase II Randomized, Partially-Blinded, Controlled, Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an M F59-
Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages. 
45. Chen, W.H., et al., Safety, Reactogenicity, and Immunogenicity of Inactivated 
Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant. Open Forum Infect Dis, 2014. 1(3): p. ofu091. 
46. Jackson, L.A., et al., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.  JAMA, 2015. 314(3): p. 237-46. 
47. Jackson, L.A., et al., Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect D is, 2012. 206(6): p. 811-20. 
48. Mulligan, M.J., et al., Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 
Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis, 2014. 1(3): p. ofu102. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
123 49. Mulligan, M.J., et al., Serological responses to an avian influenza A/H7N9 vaccine mixed 
at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA, 2014. 
312(14): p. 1409-19. 
50. Lee, Y.J., et al., Novel reassortant influenza A(H5N8) viruses, South Korea, 2014. Emerg 
Infect Dis, 2014. 20(6): p. 1087-9. 
51. Wu, H., et al., Novel reassortant influenza A(H5N8) viruses in domestic ducks, eastern 
China. Emerg Infect Dis, 2014. 20(8): p. 1315-8. 
52. Gao, R., et al., Human infection with a novel avian-origin influenza A (H7N9) virus. N 
Engl J Med, 2013. 368(20): p. 1888-97. 
53. Analysis of recent scientific information on avian influenza A(H7N9) virus. WHO  
Influenza Update, 2017. 
54. Human infection with avian influenza A(H7N9) virus – China: 07 December  2017. WHO  
Emergencies preparedness, response, 2017. 
55. WHO Emergencies preparedness, response- Disease Outbreak News 5 April 2017. 
56. Zhou, J., et al., Biological features of novel avian influenza A (H7N9) virus.  Nature, 
2013. 499(7459): p. 500-3. 
57. Zhu, H., et al., Infectivity, transmission, and pathology of human-isolated H7N9 influenza 
virus in ferrets and pigs. Science, 2013. 341(6142): p. 183-6. 
58. Li, Y., et al., Evolving HA and PB2 genes of influenza A (H7N9) viruses in the fifth wave 
- Increasing threat to both birds and humans? J Infect, 2017. 
59. Madan, A., et al., Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic 
Influenza Vaccine in a Randomized Trial in Healthy Adults. J Infect Dis, 2016. 214(11): p. 1717-1727. 
60. Lasky, T., et al., The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 
influenza vaccines. N Engl J Med, 1998. 339(25): p. 1797-802. 
61. Haber, P., et al., Guillain -Barre syndrome following influenza vaccination. JAMA, 2004. 
292(20): p. 2478-81. 
62. De Wals, P., et al., Risk of Guillain -Barre syndrome following H1N1 influenza 
vaccination in Quebec. JAMA, 2012. 308(2): p. 175-81. 
63. Juurlink, D.N., et al., Guillain -Barre syndrome after influenza vaccination in adults: a 
population-based study.  Arch Intern Med, 2006. 166(20): p. 2217-21. 
64. Salmon, D.A., et al., Association between Guillain-Barre syndrome and influenza A 
(H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.  Lancet, 
2013. 381(9876): p. 1461-8. 
65. Wise, M.E., et al., Guillain -Barre syndrome during the 2009-2010 H1N1 influenza 
vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol, 2012. 175(11): p. 1110-9. 
66. Polakowski, L.L., et al., Chart-confirmed guillain- barre syn drome after 2009 H1N1 
influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol, 2013. 178(6): p. 962-73. 
67. Dodd, C.N., et al., International collaboration to assess the risk of Guillain Barre 
Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 2013. 31(40): p. 4448-58. 
68. Sullivan, S.S., Narcolepsy in adolescents. Adolesc Med State Art Rev, 2010. 21(3): p. 
542-55, x-xi. 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
124 69. CDC, Recommended Immunizations for Adults: By Age. 2017. 
 
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
125 APPENDICES 
Appendix A: Schedule of Study Procedures and Evaluations  
Appendix B : List of Potentially Immune -Mediated Medi cal Conditions  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
126 APPENDIX A. SCHEDULE OF STUDY PROCEDURES AND 
EVALUATIONS  
Vaccination Period  
Study Visit Number  V00 V01 V02** V03 V04 V05** V06 V07 
Study Day post 1st  
vaccination  Screening 
(Optional) 
D -28 to -
1 Enrollment  
Dose 1  
D1 D4±1d  D8+2d D22+7d  D25 D29 D43 
Study Day post 2nd vaccination      Dose 2  
D1 D4±1d  D8+2d  D22+7d  
Study Procedure/Evaluation  
Obtain Informed Consent∞  X X¬       
Collect Demographic 
Information  X X†*       
Review Eligibility Criteria  X X†¬1   X†1    
Medical History@ X X†¬ X X X† X X X 
Concomitant Medications  Xς X†¬ς Xς Xς X†ς Xς Xς Xς 
Vital Signs$ 
(Oral Temperature%, Pulse, and 
BP) X X†   X†2    
Height and Weight  X X†*       
Physical Examination3 X X†*  {X} {X}†  {X} {X} 
Urine or Serum Pregnancy Test  X^ X†^   X†^    
Venous Blood Collection for 
ESR X≠ X≠*       
Venous Blood Collection for 
Clinical Safety Laboratory 
Evaluations~   X†  X X†  X  
Venous Blood Collection for 
Immunogenicity  Assays   X†  X X†Ψ  X X 
Serum Sample Collected for 
Future Research4  X†  X X†  X X 
Enrollment in AdvantageEDCSM 
and Randomization   X†       
Pre-Administration 
Reactogenicity Assessments   X†   X†    
Study Vaccination   X   X    
20-minute Evaluation After 
Study Vaccination   X   X    
Examine Study Vaccination Site   X  X X  X  
Post-Administration 
Reactogenicity Assessments   X   X    
Distribute Memory Aid and 
Study -Related Materials   X   X    
Review Memory Aid    X X  X X  
AE/SAE Assessment   X& X& X& X& X& X& X 
 
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
127  
** Phone call assessment  
∞ Prior to study procedures.  
† Prior  to study vaccination.  
1 Review results of clinical screening (ESR) or safety laboratory evaluations.  
¬ Review/confirm information or activity in subjects previously consented and screened  
@ Complete medical history will be obtained by interview of subjects at the first visit (either screening [optional ] or on Day 1 
prior to the first study vaccination ) and interim medical history will be obtained by interview of subjects at subsequent  visits . 
ς  Receipt of non -study influenza vaccines will be solicited through approximately 180 days after the last study vaccination, and 
reported in the eCRF.  
* Not required if done at the optional screening visit 
$ Vital signs assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
% Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
2 Vital signs are not required for subjects who are discontinued from receipt of the second study vaccination and are being followed for safety.  
3 At the screening (or baseline if not done at screening) visit, a physical examination will be performed on all subjects to 
include the following organs and organ systems: skin, head and neck, lun gs, heart, liver, spleen, extremities, lymph nodes, 
and nervous system  and as an assessment for signs suggestive of a PIMMC . 
{} Targeted physical examination if indicated based on review of interim medical history.  
^ May be performed on all women of childbearing potential at screening (optional) and will be performed within 24 hours prior 
to each study vaccination and results must be negative and known prior to each study vaccination.  
≠ To be performed locally by the site. The ESR value must be confirmed as  <30 mm/hr prior to randomization and first study 
vaccination . 
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr  
Ψ  Subjects who do not receive the second study vaccination will continue with follow -up safety assessments (may be conducted 
by phone call) rather than in person continuing through approximately 12 months after their first study vaccination. These subjects will also be encouraged to provide a venous blood sample for immunogenicity  assays at approximately 21 and 180 
days after their first study vaccination 
4 For subjects who have consented to collect ion of serum for future use  either by signing an informed consent form that 
includes collection of future use samples as a condition of study participation or by indicating that they opt in to sample 
collection for future use if the informed consent form allows the option to choose that option.  
& Inclusive of reactogenicity assessments performed on the day of each study vaccination through 7 days after each study 
vaccination.  
 
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
128 Follow- Up Period  (Including early termination and unscheduled visits) 
Study Visit Number  
V08** 
V09** 
V10 
V11** 
Early Termination (if 
needed)  
Unscheduled (if needed)  
Study Day post first  
study vaccination  
D82 
D142  
D202  
D387  
Study Day post second  
study vaccination  
D61±7d  
D121±14
d 
D181±14
d 
D366±14
d 
Study Procedure/Evaluation  
Medical History@   X  X X (if indicated)  
Concomitant 
Medications  Xς Xς Xς  X (if within  21 days after last study 
vaccination and receipt of any non -
study influenza vaccine will be 
recorded if within 180 days after 
the 2nd study vaccination)  X (if prior to 21 days after last 
study vaccination and receipt of 
any non-study influenza vaccine 
will be recorded if within 180 
days after the 2nd study)  
Vital Signs  
(Oral Temperature%, 
Pulse, and BP)      X (may be obtained if indicated)  X (may be obtained if indicated)  
Physical Examination3   {X}  {X} {X} 
Venous Blood 
Collection for Clinical 
Safety Laboratory 
Evaluations~      X (if within 7 days after the last 
study vaccination)  X (if indicated)  
Venous Blood 
Collection for 
Immunogenicity  Assays    XΨ  X (if within  21 days after last study 
vaccination)  X (if prior to 21 days after last 
study vaccination)  
Serum Sample 
Collected for Future 
Research4   X  X(if within  21 days after last study 
vaccination  X(if prior to 21 days after last 
study vaccination  
Examine Study 
Vaccination Site      X (if within 7 days after last study 
vaccination)  X (if within 7 days after last 
study vaccination)  
Post-Administration 
Reactogenicity 
Assessments      X (if within 7 days after last study 
vaccination)  X (if within 7 days after last 
study vaccination)  
Review Memory Aid      X (if within 7 days after last study 
vaccination)  X (if within 7 days after last 
study vaccination)  
AE/SAE Assessment  X# X# X# X# X# X# 
 
  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
129 ** Phone call assessment  
@ Complete medical history will be obtained by interview of subjects at the first visit (either screening [optional ] or on Day 1 
prior to the first study vaccination ) and interim medical history will be obtained by interview of subjects at subsequent  visits .  
ς  Receipt of non -study influenza vaccines will be solicited through approximately 180 days after the last stud y vaccination, and 
reported in the eCRF.  
% Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
{} Targeted physical examination if indicated based on review of interim medical history.  
~ Include s WBC, Hgb, PLT, ALT, T. Bili, Cr  
Ψ  Subjects who do not receive the second study vaccination will continue with follow -up safety assessments (may be conducted 
by phone call) rather than in person continuing through approximately 12 months after their first study vaccination. These 
subjects w ill also be encouraged to provide a venous blood sample for immunogenicity  assays at approximately 21 and 180 
days after their first study vaccination  
4 For subjects who have consented to collect ion of serum for future use either by signing an informed con sent form that 
includes collection of future use samples as a condition of study participation or by indicating that they opt in to sample collection for future use if the informed consent form allows the option to choose that option.  
# AEs will be limited to SAEs and MAAEs, including NOCMCs and PIMMCs if after 21 days after last study vaccination  
  
 
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
130 APPENDIX B.  LIST OF POTENTIALLY IMMUNE-MEDIATED 
MEDICAL CONDITIONS  
(also known as Adverse Events of Special Interest (AESIs)) 
 
Gastrointestinal disorders  
• Celiac disease  
• Crohn’s disease 
• Ulcerative colitis  
• Ulcerative proctitis  
Liver disorders  
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
Metabolic diseases  
• Addison’s disease 
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I  
• Grave's or Basedow’s disease  
Musculoskeletal disorders  
• Antisynthetase syndrome 
• Dermatomyositis  
• Juvenile chronic arthritis (including Still’s disease)  
• Mixed connective tissue disorder 
• Polymyalgia rh eumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis 
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome 
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter's Syndrome) 
and undiffe rentiated spondyloarthritis  
• Systemic lupus erythematosus  
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
131 • Systemic sclerosis  
Neuroinflammatory disorders  
• Acute disseminated encephalomyelitis, including site specific variants (e.g., non -
infectious encephalitis, encephalomyelitis,  myelitis, myeloradiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (e.g., Bell’s palsy) 
• Guillain -Barré syndrome, including Miller Fisher syndrome and other variants 
• Immune-mediated peripheral neuropathies and plexopathies, including chronic 
inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and 
polyneuropathies associated with monoclonal gammopathy 
• Multiple sclerosis  
• Narcolepsy  
• Optic neuritis  
• Transverse myelitis  
• Myasthenia gravis, including Eaton-Lambert syndrome 
Skin disorders  
• Alopecia areata  
• Autoimmune bullous skin diseases, including pemphigus, pemphigoid and dermatitis herpetiformis  
• Cutaneous lupus erythematosus 
• Erythema nodosum 
• Morphoea 
• Lichen planus 
• Psoriasis 
• Sweet’s syndrome 
• Vitiligo  
Vasculitides  
• Large vessels vasculitis includin g: giant cell arteritis such as Takayasu's arteritis and 
temporal arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's 
disease, microscopic polyangiitis,  Wegener's granulomatosis, Churg-Strauss syndrome 
(allerg ic granulomatous angiitis), Buerger’s disease thromboangiitis obliterans, 
necrotizing vasculitis and anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), Henoch - Schonlein purpura, Behcet's syndrome, 
leukocytoclastic vasculitis  
 
DMID Protocol 17- 0075  Version 5.0 
Sanofi 2017 H7N9 with/without AS03 in Adults/Elderly  April 3, 2019  
 
132 Others  
• Antiphospholipid syndrome 
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly 
progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, 
and mesangioprolifer ative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia 
• Good pasture syndrome 
• Idiopathic pulmonary fibrosis 
• Pernicious anemia  
• Raynaud’s phenomenon 
• Sarcoidosis 
• Sjögren’s syndrome 
• Stevens -Johnson syndrome 
• Uveitis  
 